

579

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

Radicación : 05067344 00000001

Folios: 107

Fecha (AM): 2003-08-04 15:07:38

Trámite : 011 PCT-PATENT 379 FASE NACI 329 COMPLEMEN

Dependencia: 2020 DIVISION DE NUEVAS CREACIONES

57211

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

DIVISION DE NUEVAS CREACIONES

E. S. D.

Re: Expediente No. 05 067344

Solicitud de patente PCT fase nacional

Solicitud internacional No. PCT/US2003/039079

Titular: SCHERING AKTIENGESELLSCHAFT

Yo, LUIS PATIÑO LEYVA, vecino de Bogotá D.C., portador de la tarjeta profesional No. 5903, obrando como apoderado sustituto en este negocio, manifiesto a usted que acompaño al presente memorial, para que sean agregados al expediente de la referencia, los siguientes documentos:

- La publicación corregida, que contiene las hojas Nos. 13, 31 y 33, así como la impresión de la Gaceta PCT, en la que se explica por qué fue publicada la versión corregida.
- Los documentos en los cuales consta la cesión del derecho a la patente de los inventores al solicitante, debidamente traducidos y legalizados.

Acompaño la sustitución del poder a mi favor.

Señor Superintendente,


LUIS PATIÑO LEYVA

C.C. No. 2.930.616 de Bogotá

T.P. No. 2698

CORRECTED VERSIONS OF PAMPHLETS

VERSIONS CORRIGÉES DE BROCHURES

Corrected versions of the pamphlets, identified below by their international publication number, have been published on the same date as the present issue of the PCT Gazette.

Des versions corrigées des brochures, identifiées ci-dessous par leur numéro de publication internationale, ont été publiées à la date de parution du présent numéro de la Gazette du PCT.

International Publication Numbers Numéros de publication internationale	International Application Numbers Numéros des demandes internationales	Corrections
WO 2003/001903	PCT/CA2002/000986	Form PCT/RO/134, indications relating to a Deposited Microorganism, added (2 pages) Formulaire PCT/RO/134, indications relatives à un micro-organisme déposé, ajouté (2 pages)
WO 2004/011832	PCT/US2003/021986	pages 1-7, description, replaced by correct pages 1-7; pages 9-11, claims, replaced by correct pages 8-11 pages 1-7, description, remplacées par les pages 1-7 correctes; pages 9-11, revendications, remplacées par les pages 8-11 correctes
WO 2004/027271	PCT/US2003/029302	page 11, claims, added page 11, revendications, ajoutée
WO 2004/037921	PCT/FR2003/003031	published international search report (4 pages) replaced by correct international search report (4 pages) rapport de recherche internationale publié (4 pages) remplacé par le rapport de recherche internationale correct (4 pages)
WO 2004/046094	PCT/GB2003/005035	pages 78-81, claims, replaced by correct pages 78-81, page 82, claims, added pages 78-81, revendications, remplacées par les pages 78-81 correctes, page 82, revendications, ajoutée
WO 2004/046993	PCT/EP2003/011712	page 14, claims, added page 14, revendications, ajoutée
WO 2004/052366	PCT/US2003/039079	pages 13, 31 and 33, description, replaced by correct pages 13, 31 and 33; due to late transmittal by the receiving Office pages 13, 31 et 33, description, remplacées par les pages 13, 31 et 33 correctes; en raison de la transmission tardive par l'office récepteur
WO 2004/054090	PCT/IB2003/005868	replace all pages of description and claims by correct pages remplacer toutes les pages de la description et revendications par les pages correctes
WO 2004/084375	PCT/US2004/008114	pages 22-127, description, added pages 22-127, description, ajoutées
WO 2004/097894	PCT/US2003/026322	pages 5, 15, 23 and 32, description, added; page 1/20, drawings, added; due to late transmittal by the receiving Office pages 5, 15, 23 et 32, description, ajoutées; page 1/20, dessins, ajoutée; en raison de la transmission tardive par l'office récepteur
WO 2004/110279	PCT/EP2004/051090	pages 1/23-23/23, drawings, replaced by new pages 1/23-23/23 pages 1/23-23/23, dessins, remplacées par de nouvelles pages 1/23-23/23
WO 2005/000783	PCT/JP2004/009383	pages 67, 69, 152, 161, 197, 206, 231, 239, 240, 242, 243, 257, 263, 264, 276, description, replaced by new pages 67, 69, 152, 161, 197, 206, 231, 239, 240, 242, 243, 257, 263, 264, 276; after rectification of obvious errors authorized by the International Search Authority pages 67, 69, 152, 161, 197, 206, 231, 239, 240, 242, 243, 257, 263, 264, 276, description, remplacées par de nouvelles pages 67, 69, 152, 161, 197, 206, 231, 239, 240, 242, 243, 257, 263, 264, 276; après rectification d'erreurs évidentes autorisée par l'administration chargée de la recherche internationale

(Continued on the following page)

(Suite sur la page suivante)

CORRECTED VERSION

581

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
24 June 2004 (24.06.2004)

PCT

(10) International Publication Number
WO 2004/052366 A1

(51) International Patent Classification⁷: A61K 31/4709,
C07D 215/22, 413/12, 417/12, 409/12, 215/48, A61P
9/10, 7/02

(74) Agent: HERMENAUI, Ronald, S.; Berlex Biosciences,
2600 Hilltop Drive, P.O. Box 4099, Richmond, CA 94804
(US).

(21) International Application Number:
PCT/US2003/039079

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 9 December 2003 (09.12.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/432,792 11 December 2002 (11.12.2002) US

(84) Designated States (*regional*): ARIPO patent (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,
SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): SCHER-
ING AKTIENGESELLSCHAFT [DE/DE]; Müller-
strasse 178, 13342 Berlin (DE).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): BRYANT, Judi
[US/US]; 318 Via Recodo, Mill Valley, CA 94941 (US).
BUCKMAN, Brad [US/US]; 2042 Leimert Blvd., Oak-
land, CA 94602 (US). ISLAM, Imadul [US/US]; 165
Caprice Circle, Hercules, CA 94547 (US). MOHAN,
Raju [US/US]; 3125 Caminito Ricardo, Encinitas, CA
92024 (US). MORRISSEY, Michael [US/US]; 129 Alta
Vista Way, Danville, CA 94506 (US). WEI, Guo, Ping
[US/US]; 326 Langton Court, San Ramon, CA 94583
(US). XU, Wei [CN/US]; 327 Glasgow Circle, Danville,
CA 94526 (US). YUAN, Shendong [CN/US]; 2328 Elan
Lane, San Ramon, CA 94583 (US).

Published:


— with international search report

(48) Date of publication of this corrected version:
23 June 2005

(15) Information about Correction:
see PCT Gazette No. 25/2005 of 23 June 2005, Section II

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: 2-AMINOCARBONYL-QUINOLINE COMPOUNDS AS PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS



(57) Abstract: Compounds of formula (I), where m, n, R¹, R², R³, R⁴ and R⁵ are described herein, are useful as inhibitors of platelet adenosine diphosphate. Pharmaceutical compositions containing these compounds, methods of using these compounds as antithrombotic agents and processes for synthesizing these compounds are also described herein.

WO 2004/052366 A1

This application claims priority to U.S. Provisional Application Serial No. 60/432,792 filed December 11, 2002 the entirety of which is incorporated herein by reference.

5

Field of the Invention

The invention relates to quinoline derivatives, their use as platelet adenosine diphosphate receptor antagonists, compositions containing them and processes for their preparation.

10

Background of the Invention

Platelets interact with the coagulation and fibrinolysis systems in the maintenance of hemostasis and in the pathogenesis of thrombosis and thromboembolism. Platelets rapidly adhere to damaged vascular tissue, and release a variety of prothrombotic, chemotactic, and mitogenic factors, aimed at prompting hemostasis and wound healing. Platelets also play an important role in arterial thrombosis, a common cause of death and disability in patients with cardiovascular disease. Platelet inhibitors have been successfully used for secondary prevention of arterial thrombosis in patients with coronary, cerebral, and peripheral vascular disease.

15

20

Platelets adhere to exposed subendothelium after vessel wall injury by binding to von Willebrand factor (vWf) and collagen. This induces platelets to change shape from a disc shape to a round form with pseudopodia, which enforces platelet adhesion and aggregation. The final common pathway for platelet aggregation is the activation of the fibrinogen receptor (GPIIb-IIIa). As a result, dimeric fibrinogen molecules present in plasma can bind and link platelets together to form aggregates.

25

Activated platelets secrete their granule contents, many of which act directly on blood cells, including platelets themselves, and endothelium. Platelets contain several kinds of secretory granules. The dense-granules contain adenosine diphosphate ("ADP"), adenosine triphosphate ("ATP") and serotonin. The α -granules contain several platelet-specific proteins (platelet factor 4 and β -thromboglobulin), growth factors (PDGF, TGF- β , EGF and ECGF) and coagulation factors (fibrinogen, Factor V and vWf). Platelets also secrete biologically active arachidonic acid products. Well known is TxA₂ which is inhibited by aspirin through irreversible inactivation of the cyclooxygenase producing TxA₂.

30

35

Many stimuli, such as thrombin, collagen, ADP and thromboxane A₂ (TxA₂), activate platelets by binding to their cell surface receptors. Most of these receptors are G-protein-coupled receptors. Activation of G-proteins has been shown to be an essential event in platelet activation. For example, platelets from Gq^{-/-} mice do not aggregate in response to

thrombin, collagen, ADP or TxA₂ (Offermans, S. *et al.*, *Nature* (1998), Vol. 389, No. 11, pp. 183-185). Many down-stream signaling events have been elucidated, including activation of phospholipase-C (PLC) and protein kinase C, increase in Intracellular calcium concentration, decrease in cAMP level and tyrosine phosphorylation.

5 ADP plays a pivotal role in platelet activation. ADP not only causes primary aggregation of platelets but is also responsible for the secondary aggregation following activation by other agonists such as thrombin and collagen. Contained at very high concentrations in the platelet dense-granules, ADP is released when platelets are activated to reinforce platelet aggregation.

10 ADP-induced platelet activation plays an important role in maintaining normal hemostasis. Several congenital bleeding disorders have been linked to the decreased number of platelet ADP receptors and deficiency of ADP-induced platelet aggregation. Patients having "storage pool disease", which is due to defects in the storage of nucleotides and/or their secretion from the platelet dense-granules, have impaired platelet aggregation in response to collagen and other stimuli due to the absence of the amplification effects by ADP.

15 ADP-induced platelet activation also plays a key role in the initiation and propagation of thrombosis. Administration of ADP has been shown to induce thrombus formation in rat and mice mesenteric venules. In contrast, ADP-removing enzymes have been shown to dramatically reduce platelet deposition on collagen and to inhibit laser-induced thrombosis in
20 rat mesenteric arterioles and venules, supporting the theory that ADP plays a role in mediating platelet recruitment in thrombus formation. Several ADP-induced early signaling events in platelets have been described. These include a transient rise in free cytoplasmic calcium, an inhibition of adenylate cyclase through activation of G₂, an increase in cytosolic pH by activating the Na⁺/H⁺-exchange, and exposure of the platelet binding sites for fibrinogen
25 independent of protein kinase C. While these signaling events collectively contribute to platelet aggregation, the specific role of each remains the subject of on-going investigations.

The current model of ADP-induced platelet activation involves two G-protein coupled purinergic receptors, one of which is coupled to the activation of the phospholipase-C pathway (P2Y₁) and the other is coupled to the inhibition of adenylate cyclase (P2Y_{AC}). P2Y_{AC} is the
30 best target for a platelet ADP receptor antagonist for several reasons. First, P2Y_{AC} is predominately platelet specific. Secondly, it is required for ADP-induced aggregation. Thirdly, it plays an important role in sustaining thrombin or collagen-induced aggregation. Finally, it is the molecular target for anti-aggregatory drugs such as Clopidogrel and Ticlopidine. Both of these drugs have been shown to be efficacious in various thrombosis models. However,
35 Clopidogrel has been shown to be an irreversible inhibitor of platelet aggregation with a slow onset of action. Similarly, the ATP analogues, AR-C67085 and AR-C69931MX, which are

potent antagonists for ADP-induced platelet aggregation, have also been shown to be effective in thrombosis models and are currently under clinical investigation. All these findings indicate that ADP is a critical mediator of arterial thrombus formation and hence an excellent target for antithrombotic intervention.


- 5 When the properties of current oral platelet inhibitors, such as aspirin, Clopidogrel and Ticlopidine are compared, it becomes clear that, while relatively safe, current oral platelet inhibitors are only modestly effective in preventing thrombotic complications in patients with underlying vascular disease. It is clear that there is a need in this field for a potent, selective, reversible, orally active platelet ADP receptor (P2Y_{AC}) inhibitor.

10

SUMMARY OF THE INVENTION

The compounds of the invention are antagonists of the platelet ADP receptor, P2Y_{AC}, and are therefore useful in treating disease-states characterized by thrombotic activity and in so doing are useful as antithrombotic agents in the treatment and prevention of thrombosis.

- 15 Accordingly, in one aspect, the invention is directed to compounds selected from the group consisting of the following formula (I):



wherein:

m and n are independently 1 to 4;

- 20 R¹ is hydrogen, alkyl, carboxyalkyl, aryl, aralkyl, alkylcarbonyl, aryloxyalkylcarbonyl, carboxyalkylcarbonyl, alkoxycarbonylalkylcarbonyl, alkoxycarbonylalkyl, alkoxycarbonyl, arylcarbonyl, aryloxycarbonyl, aralkoxycarbonyl, cycloalkylcarbonyl, haloalkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, alkoxycarbonylaminocarbonyl, or heterocyclcarbonyl;
- 25 R² is hydrogen, alkyl, aryl, aralkyl, alkylsulfonylalkyl, aralkoxyalkyl, hydroxyalkyl, aminoalkyl, haloalkylsulfonylaminoalkyl, carboxyalkylthioalkyl, alkoxycarbonylalkylthioalkyl, carboxyalkyl, (carboxy)(hydroxy)alkyl, carboxyalkoxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, carboxyalkoxycarbonylalkyl, alkoxycarbonylalkoxycarbonylalkyl, aminocarbonylalkyl, aralkoxycarbonylaminoalkyl,
- 30 alkoxycarbonylalkylaminocarbonylalkyl, carboxyalkylaminocarbonylalkyl, (alkoxycarbonylalkyl)(alkyl)aminocarbonylalkyl, (carboxyalkyl)(alkyl)aminocarbonylalkyl, or heterocyclalkyl;

R^3 is aryl or aryloxy each independently optionally substituted by one or more substituents selected from the group consisting of alkyl, halo, haloalkyl, cyano, nitro, tetrazolyl, $-R^8-OR^7$, $-R^8-C(O)OR^7$, $-R^8-C(O)N(R^7)_2$, $-R^8-C(O)R^7$, $-R^8-N(R^7)_2$, $-R^8-N(R^7)C(O)R^7$, $-R^8-N(R^7)C(O)OR^8$, $-R^8-N(R^7)-S(O)_2-R^7$, and $-R^8-C[N(R^7)_2]-C(O)OR^7$;

- 5 or R^3 is aralkyl or aralkoxy, wherein the alkyl radical in the aralkyl or aralkoxy substituent is optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, $-R^8-OR^7$, $-R^8-C(O)OR^7$, $-R^8-C(O)N(R^7)_2$, $-R^8-C(O)R^7$, $-R^8-N(R^7)_2$, $-R^8-N(R^7)C(O)R^7$, and $-R^8-N(R^7)C(O)OR^8$, and wherein the aryl radical in the aralkyl or aralkoxy substituent is independently optionally substituted by one or more substituents
- 10 selected from the group consisting of alkyl, halo, haloalkyl, cyano, nitro, tetrazolyl, $-R^8-OR^7$, $-R^8-C(O)OR^7$, $-R^8-C(O)N(R^7)_2$, $-R^8-C(O)R^7$, $-R^8-N(R^7)_2$, $-R^8-N(R^7)C(O)R^7$, $-R^8-N(R^7)C(O)OR^8$, $-R^8-N(R^7)-S(O)_2-R^7$, and $-R^8-C[N(R^7)_2]-C(O)OR^7$;

each R^4 is independently selected from the group consisting of hydrogen, alkyl, alkoxy, aralkoxy, halo, haloalkyl, haloalkoxy, hydroxy, cyano, alkylthio, carboxy, alkoxycarbonyl, aminocarbonyl, alkylcarbonyl, nitro, amino, monoalkylamino, dialkylamino, carboxyalkylamino, alkylcarbonylamino, di(alkylcarbonyl)amino, hydroxyalkyl, dialkylaminoalkyl, carboxyalkoxy, alkoxycarbonylalkoxy, dialkylaminoalkoxy, and heterocyclalkoxy;

each R^5 is independently selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, aralkyl, carboxy, alkoxycarbonyl, aralkoxycarbonyl, carboxyalkyl, and alkoxycarbonylalkyl;

R^6 is hydrogen, alkyl, carboxyalkyl, or alkoxycarbonylalkyl;


each R^7 is hydrogen, alkyl, aryl, aralkyl, or haloalkyl;

each R^8 is a bond or a straight or branched alkylene chain; and

- 25 each R^9 is hydrogen, alkyl, aralkyl or haloalkyl;

as a single stereoisomer, a mixture of individual stereoisomers, or a racemic mixture; or a pharmaceutically acceptable salt thereof.

In another aspect, this invention is compounds selected from the group consisting of the following formula (II):



wherein:

m and n are independently 1 to 4;

R¹ is hydrogen, alkyl, carboxyalkyl, aryl, aralkyl, alkylcarbonyl, aryloxyalkylcarbonyl, carboxyalkylcarbonyl, alkoxycarbonylalkylcarbonyl, alkoxycarbonylalkyl, alkoxycarbonyl, arylcarbonyl, aryloxycarbonyl, aralkoxycarbonyl, cycloalkylcarbonyl, haloalkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, alkoxycarbonylaminocarbonyl, or heterocyclcarbonyl;

R² is hydrogen, alkyl, aryl, aralkyl, alkylsulfonylalkyl, aralkoxyalkyl, hydroxyalkyl, aminoalkyl, haloalkylsulfonylaminoalkyl, carboxyalkylthioalkyl, alkoxycarbonylalkylthioalkyl, carboxyalkyl, (carboxy)(hydroxy)alkyl, carboxyalkoxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, carboxyalkoxycarbonylalkyl, alkoxycarbonylalkoxycarbonylalkyl, aminocarbonylalkyl, aralkoxycarbonylaminoalkyl, alkoxycarbonylalkylaminocarbonylalkyl, carboxyalkylaminocarbonylalkyl, (alkoxycarbonylalkyl)(alkyl)aminocarbonylalkyl, (carboxyalkyl)(alkyl)aminocarbonylalkyl, or heterocyclalkyl;

R³ is heteroaryl optionally substituted by one or more substituents selected from the group consisting of alkyl, halo, haloalkyl, cyano, nitro, tetrazolyl, -R⁸-OR⁷, -R⁸-C(O)OR⁷, -R⁸-C(O)N(R⁷)₂, -R⁸-C(O)R⁷, -R⁸-N(R⁷)₂, -R⁸-N(R⁷)C(O)R⁷, -R⁸-N(R⁷)C(O)OR⁸, -R⁸-N(R⁷)-S(O)₂-R⁷, and -R⁸-C[N(R⁷)₂]-C(O)OR⁷;

or **R³** is heteroarylalkoxy, wherein the alkoxy radical in the heteroarylalkoxy substituent is optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, -R⁸-OR⁷, -R⁸-C(O)OR⁷, -R⁸-C(O)N(R⁷)₂, -R⁸-C(O)R⁷, -R⁸-N(R⁷)₂, -R⁸-N(R⁷)C(O)R⁷, and -R⁸-N(R⁷)C(O)OR⁸, and wherein the heteroaryl radical in the heteroarylalkoxy substituent is independently optionally substituted by one or more substituents selected from the group consisting of alkyl, halo, haloalkyl, cyano, nitro, tetrazolyl, -R⁸-OR⁷, -R⁸-C(O)OR⁷, -R⁸-C(O)N(R⁷)₂, -R⁸-C(O)R⁷, -R⁸-N(R⁷)₂, -R⁸-N(R⁷)C(O)R⁷, -R⁸-N(R⁷)C(O)OR⁸, -R⁸-N(R⁷)-S(O)₂-R⁷, and -R⁸-C[N(R⁷)₂]-C(O)OR⁷;

each **R⁴** is independently selected from the group consisting of hydrogen, alkyl, alkoxy, aralkoxy, halo, haloalkyl, haloalkoxy, hydroxy, cyano, alkylthio, carboxy, alkoxycarbonyl, aminocarbonyl, alkylcarbonyl, nitro, amino, monoalkylamino, dialkylamino, carboxyalkylamino, alkylcarbonylamino, di(alkylcarbonyl)amino, hydroxyalkyl, dialkylaminoalkyl, carboxyalkoxy, alkoxycarbonylalkoxy, dialkylaminoalkoxy, and heterocyclalkoxy;

each **R⁵** is independently selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, aralkyl, carboxy, alkoxycarbonyl, aralkoxycarbonyl, carboxyalkyl, and alkoxycarbonylalkyl;

R⁶ is hydrogen, alkyl, carboxyalkyl, or alkoxycarbonylalkyl;

each **R⁷** is hydrogen, alkyl, aryl, aralkyl, or haloalkyl;

A
587

each R^a is a bond or a straight or branched alkylene chain; and
each R^b is hydrogen, alkyl, aralkyl or haloalkyl;
as a single stereoisomer, a mixture of individual stereoisomers, or a racemic mixture;
or a pharmaceutically acceptable salt thereof.

5 In another aspect, this invention is directed to pharmaceutical compositions useful in treating a mammal having a disease-state characterized by thrombotic activity, which composition comprises a pharmaceutically acceptable excipient and a compound of formula (I) or a compound of formula (II) as defined above.

10 In another aspect, this invention is directed to methods of treating disease-states characterized by thrombotic activity, which methods comprise administering to a mammal having a disease-state characterized by thrombotic activity a therapeutically effective amount of a compound of formula (I) or formula (II) as defined above.

Detailed Description of the Invention

15 Definitions

As used in the specification and appended claims, unless specified to the contrary, the following terms have the meaning indicated:

"Alkyl" refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to eight carbon atoms, and which is attached to the rest of the molecule by a single bond, e.g., methyl, ethyl, *n*-propyl, 1-methylethyl (*iso*-propyl), *n*-butyl, *n*-pentyl, 1,1-dimethylethyl (*t*-butyl), and the like. Unless stated otherwise specifically in the specification, it is understood that for radicals, as defined below, that contain a substituted alkyl group that the substitution can occur on any carbon of the alkyl group.

25 "Alkylene chain" refers to a straight or branched divalent hydrocarbon chain consisting solely of carbon and hydrogen, containing no unsaturation and having from one to eight carbon atoms, e.g., methylene, ethylene, propylene, *n*-butylene, and the like.

"Alkylcarbonyl" refers to a radical of the formula $-C(O)-R_a$ where R_a is an alkyl radical as defined above, e.g., acetyl, ethylcarbonyl, *n*-propylcarbonyl, and the like.

30 "Alkylcarbonylamino" refers to a radical of the formula $-N(H)-C(O)-R_a$ where R_a is an alkyl radical as defined above, e.g., acetylamino, ethylcarbonylamino, *n*-propylcarbonylamino, and the like.

"Alkylthio" refers to a radical of the formula $-S-R_a$ where R_a is an alkyl radical as defined above, e.g., methylthio, ethylthio, *n*-propylthio, and the like.

35 "Alkylsulfonylalkyl" refers to a radical of the formula $-R_a-S(O)_2-R_b$ where each R_a is independently an alkyl radical as defined above, e.g., methylsulfonylmethyl, 2-methylsulfonylethyl, 2-ethylsulfonylpropyl, and the like.

"Alkoxy" refers to a radical of the formula $-OR_a$ where R_a is an alkyl radical as defined above, e.g., methoxy, ethoxy, *n*-propoxy, 1-methylethoxy (*iso*-propoxy), *n*-butoxy, *n*-pentoxy, 1,1-dimethylethoxy (*t*-butoxy), and the like.

"Alkoxy carbonyl" refers to a radical of the formula $-C(O)OR_a$ where R_a is an alkyl radical as defined above, e.g., methoxycarbonyl, ethoxycarbonyl, *n*-propoxycarbonyl, and the like.

"Alkoxy carbonyl alkyl" refers to a radical of the formula $-R_a-C(O)OR_a$ where each R_a is independently an alkyl radical as defined above, e.g., methoxycarbonylmethyl, (1,1-dimethylethoxy)carbonylmethyl, 2-(methoxycarbonyl)ethyl, and the like.

"Alkoxy carbonyl aminocarbonyl" refers to a radical of the formula $-C(O)-N(H)-C(O)OR_a$ where R_a is an alkyl radical as defined above, e.g., methoxycarbonylaminocarbonyl, ethoxycarbonylaminocarbonyl, *n*-propoxycarbonylaminocarbonyl, and the like.

"Alkoxyalkoxyalkyl carbonyl" refers to a radical of the formula $-C(O)-R_a-O-R_a-O-R_a$ where each R_a is independently an alkyl radical as defined above, e.g., 2-(ethoxy)ethoxymethylcarbonyl, 3-(2-(*n*-butoxy)ethoxy)propylcarbonyl, and the like.

"Alkoxy carbonyl alkyl" refers to a radical of the formula $-R_a-C(O)OR_a$ where each R_a is independently an alkyl radical as defined above, e.g., methoxycarbonylmethyl, 2-(ethoxycarbonyl)ethyl, 2-(methoxycarbonyl)propyl, and the like.

"Alkoxy carbonyl alkoxy" refers to a radical of the formula $-O-R_a-C(O)OR_a$ where each R_a is independently an alkyl radical as defined above, e.g., methoxycarbonylmethoxy, 2-(ethoxycarbonyl)ethoxy, 2-(methoxycarbonyl)propoxy, and the like.

"Alkoxy carbonyl alkyl carbonyl" refers to a radical of the formula $-C(O)-R_a-C(O)OR_a$ where each R_a is independently an alkyl radical as defined above, e.g., methoxycarbonylmethylcarbonyl, 2-(ethoxycarbonyl)ethylcarbonyl, 2-(methoxycarbonyl)propylcarbonyl, and the like.

"Alkoxy carbonyl alkyl aminocarbonyl alkyl" refers to a radical of the formula $-R_a-C(O)-N(H)-R_a-C(O)OR_a$ where each R_a is independently an alkyl radical as defined above, e.g., methoxycarbonylmethyl, 2-(ethoxycarbonyl)ethylaminocarbonylmethyl, 2-(2-(methoxycarbonyl)propylaminocarbonyl)propyl, and the like.

"Alkoxy carbonyl alkyl thioalkyl" refers to a radical of the formula $-R_a-S-R_a-C(O)OR_a$ where each R_a is independently an alkyl radical as defined above, e.g., methoxycarbonylmethylthiomethyl, 2-(ethoxycarbonyl)ethylthiomethyl, 2-(2-(methoxycarbonyl)propylthio)propyl, and the like.

"Alkoxy carbonyl alkoxy carbonyl alkyl" refers to a radical of the formula $-R_a-C(O)-O-R_a-C(O)OR_a$ where each R_a is independently an alkyl radical as defined above, e.g., methoxycarbonylmethoxy, 2-(ethoxycarbonyl)ethoxycarbonylmethyl, 3-(2-(methoxycarbonyl)propoxycarbonyl)propyl, and the like.

589

"(Alkoxy carbonyl alkyl)(alkyl)aminocarbonyl alkyl" refers to a radical of the formula $-R_a-C(O)-N(R_b)-R_c-C(O)OR_d$, where each R_x is independently an alkyl radical as defined above, e.g., (methoxycarbonylmethyl)(methyl)aminocarbonylmethyl, 2-((ethoxycarbonylmethyl)(methyl)aminocarbonyl)ethyl, and the like.

5 "Amino" refers to the $-NH_2$ radical.

"Aminoalkyl" refers to a radical of the formula $-R_a-NH_2$, e.g., aminomethyl, 2-aminomethyl, 2-aminopropyl, and the like.

"Aminocarbonyl" refers to the $-C(O)NH_2$ radical.

10 "Aminocarbonylalkoxy" refers to a radical of the formula $-O-R_a-C(O)NH_2$, e.g., aminocarbonylmethoxy, 2-(aminocarbonyl)ethoxy, 2-(aminocarbonyl)propoxy, and the like.

"Aminocarbonylalkyl" refers to a radical of the formula $-R_a-C(O)NH_2$, e.g., aminocarbonylmethyl, 2-(aminocarbonyl)ethyl, 2-(aminocarbonyl)propyl, and the like.

15 "Aryl" refers to a phenyl or naphthyl radical. Unless stated otherwise specifically in the specification, the term "aryl" or the prefix "ar-" (such as in "aralkyl") is meant to include aryl radicals optionally substituted by one or more substituents selected from the group consisting of alkyl, halo, haloalkyl, cyano, nitro, tetrazolyl, $-R^6-OR^7$, $-R^6-C(O)OR^7$, $-R^6-C(O)N(R^7)_2$, $-R^6-C(O)R^7$, $-R^6-N(R^7)_2$, $-R^6-N(R^7)C(O)R^7$, $-R^6-N(R^7)C(O)OR^8$, $-R^6-N(R^7)-S(O)_2R^7$, $-R^6-C[N(R^7)_2]-C(O)OR^7$, wherein each R^7 is hydrogen, alkyl, aryl, aralkyl, or haloalkyl, each R^8 is a bond or a straight or branched alkylene chain, and each R^6 is hydrogen, alkyl, aralkyl or haloalkyl as defined herein.

20 "Aralkyl" refers to a radical of the formula $-R_aR_b$, where R_a is an alkyl radical as defined above, substituted by R_b , an aryl radical, as defined above, e.g., benzyl. The R_a radical may be optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, $-R^8-OR^7$, $-R^8-C(O)OR^7$, $-R^8-C(O)N(R^7)_2$, $-R^8-C(O)R^7$, $-R^8-N(R^7)_2$, $-R^8-N(R^7)C(O)R^7$, and $-R^8-N(R^7)C(O)OR^8$, wherein each R^7 is hydrogen, alkyl, aryl, aralkyl, or haloalkyl, each R^8 is a bond or a straight or branched alkylene chain, and each R^6 is hydrogen, alkyl, aralkyl or haloalkyl as defined herein. The R_b radical may be optionally substituted one or more substituents selected from the group consisting of alkyl, halo, haloalkyl, cyano, nitro, tetrazolyl, $-R^8-OR^7$, $-R^8-C(O)OR^7$, $-R^8-C(O)N(R^7)_2$, $-R^8-C(O)R^7$, $-R^8-N(R^7)_2$, $-R^8-N(R^7)C(O)R^7$, $-R^8-N(R^7)C(O)OR^8$, $-R^8-N(R^7)-S(O)_2R^7$, $-R^8-C[N(R^7)_2]-C(O)OR^7$, wherein each R^7 is hydrogen, alkyl, aryl, aralkyl, or haloalkyl, each R^8 is a bond or a straight or branched alkylene chain, and each R^6 is hydrogen, alkyl, aralkyl or haloalkyl as defined herein.

"Aryloxy" refers to a radical of the formula $-OR_b$, where R_b is an optionally substituted aryl radical as defined above, e.g., phenoxy.

35 "Arylcarbonyl" refers to a radical of the formula $-C(O)-R_b$, where R_b is an optionally substituted aryl radical as defined above, e.g., phenylcarbonyl, (4-acetylaminophenyl)carbonyl,

590

(2-methoxyphenyl)carbonyl, and the like. For R^1 , preferred arylcarbonyl radicals are those radicals wherein the R_6 group is optionally substituted by one or more substituents independently selected from the group consisting of acetylamino, carboxy, aminocarbonyl, alkoxycarbonyl, haloalkoxy, alkoxy, and alkyl.

5 "Aryloxy" refers to a radical of the formula $-C(O)OR_6$ where R_6 is an optionally substituted aryl radical as defined above, e.g., phenoxycarbonyl.

"Aryloxyalkyl" refers to a radical of the formula $-C(O)OR_6R_7$ where R_6 is an alkyl radical, as defined above, substituted by R_7 , an optionally substituted aryl radical, as defined above, e.g., phenoxymethylcarbonyl, (2-phenoxyethyl)carbonyl, and the like.

10 "Aralkoxy" refers to a radical of the formula $-OR_6$ where R_6 is an optionally substituted aralkyl radical as defined above, e.g., benzyloxy, 3-phenylpropoxy, and the like.

"Aralkoxyalkyl" refers to a radical of the formula $-R_6-OR_7$ where R_6 is an alkyl radical as defined above and R_7 is an optionally substituted aralkyl radical as defined above, e.g., benzyloxymethyl, 2-(benzyloxy)ethyl, 2-(benzyloxy)propyl, and the like.

15 "Aralkoxycarbonyl" refers to a radical of the formula $-C(O)OR_6$ where R_6 is an optionally substituted aralkyl radical as defined above, e.g., benzyloxycarbonyl, and the like.

"Aralkoxycarbonylalkyl" refers to a radical of the formula $-R_6-C(O)OR_7$ where R_6 is an alkyl radical as defined above and R_7 is an optionally substituted aralkyl radical as defined above, e.g., benzyloxycarbonylmethyl, 2-(benzyloxycarbonyl)ethyl, 3-((naphthalen-2-yl)oxy)carbonyl)propyl, and the like.

20 "Aralkoxycarbonylaminoalkyl" refers to a radical of the formula $-R_6-N(H)-C(O)OR_7$ where R_6 is an alkyl radical as defined above and R_7 is an optionally substituted aralkyl radical as defined above, e.g., benzyloxycarbonylaminomethyl, 2-(benzyloxycarbonylamino)ethyl, 2-(benzyloxycarbonylamino)propyl, and the like.

25 "Carboxy" refers to the $-C(O)OH$ radical.

"Carboxyalkyl" refers to a radical of the formula $-R_6-C(O)OH$, where R_6 is an alkyl radical as defined above, e.g., carboxymethyl, 2-carboxyethyl, 2-carboxypropyl and the like.

"Carboxyalkoxy" refers to a radical of the formula $-O-R_6-C(O)OH$, where R_6 is an alkyl radical as defined above, e.g., carboxymethoxy, 2-carboxyethoxy, 2-carboxypropoxy, and the like.

30 "Carboxyalkylcarbonyl" refers to a radical of the formula $-C(O)-R_6-C(O)OH$, where R_6 is an alkyl radical as defined above, e.g., 2-carboxyethylcarbonyl, carboxymethylcarbonyl, 3-carboxypropylcarbonyl, and the like.

35 "Carboxyalkylamino" refers to a radical of the formula $-N(H)-R_6-C(O)OH$ where R_6 is an alkyl radical as defined above, e.g., carboxymethylamino, 2-carboxyethylamino, 3-carboxypropylamino, and the like.

591

"Carboxyalkylaminocarbonylalkyl" refers to a radical of the formula $-R_a-C(O)-N(H)-R_b-C(O)OH$ where each R_a is independently an alkyl radical as defined above, e.g., carboxymethylaminocarbonylmethyl, 2-(carboxymethylaminocarbonyl)ethyl, 2-(2-carboxyethyl)aminocarbonyl)ethyl, 3-(2-carboxyethyl)aminocarbonyl)butyl, and the like.

5 "Carboxyalkylthioalkyl" refers to a radical of the formula $-R_a-S-R_b-C(O)OH$ where each R_a is independently an alkyl radical as defined above, e.g., carboxymethylthiomethyl, (1-carboxyethyl)thiomethyl, 2-((1-carboxypropyl)thio)ethyl, and the like.

"Carboxyalkoxyalkyl" refers to a radical of the formula $-R_a-O-R_b-C(O)OH$ where each R_a is independently an alkyl radical as defined above, e.g., 2-(carboxymethoxy)ethyl, 10 (2-carboxyethoxy)methyl, 3-(2-carboxypropoxy)propyl, and the like.

"Carboxyalkoxycarbonylalkyl" refers to a radical of the formula $-R_a-C(O)-O-R_b-C(O)OH$ where each R_a is independently an alkyl radical as defined above, e.g., carboxymethoxycarbonylmethyl, 2-(carboxymethoxycarbonyl)ethyl, 2-((2-carboxyethoxy)carbonyl)propyl, and the like.

15 "Cycloalkyl" refers to a stable 3- to 10-membered monocyclic or bicyclic radical which is saturated, and which consist solely of carbon and hydrogen atoms, e.g., cyclopropyl, cyclobutyl, cyclobutyl, cyclohexyl, decalyl and the like. Unless otherwise stated specifically in the specification, the term "cycloalkyl" is meant to include cycloalkyl radicals which are optionally substituted one or more substituents selected from the group consisting of alkyl, 20 halo, haloalkyl, cyano, nitro, tetrazolyl, $-R^8-OR^7$, $-R^8-C(O)OR^7$, $-R^8-C(O)N(R^7)_2$, $-R^8-C(O)R^7$, $-R^8-N(R^7)_2$, $-R^8-N(R^7)C(O)R^7$, $-R^8-N(R^7)C(O)OR^8$, $-R^8-N(R^7)-S(O)_2-R^7$, $-R^8-C[N(R^7)_2]-C(O)OR^7$, wherein each R^7 is hydrogen, alkyl, aryl, aralkyl, or haloalkyl, each R^8 is a bond or a straight or branched alkylene chain, and each R^9 is hydrogen, alkyl, aralkyl or haloalkyl as defined herein.

"Cycloalkylcarbonyl" refers to a radical of the formula $-C(O)-R_c$ where R_c is a cycloalkyl radical as defined above, e.g., cyclobutylcarbonyl, cyclopropylcarbonyl, and the like. For R^1 , a preferred cycloalkylcarbonyl radical is that radical wherein the R_c group is optionally substituted by a phenyl group.

"(Carboxy)(hydroxy)alkyl" refers to a radical of the formula $-R_a(OH)-C(O)OH$ wherein R_a is an alkyl radical defined above substituted by an hydroxy radical and a carboxy radical, as 30 defined herein, e.g., 1-carboxy-3-hydroxypropyl, 2-carboxy-4-hydroxybutyl, 1-carboxy-5-hydroxypent-2-yl, and the like.

"(Carboxyalkyl)(alkyl)aminocarbonylalkyl" refers to a radical of the formula $-R_a-C(O)-N(R_b)-R_c-C(O)OH$ wherein each R_a is independently an alkyl radical as defined above, and wherein the nitrogen atom is substituted by the R_b group and the $-R_c-C(O)OH$ group, e.g., (carboxyethyl)(ethyl)aminocarbonylmethyl, 2-((2-carboxyethyl)(methyl)aminocarbonyl)ethyl, and the like.

14
592

"Cyano" refers to the $-C\equiv N$ radical.

"Dialkylamino" refers to a radical of the formula $-N(R_a)_2R_b$ where each R_a is independently an alkyl radical, e.g., dimethylamino, diethylamino, methylethylamino, and the like.

5 "Dialkylaminocarbonyl" refers to a radical of the formula $-C(O)-N(R_a)_2R_b$ where each R_a is independently an alkyl radical, e.g., dimethylaminocarbonyl, diethylaminocarbonyl, methyl(ethyl)aminocarbonyl, and the like.

"Dialkylaminoalkyl" refers to a radical of the formula $-R_a-N(R_a)_2R_b$ where each R_a is independently an alkyl radical as defined above, e.g., dimethylaminomethyl,

10 2-(diethylamino)ethyl, 3-(methyl(ethyl)amino)propyl, and the like.

"Dialkylaminoalkoxy" refers to a radical of the formula $-O-R_a-N(R_a)_2R_b$ where each R_a is independently an alkyl radical as defined above, e.g., dimethylaminomethoxy, 2-(diethylamino)ethoxy, 3-(methyl(ethyl)amino)propoxy, and the like.

"Di(alkylcarbonyl)amino" refers to a radical of the formula $-N(C(O)-R_a)_2C(O)-R_b$ where
15 each R_a is independently an alkyl radical as defined above, e.g., di(acetyl)amino, di(ethylcarbonyl)amino, and the like.

"Halo" refers to bromo, chloro, iodo or fluoro.

"Haloalkyl" refers to an alkyl radical, as defined above, that is substituted by one or more halo radicals, as defined above, e.g., trifluoromethyl, difluoromethyl, trichloromethyl,

20 2,2,2-trifluoroethyl, 1-fluoromethyl-2-fluoroethyl, 3-bromo-2-fluoropropyl, 1-bromomethyl-2-bromoethyl, and the like.

"Haloalkylsulfonylaminoalkyl" refers to a radical of the formula $-R_a-N(H)-S(O)_2R_b$ where R_a is an alkyl radical as defined above and R_b is a haloalkyl radical as defined above, e.g., 2-(trifluoromethoxysulfonylamino)ethyl, 3-(trifluoromethoxysulfonylamino)propyl, and the like.

25 "Haloalkoxy" refers to a radical of the formula $-OR_b$ where R_b is an haloalkyl radical as defined above, e.g., trifluoromethoxy, difluoromethoxy, trichloromethoxy, 2,2,2-trifluoroethoxy, 1-fluoromethyl-2-fluoroethoxy, 3-bromo-2-fluoropropoxy, 1-bromomethyl-2-bromoethoxy, and the like.

"Haloalkenyloxy" refers to a radical of the formula $-OR_b$ where R_b is an haloalkenyl radical as defined above, as defined above, e.g., 1,2-difluoroethenyloxy, 3-bromo-2-fluoroprop-1-enyloxy, 1,2-dibromoethenyloxy, and the like.

"Haloalkoxycarbonyl" refers to a radical of the formula $-C(O)OR_b$ where R_b is an haloalkyl radical as defined above, e.g., trifluoromethoxycarbonyl, difluoromethoxycarbonyl, trichloromethoxycarbonyl, 2,2,2-trifluoroethoxycarbonyl, 1-fluoromethyl-2-fluoroethoxycarbonyl,
35 3-bromo-2-fluoropropoxycarbonyl, 1-bromomethyl-2-bromoethoxycarbonyl, and the like.

"Hydroxy" refers to the $-OH$ radical.

15
593

"Hydroxyalkyl" refers to a alkyl radical as defined above that is substituted by a hydroxy radical, e.g., hydroxymethyl, 2-hydroxyethyl, 2-hydroxypropyl, 3-hydroxypropyl, 4-hydroxybutyl, 3-hydroxybutyl, and the like.

"Heterocyclyl" refers to a stable 3- to 15-membered ring radical which consists of carbon atoms and from one to five heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur. For purposes of this invention, the heterocyclyl radical may be a monocyclic, bicyclic or tricyclic ring system, which may include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heterocyclyl radical may be optionally oxidized; the nitrogen atom may be optionally quaternized; and the heterocyclyl radical may be aromatic or partially or fully saturated. The heterocyclyl radical may be attached to the main structure at any heteroatom or carbon atom which results in the creation of a stable compound. Examples of such heterocyclyl radicals include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzthiazolyl, benzoxazolyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothieryl, carbazolyl, cinnolinyl, decahydroisoquinolyl, dioxolanyl, furanyl, furanonyl, isothiazolyl, imidazolyl, imidazolynyl, imidazolidinyl, isothiazolidinyl, indolyl, isoindolyl, indolynyl, isoindolynyl, indanyl, indolizynyl, isoxazolyl, isoxazolidinyl, morpholynyl, naphthyridinyl, oxadiazolyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxoazepinyl, oxazolyl, oxazolidinyl, oxiranyl, piperidinyl, piperazinyl, 4-piperidonyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinazolinyl, quinoxalinyl, quinolinyl, quinuclidinyl, isoquinolinyl, thiazolyl, thiazolidinyl, thiadiazolyl, triazolyl, tetrazolyl, tetrahydrofuryl, triazinyl, tetrahydropyranyl, thienyl, thiamorpholinyl, thiamorpholinyl sulfoxide, and thiamorpholinyl sulfone. Unless stated otherwise specifically in the specification, the term "heterocyclyl" is meant to include heterocyclyl radicals as defined above which are optionally substituted one or more substituents selected from the group consisting of alkyl, halo, haloalkyl, cyano, nitro, tetrazolyl, $-R^8-OR^7$, $-R^8-C(O)OR^7$, $-R^8-C(O)N(R^7)_2$, $-R^8-C(O)R^7$, $-R^8-N(R^7)_2$, $-R^8-N(R^7)C(O)R^7$, $-R^8-N(R^7)C(O)OR^8$, $-R^8-N(R^7)-S(O)_2R^7$, $-R^8-C[N(R^7)_2]-C(O)OR^7$, wherein each R^7 is hydrogen, alkyl, aryl, aralkyl, or haloalkyl, each R^8 is a bond or a straight or branched alkylene chain, and each R^9 is hydrogen, alkyl, aralkyl or haloalkyl as defined herein.

"Heteroaryl" refers to a heterocyclyl radical as defined above wherein the heterocyclyl radical is partially or fully aromatic.

"Heterocyclylalkyl" refers to a radical of the formula $-R_a-R_h$ where R_a is an alkyl radical as defined above and R_h is an heterocyclyl radical as defined above, e.g., imidazol-3-ylmethyl, triazol-3-ylmethyl, 2-tetrazolylethyl, and the like. For R^2 , preferred heterocyclylalkylradicals are

those radicals where R_n is selected from the group consisting of imidazolyl (optionally substituted by carboxyalkyl), indolyl, triazolyl and tetrazolyl.

"Heterocyclialkoxy" refers to a radical of the formula $-O-R_a-R_n$ where R_a is an alkyl radical as defined above and R_n is a heterocyclyl radical as defined above, e.g.,

5 1-tetrazolyloxy, oxiranylmethoxy, and the like. For R^3 , preferred heterocyclialkoxy radicals are those radicals where R_n is selected from the group consisting of oxiranyl or tetrazolyl. For R^4 , preferred heterocyclialkoxy radicals are those radicals where R_n is pyrrolidinyl (optionally substituted by one or more substituents independently selected from the group consisting of hydroxy and carboxy).

10 "Heteroarylalkoxy" refers to a heterocyclialkoxy radical as defined above wherein the heterocyclyl radical is partially or fully aromatic.

"Heterocyclycarbonyl" refers to a radical of the formula $-C(O)-R_n$ where R_n is a heterocyclyl radical as defined above, e.g., furan-2-ylcarbonyl, piperidin-4-ylcarbonyl, thien-2-ylcarbonyl, morpholin-4-ylcarbonyl, and the like. For R^1 , preferred heterocyclycarbonyl
15 radicals are those radicals wherein R_n is selected from the group consisting of furanyl, thienyl, piperidinyl, morpholinyl and pyridinyl (optionally substituted by one or more substituents independently selected from the group consisting of hydroxy, halo and alkyl).

"Monoalkylamino" refers to a radical of the formula $-N(H)-R_a$ where R_a is an alkyl radical as defined above, e.g., methylamino, ethylamino, *n*-propylamino, and the like.

20 "Monoalkylaminocarbonyl" refers to a radical of the formula $-C(O)-N(H)-R_a$ where R_a is an alkyl radical as defined above, e.g., methylaminocarbonyl, ethylaminocarbonyl, *n*-propylaminocarbonyl, and the like.

"Mammal" includes humans and domesticated animals, such as cats, dogs, swine, cattle, sheep, goats, horses, rabbits, and the like.

25 "Nitro" refers to the $-NO_2$ radical.

As used herein, "methods known to one of ordinary skill in the art" may be identified though various reference books and databases. Suitable reference books and treatise that detail the synthesis of reactants useful in the preparation of compounds of the present invention, or provide references to articles that describe the preparation, include for example, "Synthetic
30 Organic Chemistry", John Wiley & Sons, Inc., New York; S. R. Sandler et al., "Organic Functional Group Preparations," 2nd Ed., Academic Press, New York, 1983; H. O. House, "Modern Synthetic Reactions", 2nd Ed., W. A. Benjamin, Inc. Menlo Park, Calif. 1972; T. L. Glöckner, "Heterocyclic Chemistry", 2nd Ed., John Wiley & Sons, New York, 1992; J. March, "Advanced Organic Chemistry: Reactions, Mechanisms and Structure", 4th Ed., Wiley-Interscience, New
35 York, 1992. Specific and analogous reactants may also be identified through the indices of known chemicals prepared by the Chemical Abstract Service of the American Chemical Society.

595

which are available in most public and university libraries, as well as through on-line databases (the American Chemical Society, Washington, D.C. may be contacted for more details).

Chemicals that are known but not commercially available in catalogs may be prepared by custom chemical synthesis houses, where many of the standard chemical supply houses (e.g., those listed above) provide custom synthesis services.

"Prodrugs" is meant to indicate a compound that may be converted under physiological conditions or by solvolysis to a biologically active compound of the invention. Thus, the term "prodrug" refers to a metabolic precursor of a compound of the invention that is pharmaceutically acceptable. A prodrug may be inactive when administered to a subject in need thereof, but is converted in vivo to an active compound of the invention. Prodrugs are typically rapidly transformed in vivo to yield the parent compound of the invention, for example, by hydrolysis in blood. The prodrug compound often offers advantages of solubility, tissue compatibility or delayed release in a mammalian organism (see, Bundgard, H., Design of Prodrugs (1985), pp. 7-9, 21-24 (Elsevier, Amsterdam).

A discussion of prodrugs is provided in Higuchi, T., et al., "Pro-drugs as Novel Delivery Systems," A.C.S. Symposium Series, Vol. 14, and in Bioreversible Carriers In Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated in full by reference herein.

The term "prodrug" is also meant to include any covalently bonded carriers which release the active compound of the invention in vivo when such prodrug is administered to a mammalian subject. Prodrugs of a compound of the invention may be prepared by modifying functional groups present in the compound of the invention in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compound of the invention. Prodrugs include compounds of the invention wherein a hydroxy, amino or mercapto group is bonded to any group that, when the prodrug of the compound of the invention is administered to a mammalian subject, cleaves to form a free hydroxy, free amino or free mercapto group, respectively. Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups in the compounds of the invention and the like.

"Stable compound" and "stable structure" are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.

"Optional" or "optionally" means that the subsequently described event or circumstances may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. For example, "optionally substituted aryl" means that the aryl radical may or may not be substituted and that the description includes both substituted aryl radicals and aryl radicals having no substitution.

18
596

"Pharmaceutically acceptable salt" includes both acid and base addition salts.

5 "Pharmaceutically acceptable acid addition salt" refers to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise undesirable, and which are formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, *p*-toluenesulfonic acid, salicylic acid, and the like.

10 "Pharmaceutically acceptable base addition salt" refers to those salts which retain the biological effectiveness and properties of the free acids, which are not biologically or otherwise undesirable. These salts are prepared from addition of an inorganic base or an organic base to the free acid. Salts derived from inorganic bases include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Preferred inorganic salts are the ammonium, sodium, potassium, calcium, and
15 magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine,
20 methylglucamine, theobromine, purines, piperazine, piperidine, *N*-ethylpiperidine, polyamine resins and the like. Particularly preferred organic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline and caffeine.

25 "Therapeutically effective amount" refers to that amount of a compound of the invention which, when administered to a human in need thereof, is sufficient to effect treatment, as defined below, for a disease-state characterized by thrombotic activity. The amount of a compound of the invention which constitutes a "therapeutically effective amount" will vary depending on the compound, the condition and its severity, and the age of the human to be treated, but can be determined routinely by one of ordinary skill in the art having regard to his own knowledge and to
30 this disclosure.

"Treating" or "treatment" as used herein covers the treatment of a disease-state in a mammal, preferably a human, which disease-state is characterized by thrombotic activity, and includes:


- 35 (i) preventing the condition from occurring in a human, in particular, when such human is predisposed to the condition but has not yet been diagnosed as having it;
- (ii) inhibiting the condition, *i.e.*, arresting its development; or

19
597

(iii) relieving the condition, *i.e.*, causing regression of the condition.


In the above definitions, the use of parentheses in a formula is used to conserve space.

Accordingly, the use of parenthesis in a formula indicates that the group enclosed within the parentheses is attached directly to the atom preceding the parenthesis. For example, the term
 5 "(carboxy)(hydroxy)alkyl" is defined as a radical of the formula $-R_a(OH)-C(O)OH$. This formula can be drawn as follows:



It will also be appreciated that certain compounds of the invention or pharmaceutically acceptable salts thereof, may exist in, and be isolated in, isomeric forms, including tautomeric
 10 forms, *cis*- or *trans*-isomers. In addition, certain compounds of the invention or pharmaceutically acceptable salts thereof may contain one or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, such as (*R*)- or (*S*)-. The present invention is meant to include all such possible isomers, as well as their racemic and optically pure forms. Optically active (*R*)-
 15 and (*S*)- isomers may be prepared using chiral synthons or chiral reagents by methods known to those of ordinary skill in the art, or resolved using conventional techniques. When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both *E* and *Z* geometric isomers.

20 The nomenclature used herein is a modified form of the I.U.P.A.C. nomenclature system wherein the compounds of the invention are named herein as derivatives of the quinoline moiety.



20
598

is named herein as 2-[1S-(4-(methoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-phenyl-1-carboxy)methoxyquinoline.

Unless otherwise indicated, compound names are intended to include any single stereoisomer, enantiomer, racemate or mixtures thereof.

5

Utility of the Compounds of the Invention

The compounds of the invention act as reversible, selective antagonists of the platelet ADP receptor, P2Y_{AC}. Accordingly, the compounds are useful in treating disease-states which are characterized as having thrombotic activity. In particular, the compounds are useful as

10 Inhibitors of platelet activation, aggregation and degranulation, anti-thrombotic agents or in the treatment or prophylaxis of unstable angina, coronary angioplasty (PTCA), myocardial infarction, perithrombolysis, primary arterial thrombotic complications of atherosclerosis such as thrombotic or embolic stroke, peripheral vascular disease, myocardial infarction with or without thrombolysis, arterial complications due to interventions in atherosclerotic disease such

15 as angioplasty, endarterectomy, stent placement, coronary and other vascular graft surgery, thrombotic complications of surgical or mechanical damage such as tissue salvage following accidental or surgical trauma, reconstructive surgery including skin and muscle flaps, conditions with a diffuse thrombotic/platelet consumption component such as disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, hemolytic uremic syndrome,

20 thrombotic complications of septicemia, adult respiratory distress syndrome, anti-phospholipid syndrome, heparin-induced thrombocytopenia and pre-eclampsia/eclampsia, or venous thrombosis such as deep vein thrombosis, venoocclusive disease, hematological conditions such as myeloproliferative disease, including thrombocythemia; or in the prevention of mechanically-induced platelet activation *in vivo*, such as cardiopulmonary bypass (prevention

25 of microthromboembolism), mechanically-induced platelet activation *in vitro*, such as use in the preservation of blood products, e.g. platelet concentrates, or shunt occlusion such as in renal dialysis and plasmapheresis, thrombosis secondary to vascular damage/inflammation such as vasculitis, arteritis, glomerulonephritis, inflammatory bowel disease and organ graft rejection, conditions such as migraine, Raynaud's phenomenon, atheromatous plaque

30 formation/progression, vascular stenosis/restenosis and asthma, in which platelet-derived factors are implicated in the disease process.

The compounds of formula (I) are also useful as standard or reference compounds, for example, as a quality standard or control, in tests or assays involving the inhibition of the platelet ADP receptor, P2Y_{AC}. Such compounds may be provided in a commercial kit, for

35 example, for use in pharmaceutical research involving the platelet ADP receptor, P2Y_{AC}. For example, a compound of formula (I) could be used as a reference in an assay to compare its

21
599

known activity to a compound with an unknown activity. This would ensure that the experimenter that the assay was being performed properly and provide a basis for comparison, especially if the test compound was a derivative of the reference compound. When developing new assays or protocols, compounds of formula (I) could be used to test their effectiveness.

5

Testing of the Compounds of the Invention

The ability of the compounds to inhibit the platelet adenosine diphosphate receptor known as the P2Y_{AC} receptor, and its biological effects may be tested in a variety of *in vitro*, *ex vivo* and *in vivo* assays. For example, the ability of the compounds to bind to the P2Y_{AC} receptor may be measured by methods similar to those described in Gachet, C. *et al.*, *Br. J. Haematol.* (1995), Vol. 91, pp. 434-444 and Mills, D.C.B., *Thromb. Haemost.* (1996), Vol. 76, No. 6, pp. 835-856, and by the method described below in Example 4. The ability of the compounds to inhibit ADP-induced aggregation of platelets may be measured by methods similar to those described in R.G. Humphries, *Br. J. Pharm.* (1995), Vol. 115, pp. 1110-1116 and *Methods in Enzymology*, Vol. 169, p. 3 and by the method described below in Example 5. The ability of the compounds to inhibit thrombus formation *in vivo* or *ex vivo* may be measured by methods similar to those described in J.M. Herbert, *Cardiovasc. Drug Reviews* (1993), Vol. 11, No. 2, pp. 180-198 or J.D. Folts, *Circulation* (1976), Vol. 54, No. 3, p. 365, or by the methods described below in Example 6. The results of these assays clearly demonstrate that the compounds of the invention are functional antagonists of the platelet adenosine diphosphate receptor and are therefore useful in inhibiting platelet aggregation and thrombus formation.

Administration of the Compounds of the Invention

Administration of the compounds of the invention, or their pharmaceutically acceptable salts, in pure form or in an appropriate pharmaceutical composition, can be carried out via any of the accepted modes of administration or agents for serving similar utilities. Thus, administration can be, for example, orally, nasally, parenterally, topically, transdermally, or rectally, in the form of solid, semi-solid, lyophilized powder, or liquid dosage forms, such as for example, tablets, suppositories, pills, soft elastic and hard gelatin capsules, powders, solutions, suspensions, or aerosols, or the like, preferably in unit dosage forms suitable for simple administration of precise dosages. The compositions will include a conventional pharmaceutical carrier or excipient and a compound of the invention as the/an active agent, and, in addition, may include other medicinal agents, pharmaceutical agents, carriers, adjuvants, etc.

Generally, depending on the intended mode of administration, the pharmaceutically acceptable compositions will contain about 1% to about 99% by weight of a compound(s) of the

660

invention, or a pharmaceutically acceptable salt thereof, and 99% to 1% by weight of a suitable pharmaceutical excipient. Preferably, the composition will be about 5% to 75% by weight of a compound(s) of the invention, or a pharmaceutically acceptable salt thereof, with the rest being suitable pharmaceutical excipients.

5 The preferred route of administration is oral, using a convenient daily dosage regimen which can be adjusted according to the degree of severity of the disease-state to be treated. For such oral administration, a pharmaceutically acceptable composition containing a compound(s) of the invention, or a pharmaceutically acceptable salt thereof, is formed by the incorporation of any of the normally employed excipients, such as, for example, pharmaceutical grades of mannitol,
10 lactose, starch, pregelatinized starch, magnesium stearate, sodium saccharine, talcum, cellulose ether derivatives, glucose, gelatin, sucrose, citrate, propyl gallate, and the like. Such compositions take the form of solutions, suspensions, tablets, pills, capsules, powders, sustained release formulations and the like.

15 Preferably such compositions will take the form of capsule, caplet or tablet and therefore will also contain a diluent such as lactose, sucrose, dicalcium phosphate, and the like; a disintegrant such as croscarmellose sodium or derivatives thereof; a lubricant such as magnesium stearate and the like; and a binder such as a starch, gum acacia, polyvinylpyrrolidone, gelatin, cellulose ether derivatives, and the like.

20 The compounds of the invention, or their pharmaceutically acceptable salts, may also be formulated into a suppository using, for example, about 0.5% to about 50% active ingredient disposed in a carrier that slowly dissolves within the body, e.g., polyoxyethylene glycols and polyethylene glycols (PEG), e.g., PEG 1000 (96%) and PEG 4000 (4%).

25 Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, etc., a compound(s) of the invention (about 0.5% to about 20%), or a pharmaceutically acceptable salt thereof, and optional pharmaceutical adjuvants in a carrier, such as, for example, water, saline, aqueous dextrose, glycerol, ethanol and the like, to thereby form a solution or suspension.

30 If desired, a pharmaceutical composition of the invention may also contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, antioxidants, and the like, such as, for example, citric acid, sorbitan monolaurate, triethanolamine oleate, butylated hydroxytoluene, etc.

35 Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see *Remington's Pharmaceutical Sciences*, 18th Ed., (Mack Publishing Company, Easton, Pennsylvania, 1990). The composition to be administered will, in any event, contain a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, for treatment of a disease-state characterized by

601

thrombotic activity in accordance with the teachings of this invention.

The compounds of the invention, or their pharmaceutically acceptable salts, are administered in a therapeutically effective amount which will vary depending upon a variety of factors including the activity of the specific compound employed; the metabolic stability and length of action of the compound; the age, body weight, general health, sex, and diet of the patient; the mode and time of administration; the rate of excretion; the drug combination; the severity of the particular disease-states; and the host undergoing therapy. Generally, a therapeutically effective daily dose is from about 0.14 mg to about 14.3 mg/kg of body weight per day of a compound of the invention, or a pharmaceutically acceptable salt thereof; preferably, from about 0.7 mg to about 10 mg/kg of body weight per day, and most preferably, from about 1.4 mg to about 7.2 mg/kg of body weight per day. For example, for administration to a 70 kg person, the dosage range would be from about 10 mg to about 1.0 gram per day of a compound of the invention, or a pharmaceutically acceptable salt thereof, preferably from about 50 mg to about 700 mg per day, and most preferably from about 100 mg to about 500 mg per day.

Preferred Embodiments

Of the compounds of the invention as set forth above in the Summary of the Invention, several groups of compounds are particularly preferred.

Of the compounds of formula (I) as set forth above in the Summary of the Invention, a preferred group of compounds is that group of compounds wherein:

m is 1;

n is 1 or 2;

R¹ is hydrogen, aryl, aralkyl, or alkoxycarbonyl;

R² is hydrogen, carboxyalkyl, alkoxycarbonylalkyl or aralkoxycarbonylalkyl;

R³ is aryl optionally substituted by one or more substituents selected from the group consisting of alkyl, halo, haloalkyl, cyano, nitro, -R⁸-OR⁷, -R⁸-C(O)OR⁷, -R⁸-C(O)N(R⁷)₂, -R⁸-C(O)R⁷, -R⁸-N(R⁷)₂, -R⁸-N(R⁷)C(O)R⁷, and -R⁸-N(R⁷)C(O)OR⁸;

each R⁴ is independently selected from the group consisting of hydrogen, alkyl, alkoxy, aralkoxy, halo, haloalkyl, haloalkoxy, hydroxy, cyano, alkylthio, carboxy, alkoxycarbonyl, aminocarbonyl, alkylcarbonyl, nitro, amino, monoalkylamino, dialkylamino, carboxyalkylamino, alkylcarbonylamino, di(alkylcarbonyl)amino, hydroxyalkyl, dialkylaminoalkyl, carboxyalkoxy, alkoxycarbonylalkoxy, dialkylaminoalkoxy, and heterocyclalkoxy;

R⁵ is hydrogen;

R⁶ is hydrogen or alkyl;

each R⁷ is hydrogen, alkyl, aryl, aralkyl, or haloalkyl;

each R^8 is a bond or a straight or branched alkylene chain; and
 R^9 is hydrogen, alkyl, aralkyl or haloalkyl.

Of this preferred group of compounds, a preferred subgroup of compounds is that subgroup of compounds wherein:

602

- 5 m is 1;
 n is 1 or 2;
 R^1 is hydrogen or alkoxycarbonyl;
 R^2 is hydrogen, carboxyalkyl, alkoxycarbonylalkyl or aralkoxycarbonylalkyl;
 R^3 is aryl optionally substituted by one or more substituents selected from the group consisting
 10 of carboxy or alkoxycarbonyl;
 each R^4 is independently selected from the group consisting of hydrogen, alkyl, halo, or haloalkyl;
 R^5 is hydrogen; and
 R^6 is hydrogen.

- 15 Of this preferred subgroup of compounds, a preferred compound is 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(3-carboxy)phenylquinoline in trifluoroacetic acid.

Another preferred group of compounds of formula (I) is that group of compounds wherein:

- 20 m is 1;
 n is 1 or 2;
 R^1 is hydrogen, aryl, aralkyl, or alkoxycarbonyl;
 R^2 is hydrogen, carboxyalkyl, alkoxycarbonylalkyl or aralkoxycarbonylalkyl;
 R^3 is aryloxy optionally substituted by one or more substituents selected from the group
 25 consisting of alkyl, halo, haloalkyl, cyano, nitro, tetrazolyl, $-R^5-OR^7$, $-R^5-C(O)OR^7$,
 $-R^5-C(O)N(R^7)_2$, $-R^5-C(O)R^7$, $-R^5-N(R^7)_2$, $-R^5-N(R^7)C(O)R^7$, $-R^5-N(R^7)C(O)OR^8$,
 $-R^5-N(R^7)-S(O)_2R^7$, and $-R^5-C[N(R^7)_2]-C(O)OR^7$;
 each R^4 is independently selected from the group consisting of hydrogen, alkyl, alkoxy,
 aralkoxy, halo, haloalkyl, haloalkoxy, hydroxy, cyano, alkylthio, carboxy, alkoxycarbonyl,
 30 aminocarbonyl, alkylcarbonyl, nitro, amino, monoalkylamino, dialkylamino,
 carboxyalkylamino, alkylcarbonylamino, di(alkylcarbonyl)amino, hydroxyalkyl,
 dialkylaminoalkyl, carboxyalkoxy, alkoxycarbonylalkoxy, dialkylaminoalkoxy, and
 heterocyclialkoxyl;
 R^5 is selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, aralkyl, carboxy,
 35 alkoxycarbonyl, aralkoxycarbonyl, carboxyalkyl, and alkoxycarbonylalkyl;
 R^6 is hydrogen, alkyl, carboxyalkyl, or alkoxycarbonylalkyl;

25

603

each R^7 is hydrogen, alkyl, aryl, aralkyl, or haloalkyl;

each R^8 is a bond or a straight or branched alkylene chain; and

R^9 is hydrogen, alkyl, aralkyl or haloalkyl.

Of this preferred group of compounds, a preferred subgroup of compounds is that

5 subgroup of compounds wherein:

m is 1;

n is 1 or 2;

R^1 is hydrogen or alkoxy carbonyl;

R^2 is hydrogen, carboxyalkyl, alkoxy carbonylalkyl or aralkoxy carbonylalkyl;

10 R^3 is aryloxy optionally substituted by one or more substituents selected from the group consisting of alkyl, tetrazolyl, $-R^5-C(O)OR^7$, $-R^5-N(R^7)_2$, $-R^5-N(R^7)-S(O)_2-R^7$, and $-R^5-C[N(R^7)_2]-C(O)OR^7$;

each R^4 is independently selected from the group consisting of hydrogen, alkyl, halo, or haloalkyl;

15 R^5 is hydrogen;

R^6 is hydrogen;

each R^7 is hydrogen, alkyl, aryl, aralkyl, or haloalkyl; and

each R^8 is a bond or a straight or branched alkylene chain.

Of this preferred subgroup of compounds, preferred compounds are selected from the

20 group consisting of the following:

2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(3-carboxy)phenoxyquinoline in 2,2,2-trifluoro-1,1-ethanediol;

2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(2-carboxy)phenoxyquinoline in 2,2,2-trifluoro-1,1-ethanediol;

25 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(2-amino-5-carboxy)phenoxyquinoline in 2,2,2-trifluoro-1,1-ethanediol;

2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(4-carboxy)phenoxyquinoline in 2,2,2-trifluoro-1,1-ethanediol;

30 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(3-carboxymethyl)phenoxyquinoline in trifluoroacetic acid;

2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(3-(1-amino-1-carboxy)methyl)phenoxyquinoline in trifluoroacetic acid;

2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(3-(2-amino-2-carboxy)ethyl)phenoxyquinoline in trifluoroacetic acid;

35 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(2-methyl-5-carboxy)phenoxyquinoline in trifluoroacetic acid;

26

- 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(5-carboxy-
2-diethylaminomethyl)phenoxyquinoline in trifluoroacetic acid; 604
- 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(3-tetrazol-
5-yl)phenoxyquinoline in 2,2,2-trifluoro-1,1-ethanediol;
- 5 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(3-
trifluoromethylsulfonylamino)phenoxyquinoline in trifluoroacetic acid; and
- 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-
(3-carboxy)phenoxyquinoline in trifluoroacetic acid.

Another preferred group of compounds of formula (I) is that group of compounds

10 wherein:

m is 1;

n is 1 or 2;

R¹ is hydrogen, aryl, aralkyl, or alkoxycarbonyl;

R² is hydrogen, carboxyalkyl, alkoxycarbonylalkyl or aralkoxycarbonylalkyl;

- 15 R³ is aralkyl wherein the alkyl radical in the aralkyl substituent is optionally substituted by one or
more substituents selected from the group consisting of halo, cyano, nitro, -R⁸-OR⁷,
-R⁸-C(O)OR⁷, -R⁸-C(O)N(R⁷)₂, -R⁸-C(O)R⁷, -R⁸-N(R⁷)₂, -R⁸-N(R⁷)C(O)R⁷, and
-R⁸-N(R⁷)C(O)OR⁸, and wherein the aryl radical in the aralkyl substituent is
independently optionally substituted by one or more substituents selected from the
20 group consisting of alkyl, halo, haloalkyl, cyano, nitro, tetrazolyl, -R⁸-OR⁷, -R⁸-C(O)OR⁷,
-R⁸-C(O)N(R⁷)₂, -R⁸-C(O)R⁷, -R⁸-N(R⁷)₂, -R⁸-N(R⁷)C(O)R⁷, -R⁸-N(R⁷)C(O)OR⁸,
-R⁸-N(R⁷)-S(O)₂-R⁷, and -R⁸-C[N(R⁷)₂]-C(O)OR⁷;

each R⁴ is independently selected from the group consisting of hydrogen, alkyl, alkoxy,
aralkoxy, halo, haloalkyl, haloalkoxy, hydroxy, cyano, alkylthio, carboxy, alkoxycarbonyl,
25 aminocarbonyl, alkylcarbonyl, nitro, amino, monoalkylamino, dialkylamino,
carboxyalkylamino, alkylcarbonylamino, di(alkylcarbonyl)amino, hydroxyalkyl,
dialkylaminoalkyl, carboxyalkoxy, alkoxycarbonylalkoxy, dialkylaminoalkoxy, and
heterocyclalkoxy;

R⁵ is selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, aralkyl, carboxy,
30 alkoxycarbonyl, aralkoxycarbonyl, carboxyalkyl, and alkoxycarbonylalkyl;

R⁶ is hydrogen, alkyl, carboxyalkyl, or alkoxycarbonylalkyl;

each R⁷ is hydrogen, alkyl, aryl, aralkyl, or haloalkyl;

each R⁸ is a bond or a straight or branched alkylene chain; and

R⁹ is hydrogen, alkyl, aralkyl or haloalkyl.

- 35 Another preferred group of compounds of formula (I) is that group of compounds
wherein:

EF
605

m is 1;

n is 1 or 2;

R¹ is hydrogen, aryl, aralkyl, or alkoxycarbonyl;

R² is hydrogen, carboxyalkyl, alkoxycarbonylalkyl or aralkoxycarbonylalkyl;

- 5 R³ is aralkoxy wherein the alkyl radical in the aralkyl substituent is not optionally substituted and wherein the aryl radical in the aralkoxy substituent is optionally substituted by one or more substituents selected from the group consisting of alkyl, halo, haloalkyl, cyano, nitro, tetrazolyl, -R⁸-OR⁷, -R⁸-C(O)OR⁷, -R⁸-C(O)N(R⁷)₂, -R⁸-C(O)R⁷, -R⁸-N(R⁷)₂, -R⁸-N(R⁷)C(O)R⁷, -R⁸-N(R⁷)C(O)OR⁸, -R⁸-N(R⁷)-S(O)₂-R⁷, and -R⁸-C[N(R⁷)₂]-C(O)OR⁷;

- 10 each R⁴ is independently selected from the group consisting of hydrogen, alkyl, alkoxy, aralkoxy, halo, haloalkyl, haloalkoxy, hydroxy, cyano, alkylthio, carboxy, alkoxycarbonyl, aminocarbonyl, alkylcarbonyl, nitro, amino, monoalkylamino, dialkylamino, carboxyalkylamino, alkylcarbonylamino, di(alkylcarbonyl)amino, hydroxyalkyl, dialkylaminoalkyl, carboxyalkoxy, alkoxycarbonylalkoxy, dialkylaminoalkoxy, and
15 heterocyclalkoxy;

R⁵ is selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, aralkyl, carboxy, alkoxycarbonyl, aralkoxycarbonyl, carboxyalkyl, and alkoxycarbonylalkyl;

R⁶ is hydrogen, alkyl, carboxyalkyl, or alkoxycarbonylalkyl;

each R⁷ is hydrogen, alkyl, aryl, aralkyl, or haloalkyl;

- 20 each R⁸ is a bond or a straight or branched alkylene chain; and

R⁹ is hydrogen, alkyl, aralkyl or haloalkyl.

Of this preferred group of compounds, a preferred subgroup of compounds is that subgroup of compounds wherein:

m is 1;

- 25 n is 1 or 2;

R¹ is hydrogen, aryl, aralkyl, or alkoxycarbonyl;

R² is hydrogen, carboxyalkyl, alkoxycarbonylalkyl or aralkoxycarbonylalkyl;

R³ is aralkoxy wherein the aryl radical in the aralkoxy substituent is optionally substituted by one or more substituents selected from the group consisting of alkyl, halo, haloalkyl,
30 -R⁸-OR⁷, -R⁸-C(O)OR⁷, -R⁸-C(O)N(R⁷)₂, and -R⁸-N(R⁷)₂;

each R⁴ is independently selected from the group consisting of hydrogen, alkyl, alkoxy, halo, or haloalkyl;

R⁵ is hydrogen;

R⁶ is hydrogen;

- 35 each R⁷ is hydrogen, alkyl, aryl, aralkyl, or haloalkyl; and

each R⁸ is a bond or a straight or branched alkylene chain.

425
606

Of this preferred subgroup of compounds, preferred compounds are selected from the group consisting of the following:

- 2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-benzyloxyquinoline;
 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-benzyloxycarbonylpropyl]aminocarbonyl-4-
 5 benzyloxyquinoline;
 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-
 benzyloxyquinoline;
 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-benzyloxycarbonylpropyl]aminocarbonyl-4-
 benzyloxy-8-methoxyquinoline;
 10 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-benzyloxy-
 8-methoxyquinoline;
 2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(4-
 methoxycarbonyl)benzyloxyquinoline;
 2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(4-
 15 carboxy)benzyloxyquinoline;
 2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(3-
 methoxycarbonyl)benzyloxyquinoline;
 2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(3-
 carboxy)benzyloxyquinoline;
 20 2-[1S-(4-(3-methylphenyl)piperazin-1-yl)carbonyl-3-(1,1-
 dimethylethoxycarbonyl)propyl]aminocarbonyl-4-benzyloxyquinoline; and
 2-[1S-(4-(3-methylphenyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-
 benzyloxyquinoline.

Another preferred group of compounds of formula (I) is that group of compounds

25 wherein:

m is 1;

n is 1 or 2;

R¹ is hydrogen, aryl, aralkyl, or alkoxycarbonyl;

R² is hydrogen, carboxyalkyl, alkoxycarbonylalkyl or aralkoxycarbonylalkyl;

30 R³ is aralkoxy wherein the alkyl radical in the aralkoxy substituent is substituted by one or more
 substituents selected from the group consisting of halo, cyano, nitro, -R⁶-OR⁷,
 -R⁶-C(O)OR⁷, -R⁶-C(O)N(R⁷)₂, -R⁶-C(O)R⁷, -R⁶-N(R⁷)₂, -R⁶-N(R⁷)C(O)R⁷, and
 -R⁶-N(R⁷)C(O)OR⁸), and wherein the aryl radical in the aralkoxy substituent is optionally
 substituted by one or more substituents selected from the group consisting of alkyl,
 35 halo, haloalkyl, cyano, nitro, tetrazolyl, -R⁶-OR⁷, -R⁶-C(O)OR⁷, -R⁶-C(O)N(R⁷)₂.

$-R^5-C(O)R^7$, $-R^5-N(R^7)_2$, $-R^5-N(R^7)C(O)R^7$, $-R^5-N(R^7)C(O)OR^9$, $-R^5-N(R^7)-S(O)_2-R^7$, and $-R^5-C[N(R^7)_2]-C(O)OR^7$; 607

each R^4 is independently selected from the group consisting of hydrogen, alkyl, alkoxy, aralkoxy, halo, haloalkyl, haloalkoxy, hydroxy, cyano, alkylthio, carboxy, alkoxycarbonyl, aminocarbonyl, alkylcarbonyl, nitro, amino, monoalkylamino, dialkylamino, carboxyalkylamino, alkylcarbonylamino, di(alkylcarbonyl)amino, hydroxyalkyl, dialkylaminoalkyl, carboxyalkoxy, alkoxycarbonylalkoxy, dialkylaminoalkoxy, and heterocyclalkoxy;

R^5 is selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, aralkyl, carboxy, alkoxycarbonyl, aralkoxycarbonyl, carboxyalkyl, and alkoxycarbonylalkyl;

R^6 is hydrogen, alkyl, carboxyalkyl, or alkoxycarbonylalkyl;

each R^7 is hydrogen, alkyl, aryl, aralkyl, or haloalkyl;

each R^8 is a bond or a straight or branched alkylene chain; and

R^9 is hydrogen, alkyl, aralkyl or haloalkyl.

Of this preferred group of compounds, a preferred subgroup of compounds is that subgroup of compounds wherein:

m is 1;

n is 1 or 2;

R^1 is hydrogen, aryl, aralkyl, or alkoxycarbonyl;

R^2 is hydrogen, carboxyalkyl, alkoxycarbonylalkyl or aralkoxycarbonylalkyl;

R^3 is aralkoxy wherein the alkyl radical in the aralkoxy substituent is substituted by

$-R^5-C(O)OR^7$, and wherein the aryl radical in the aralkoxy substituent is optionally substituted by one or more substituents selected from the group consisting of halo and $-R^5-OR^7$;

each R^4 is independently selected from the group consisting of hydrogen, alkyl, alkoxy, halo, haloalkyl, amino, monoalkylamino, or dialkylamino;

R^5 is hydrogen;

R^6 is hydrogen;

each R^7 is hydrogen, alkyl, aryl, aralkyl, or haloalkyl; and

each R^8 is a bond or a straight or branched alkylene chain.

Of this preferred subgroup of compounds, preferred compounds are selected from the group consisting of the following:

2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-4-(1-phenyl-1-methoxycarbonyl)methoxyquinoline;

20

608

- 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(1-phenyl-1-methoxycarbonyl)methoxyquinoline;
- 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(1-phenyl-1-carboxy)methoxyquinoline;
- 5 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-phenyl-1-carboxy)methoxyquinoline;
- 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-phenyl-1-carboxy)methoxyquinoline;
- 10 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-chloro-4-(1-carboxy-1-phenyl)methoxyquinoline in trifluoroacetic acid;
- 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-naphth-1-yl-1-carboxy)methoxyquinoline;
- 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-chloro-8-fluoro-4-(1-methoxycarbonyl-1-phenyl)methoxyquinoline in acetic acid;
- 15 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-chloro-8-fluoro-4-(1-carboxy-1-phenyl)methoxyquinoline in acetic acid;
- 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-6-fluoro-4-(1-carboxy-1-(2-fluoro)phenyl)methoxyquinoline in trifluoroacetic acid;
- 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-ethoxycarbonyl-1-phenyl)methoxyquinoline in trifluoroacetic acid;
- 20 2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-phenyl-1-carboxy)methoxyquinoline;
- 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-6-fluoro-4-(1-carboxy-1-(4-chloro)phenyl)methoxyquinoline in trifluoroacetic acid;
- 25 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-6-fluoro-4-(1-carboxy-1-(3-methoxy)phenyl)methoxyquinoline in trifluoroacetic acid;
- 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6,8-difluoro-4-(1-carboxy-1-phenyl)methoxyquinoline in trifluoroacetic acid;
- 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-dimethylamino-4-(1-phenyl-1-carboxy)methoxyquinoline;
- 30 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-chloro-6-methyl-4-(1-phenyl-1-carboxy)methoxyquinoline in trifluoroacetic acid;
- 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-6-chloro-4-(1-phenyl-1-carboxy)methoxyquinoline in trifluoroacetic acid;

609

2-[1S-(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)carbonyl-3-

methoxycarbonylpropyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-phenyl-1-carboxy)methoxyquinoline;

2-[1S-(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-phenyl-1-carboxy)methoxyquinoline;

2-[1S-(4-(methoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-phenyl-1-carboxy)methoxyquinoline in trifluoroacetic acid;

2-[1S-(4-(1,1-dimethylethylaminocarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-phenyl-1-carboxy)methoxyquinoline in trifluoroacetic acid;

2-[1S-(4-(furan-2-ylcarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-phenyl-1-carboxy)methoxyquinoline in trifluoroacetic acid;

2-[1S-(4-(3-methylphenyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-phenyl-1-carboxy)methoxyquinoline;

2-[1S-(4-(3-methylphenyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-phenyl-1-carboxy)methoxyquinoline in trifluoroacetic acid;

2-[1S-(4-(phenyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-phenyl-1-carboxy)methoxyquinoline; and

2-[1S-(4-(phenyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-phenyl-1-carboxy)methoxyquinoline in trifluoroacetic acid.

Of the compounds of formula (II) as set forth above in the Summary of the Invention, a preferred group of compounds is that group of compounds wherein:

m is 1;

n is 1 or 2;

R¹ is hydrogen, aryl, aralkyl, or alkoxycarbonyl;

R² is hydrogen, carboxyalkyl, alkoxycarbonylalkyl or aralkoxycarbonylalkyl;

R³ is heteroaryl optionally substituted by one or more substituents selected from the group consisting of alkyl, halo, haloalkyl, -R⁸-OR⁷, -R⁸-C(O)OR⁷, -R⁸-C(O)N(R⁷)₂, and -R⁸-N(R⁷)₂;

each R⁴ is independently selected from the group consisting of hydrogen, alkyl, alkoxy, halo, haloalkyl, amino, monoalkylamino, or dialkylamino;

R⁵ is hydrogen;

R⁶ is hydrogen;

each R⁷ is hydrogen, alkyl, aryl, aralkyl, or haloalkyl; and

each R⁸ is a bond or a straight or branched alkylene chain.

Of this preferred group of compounds, a preferred compound is 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)quinoline in trifluoroacetic acid.

Another preferred group of compounds of formula (II) is that group of compounds

5 wherein:

m is 1;

n is 1 or 2;

R¹ is hydrogen, aryl, aralkyl, or alkoxycarbonyl;

R² is hydrogen, carboxyalkyl, alkoxycarbonylalkyl or aralkoxycarbonylalkyl;

10 R³ is heteroarylalkoxy, wherein the alkoxy radical in the heteroarylalkoxy substituent is optionally substituted by one or more substituents selected from the group consisting of halo and -R⁸-C(O)OR⁷, and wherein the heteroaryl radical in the heteroarylalkoxy substituent is independently optionally substituted by one or more substituents selected from the group consisting of alkyl, halo, haloalkyl, -R⁸-OR⁷, -R⁸-C(O)OR⁷,
15 -R⁸-C(O)N(R⁷)₂, and -R⁸-N(R⁷)₂;

each R⁴ is independently selected from the group consisting of hydrogen, alkyl, alkoxy, halo, haloalkyl, amino, monoalkylamino, or dialkylamino;

R⁵ is hydrogen;

R⁶ is hydrogen;

20 each R⁷ is hydrogen, alkyl, aryl, aralkyl, or haloalkyl; and

each R⁸ is a bond or a straight or branched alkylene chain.

Of this preferred group of compounds, preferred compounds are selected from the group consisting of the following:

25 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(5-methylisoxazol-3-yl)methoxyquinoline in trifluoroacetic acid;

2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(2-methylthiazol-4-yl)methoxyquinoline in trifluoroacetic acid;

2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-methoxycarbonylpropyl]aminocarbonyl-4-(1-phenyl-1-ethoxycarbonyl-1-chloro)methoxyquinoline;

30 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-8-fluoro-4-(1-carboxy-1-thien-3-yl)methoxyquinoline in trifluoroacetic acid;

2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-chloro-7-methyl-4-(5-methylisoxazol-3-yl)methoxyquinoline; and

35 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-chloro-7-methyl-4-(2-methylthiazol-4-yl)methoxyquinoline in trifluoroacetic acid.

Preparation of the Compounds of the Invention

The compounds of the invention are prepared according to the methods described below in the following Reaction Schemes. It is understood that those compounds of the invention which are not specifically prepared in the following Reaction Schemes may be prepared by similar synthetic processes with the appropriately substituted starting materials and reagents. It is also understood that during the preparation of the compounds of the invention, as described below, additional reactive groups (for example, hydroxy, amino or carboxy groups) on the intermediate compounds utilized in the preparation may be protected as needed by the appropriate protecting group by treating the intermediate compound prior to the desired reaction with the appropriate protecting group precursor by methods known to those of ordinary skill in the art. The protecting groups may then be removed as desired by methods known to those of ordinary skill in the art, for example, by acidic or basic hydrolysis. Such protecting groups and methods are described in detail in Greene, T.W. and Wuts, P.G.M., *Protective Groups in Organic Synthesis*, 2nd Edition, 1991, John Wiley & Sons. Preferred nitrogen-protecting groups are "Boc" (t-butoxycarbonyl) and "CBZ" (benzyloxycarbonyl).

It will also be appreciated by those skilled in the art, although such protected derivatives of compounds of the invention as described above in the Summary of the Invention, may not possess pharmacological activity as such, they may be administered to a mammal having a disease-state characterized by thrombotic activity and thereafter metabolized in the body to form compounds of the invention which are pharmacologically active. Such derivatives may therefore be described as "prodrugs". All prodrugs of compounds of the invention are included within the scope of the invention.

It is understood that in the following description, combinations of substituents and/or variables of the depicted formulae are permissible only if such combinations result in stable compounds which can be isolated by methods known to those of ordinary skill in the art. Transient compounds are indicated by brackets.


For purposes of convenience, the preparation of compounds of formula (I) (where R³ is aryl, aralkyl, aryloxy or aralkoxy) are only described below. However, one of ordinary skill in the art would understand that in order to prepare the corresponding compounds of formula (II), all that one would need to do is replace the pertinent intermediates (such as compounds of formula (J)) with the appropriate compound (such as compounds of formula (J) where R^{3a} is heteroarylalkyl) and to adjust the experimental parameters accordingly.

A. Preparation of Compounds of formula (D)

Compounds of formula (D) are intermediates used in the preparation of the compounds of the invention. They may be prepared as described below in Reaction Scheme 1 wherein m , R^1 , R^2 , R^5 , and R^6 are as described above in the Summary of the Invention; PG is a nitrogen-protecting group; and R^{1a} is hydrogen (or a nitrogen protecting group if R^1 is hydrogen):

5

REACTION SCHEME 1



Compounds of formulae (A) and (B) are commercially available, for example, from Aldrich, or may be prepared according to methods known to those of ordinary skill in the art, or by methods as described herein.

In general, compounds of formula (D) are prepared by first treating a compound of formula (B) in an aprotic solvent mixture, such as tetrahydrofuran (THF) and methylene chloride, with a slightly excess molar amount of a peptide coupling reaction additive, such as 1-hydroxybenzotriazole (HOBt) and a slightly excess molar amount of coupling agent for amide formation, such as 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDCI) at ambient temperature. To this mixture is added a slightly excess molar amount of a compound of formula (A) where R^{1a} is hydrogen and the resulting reaction mixture is allowed to stir overnight at ambient temperature. The compound of formula (C) is isolated from the reaction mixture by standard isolation techniques, such as evaporation and extraction.

Depending on what PG is, the compound of formula (C) is then reduced under standard hydrogenation conditions, such as treatment with platinum over carbon under hydrogen or treated under standard hydrolysis conditions to form a compound of formula (D), which is isolated from the reaction mixture by filtration.

Alternatively, compounds of formula (A) where R^1 is hydrogen and R^{1a} is a nitrogen protecting group can be treated with the appropriately substituted acid halide, carbamoyl halide or isocyanate to yield the corresponding appropriately substituted compounds of formula (A),

613.


which can then be treated to standard deprotecting procedures to remove the R^{1a} nitrogen protecting group prior to being reacted with the compound of formula (B) to form compounds of formula (C) and (D) wherein R¹ is as described above in the Summary of the Invention.

5 B. Preparation of Compounds of formula (H)

Compounds of formula (H) are intermediates in the preparation of compounds of formula (I) and are prepared as described below in Reaction Scheme 2a wherein n is as described as above in the Summary of the Invention; R⁴ is as described above in the Summary of the Invention; and R¹⁰ is alkyl or aralkyl:

10

REACTION SCHEME 2a




Compounds of formulae (E), and (F) are commercially available, for example, from Aldrich, or may be prepared according to methods known to those of ordinary skill in the art. Compounds of formula (G) and formula (H) may alternatively be prepared by methods disclosed in Great Britain Patent No. 1,334,705.

In general, compounds of formula (H) are prepared by first treating a compound of formula (F) in a protic solvent, such as methanol, with an equimolar amount of a compound of formula (E) with stirring at ambient temperature for about 30 minutes to about an hour, preferably for about 30 minutes. The solvent is removed by evaporation to form a residue.

To an aprotic polar solvent, such as diphenyl ether, heated to between about 200°C and about 250°C, preferably to about 250°C is then added the residue and the temperature of the reaction mixture is maintained at the high temperature for about 30 minutes to an hour, preferably for about 30 minutes, at which point the reaction mixture is allowed to cool to ambient temperature. The resulting precipitate is collected and washed with a aprotic polar

- solvent, such as ether, which is previously heated to below boiling temperature, to give compounds of formula (G). Further purification, for example, by dissolving the mixture in a protic solvent at boiling temperature, such as methanol, and then allowing the mixture to cool to ambient temperature for a period of about 1 to about 2 days, preferably for about 2 days, yields a compound of formula (H), which is isolated from the reaction mixture by standard techniques.


Alternatively, compounds of formula (D) as prepared above in Reaction Scheme 1 can be reacted with compounds of the following structure:



- 10 which are commercially available or prepared by methods known to one of ordinary skill in the art, under standard acylation conditions to form additional compounds of the invention.

- A preferred method of making intermediates used in the preparation of the compounds of the invention which avoids the formation of undesired regioisomers with respect to the substitution on the quinoline ring is illustrated below in Reaction Scheme 2b wherein R^{9a} is alkyl, alkoxy, aralkoxy, carboxy, alkoxycarbonyl, aminocarbonyl, alkylcarbonylamino, di(alkylcarbonyl)amino, carboxyalkoxy, alkoxycarbonylalkoxy or heterocyclylalkoxy; X is iodo, chloro or bromo; and R¹⁰ is alkyl or aralkyl:

REACTION SCHEME 2b



Compounds of formula (Fa) and formula (E) are commercially available, or can
5 prepared according to methods known to those of ordinary skill in the art.

In general, compounds of formula (Gb) are prepared by first treating a compound of
formula (Fa) with a reducing agent, such as tin (II) chloride dihydrate, under standard chemical
reduction conditions, such as in a protic solvent, to form the compound of formula (Fb), which
is isolated from the reaction mixture by standard isolation techniques.

10 The compound of formula (Fb) in a protic solvent, such as methanol, is then treated
with a slightly excess molar amount of a compound of formula (E) at reflux temperatures for
about 2 to about 4 hours, preferably for about 4 hours. The reaction mixture is then
concentrated. An organic solvent is heated to a non-boiling point temperature of between
about 240°C and about 260°C, and the concentrate is then added to the solvent. The
15 temperature of the mixture is maintained at the non-boiling point temperature for about 10 to
20 minutes, preferably for about 20 minutes. The reaction mixture is then cooled slowly to
ambient temperature and diluted with an organic solvent. The compound of formula (Ga) is
isolated from the reaction mixture by standard isolation techniques, such as filtration.

68
616


The compound of formula (Ga) is treated with a hydrolyzing agent under standard hydrolysis conditions and then treated under standard reducing conditions, such as hydrogen gas and palladium over carbon, to form a compound of formula (Gb).

Compounds of formula (Gb) may then be used instead of compounds of formula (H) in subsequent Reaction Schemes to prepare compounds of the invention.

C. Preparation of Compounds of Formula (Ia)

Compounds of formula (Ia) are compound of the invention and are prepared as described below in Reaction Scheme 3 wherein m, n, R¹, R², R⁴, R⁵, and R⁶ are as defined above in the Summary of the Invention, R^{3a} is aryl or aralkyl, and X is halo:

REACTION SCHEME 3



617

Compounds of formulae (D) and (H) are prepared by methods disclosed herein.

Compounds of formula (J) are commercially available, for example, from Aldrich Co., or can be prepared according to methods known to one of ordinary skill in the art.

5 In general, compounds of formula (Ia) are prepared by first treating a compound of formula (H) under standard Williamson synthesis conditions, such as in the presence of a base in an aprotic solvent, for example, cesium carbonate in *N,N*-dimethylformamide ("DMF"), with an equimolar amount of a compound of formula (J) at temperatures between about ambient temperature and about 100°C. The reaction mixture is stirred from about 2 hours to about 10 hours, preferably for about 10 hours, to yield the compound of formula (K), which is then
10 treated under standard hydrolysis conditions to yield the compound of formula (L).


The compound of formula (L) in an aprotic solvent mixture, for example, methylene chloride and DMF or methylene chloride and triethylamine, is then treated with a slightly excess molar amount of a peptide coupling reaction additive, such as 1-hydroxybenzotriazole ("HOBT") and a slightly excess molar amount a coupling agent for amide formation, such as 1-
15 (3-dimethylaminopropyl)-3-ethylcarbodiimide ("EDCI") at ambient temperature. An equimolar amount of a compound of formula (D) in an aprotic solvent, such as methylene chloride, is then added to the reaction mixture. The reaction mixture is stirred at ambient temperature for about 4 to about 12 hours, preferably for about 12 hours. The compound of formula (Ia) is then isolated from the reaction mixture by standard isolation techniques, such as evaporation of the
20 solvents, extraction and concentration.

If desired, compounds of formula (Ia) may be deprotected to yield the corresponding free acid or free amine derivatives. Furthermore, compounds of formula (Ia) wherein R¹ is a nitrogen-protecting group, such as an alkyl carbonyl, can be hydrolyzed under standard acid hydrolysis conditions to yield the corresponding compound of formula (Ia) wherein R¹ is
25 hydrogen, which can then be treated with the appropriately substituted acid halide, carbamoyl halide or isocyanate to yield the appropriately substituted R¹ compound of formula (Ia).

D. Preparation of Compounds of Formula (Ib)

Compounds of formula (Ib) are compounds of the invention and are prepared as
30 described below in Reaction Scheme 4 wherein n, R¹, R², R⁴, R⁵ and R⁶ are as described above in the Summary of the Invention, R^{3a} is aryl or aralkyl and X is halo:

REACTION SCHEME 4



Compounds of formula (D) are prepared as described herein or may be prepared by methods known to one of ordinary skill in the art. Compounds of formula (H) are prepared as described herein or may be prepared by methods known to one of ordinary skill in the art, such as those found in Great Britain Patent No. 1,334,705.

In general, compounds of formula (lb) are prepared by first treating a suspension of a compound of formula (H) in an aprotic solvent mixture, such as methylene chloride and DMF, with a slightly excess molar amount of a peptide coupling reaction additive, such as 1-hydroxybenzotriazole ("HOBT") and a slightly excess molar amount a coupling agent for amide formation, such as 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide ("EDCI") at ambient temperature. An equimolar amount of a compound of formula (D) in an aprotic solvent, such as methylene chloride, is then added to the reaction mixture. The reaction mixture is stirred at ambient temperature for a period of time of between about 4 hours and about 12 hours, preferably for a period of time of between about 6 hours and about 12 hours. The compound

at
619

of formula (M) is then isolated from the reaction mixture by standard isolation techniques, such as evaporation of the solvents, extraction and concentration.


The compound of formula (M) is then treated under standard Williamson synthesis conditions, such as in the presence of base in an aprotic solvent, for example, cesium carbonate in acetonitrile:DMF, with an an equimolar amount of a compound of formula (J) at a temperature of between about ambient temperature and 100°C. The reaction mixture is stirred for a period of time of between 30 minutes and about 10 hours, preferably for about 30 minutes. The compound of formula (Ib) is then isolated from the reaction mixture by standard isolation techniques, such as organic extraction and concentration.

If desired, compounds of formula (Ib) can be treated under standard hydrolysis conditions to yield the corresponding free amine or acid.

E. Preparation of Compounds of Formulae (Ic), (Id) and (Ie)

Compounds of formulae (Ic), (Id) and (Ie) are compounds of the invention and are prepared as described below in Reaction Scheme 5 wherein m, n, R¹, R², R⁴, R⁵ and R⁶ are as described above in the Summary of the Invention, X is halo, R^{2b} is aryl or aralkyl, and R^{2c} is heteroaryl:

REACTION SCHEME 5



Compounds of formulae (H) and (D) are prepared as described herein or can be prepared according to methods known to one of ordinary skill in the art. Compounds of formulae (P), (Q) and (R) are commercially available, for example, from Aldrich Chemical Co., or can be prepared according to methods known to one of ordinary skill in the art.

In general, compounds of formulae (Ic), (Id) and (Ie) are prepared by first treating a compound of formula (H) with a halogenating agent, such as phosphorus pentachloride or phosphorus oxychloride, under standard halogenating conditions. The compound of formula (N) is isolated from the reaction mixture by standard isolation techniques.

43
621

The compound of formula (N) is then treated with a compound of formula (D) under standard peptide coupling conditions, as described herein, to yield a compound of formula (O), which is isolated from the reaction mixture by standard isolation techniques.

The compound of formula (O) in an polar aprotic solvent, such as DMSO, in the presence of a base, such as cesium carbonate, is then treated with a compound of formula (P). The resulting reaction mixture is heated to a temperature of between about 40°C and about 60°C, preferably at about 60°C for a period of time of between about 4 hours and about 16 hours, preferably for about 16 hours. The compound of formula (Ic) is then isolated from the reaction mixture by standard isolation techniques, such as filtration and purification by preparative HPLC. If desired, the compound of formula (Ic) can be treated under standard hydrolysis conditions to further yield the corresponding free acid or amine.

Alternatively, a mixture of a compound of formula (O) and a compound of formula (Q) in a polar aprotic solvent, such as DMSO, is heated to a temperature of between about 80°C and 105°C, preferably to about 100°C, for a period of time of between about 6 hours and 18 hours, preferably for about 18 hours. The compound of formula (Id) is then isolated from the reaction mixture by standard isolation techniques, such as purification by reverse phase HPLC. If desired, the compound of formula (Id) can be hydrolyzed under standard hydrolysis conditions to further yield the corresponding amine or acid.

Alternatively, a compound of formula (O) is treated with a compound of formula (R) under standard boronic acid/palladium coupling conditions to yield the corresponding compound of formula (Ie), which is isolated from the reaction mixture by standard isolation techniques. If desired, the compound of formula (Ie) can be hydrolyzed under standard hydrolysis conditions to further yield the corresponding amine or acid.

Alternatively, compounds of formula (Gb) may be used in the above Reaction Schemes in place of the compounds of formula (H).

All compounds of the invention as prepared above which exist in free base or acid form may be converted to their pharmaceutically acceptable salts by treatment with the appropriate inorganic or organic base or acid. Salts of the compounds prepared above may be converted to their free base or acid form by standard techniques.

The following specific preparations and examples are provided as a guide to assist in the practice of the invention, and are not intended as a limitation on the scope of the invention.

PREPARATION 1

Compounds of formula (D)

44
622

A. To a solution of *N*-benzyloxycarbonyl-L-glutamic acid γ -*t*-butyl ester (24.4 g, 72.3 mmol) in tetrahydrofuran ("THF") (400 mL) and CH_2Cl_2 (100 mL) was added 1-hydroxybenzotriazole ("HOBT") (10.7 g, 79.5 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide ("EDCI") (15.3 g, 79.5 mmol). After 5 minutes, 1-ethoxycarbonylpiperazine (11.7 mL, 79.5 mmol) was added and the reaction was stirred overnight. The reaction mixture was evaporated *in vacuo* to afford an oil, which was dissolved in ethyl acetate, and washed with saturated NaHCO_3 , 1M NaHSO_4 , and brine. The organic layer was evaporated *in vacuo* to afford 4-ethoxycarbonyl-1-(1-amino-3-(1,1-dimethylethoxycarbonyl)propyl)carbonylpiperazine (40.7 g), as an oil that was used without further purification. To 4-ethoxycarbonyl-1-(1-(benzyloxycarbonyl)amino-3-(1,1-dimethylethoxycarbonyl)propyl)carbonylpiperazine in MeOH (100 mL) was added 10% Pd/C (1 g) and the mixture was shaken under 50 psi H_2 overnight. The reaction was filtered and stripped to 4-ethoxycarbonyl-1-(1-amino-3-(1,1-dimethylethoxycarbonyl)propyl)carbonylpiperazine (25 g, 99%) and used without further purification; NMR (CDCl_3) 1.25 (t, 3), 1.43 (s, 9), 2.55 (m, 1), 1.90 (m, 1), 2.37 (m, 1), 2.55 (m, 1), 3.40-3.70 (m, 8), 3.80 (m, 1), 4.18 (q, 2) ppm. ¶

B. In a similar manner, other compounds of formula (D) were prepared.

4-ethoxycarbonyl-1-(aminomethyl)carbonylpiperazine;
4-ethoxycarbonyl-1-(1-amino-3-carboxypropyl)carbonylpiperazine;
4-ethoxycarbonyl-2-methyl-1-(aminomethyl)carbonylpiperazine;
20 4-ethoxycarbonyl-3-methyl-1-(aminomethyl)carbonylpiperazine;
4-ethoxycarbonyl-1-(1-amino-5-((2-chlorobenzyloxy)carbonylamino)pentyl)carbonylpiperazine;
4-ethoxycarbonyl-1-(1-amino-2-(benzyloxycarbonyl)ethyl)carbonylpiperazine;
4-ethoxycarbonyl-1-(1-amino-2-phenylethyl)carbonylpiperazine;
4-ethoxycarbonyl-1-(1-amino-2-methylpropyl)carbonylpiperazine;
25 4-ethoxycarbonyl-1-(1-amino-2-carboxyethyl)carbonylpiperazine; and
4-ethoxycarbonyl-1-(1,5-diaminopentyl)carbonylpiperazine.

C. Alternatively, *N*-benzyloxycarbonyl-L-glutamic acid γ -*t*-butyl ester (34 g, 100 mmol) and EDCI (22 g, 110 mmol), HOBT (15 g, 110 mmol) were combined in 800 mL CH_2Cl_2 with triethylamine (24 mL, 172 mmol). The resulting reaction mixture was stirred at ambient temperature for 20 minutes, then 1-ethoxycarbonylpiperazine (18 g, 120 mmol) was added. The resulting mixture was stirred at ambient temperature for 15 hours. The reaction mixture was then washed with water, 2N NaHSO_4 , and brine, then concentrated *in vacuo* to afford an oil, which was purified by flash column chromatography on silica gel (acetate/hexane=1/1) to afford 4-ethoxycarbonyl-1-(1-(benzyloxycarbonyl)amino-3-(1,1-dimethylethoxycarbonyl)propyl)carbonylpiperazine (40 g). 4-ethoxycarbonyl-1-(1-(benzyloxycarbonyl)amino-3-(1,1-dimethylethoxycarbonyl)propyl)carbonylpiperazine (40g) was

45
623

dissolved in 200 mL of MeOH, 2 g Pd/C(10%) was added and hydrogenated at 50 psi for 1 hour. Regular work up afforded 4-ethoxycarbonyl-1-(1-amino-3-(1,1-dimethylethoxycarbonyl)propyl)carbonylpiperazine (25 g).

5

PREPARATION 2**Compounds of formula (G)**

A. To a solution of *m*-toluidine (20.0 g, 0.186 mol) in methanol (300 mL), dimethyl acetylenedicarboxylate (26.42 g, 0.186 mol) was added drop-wise and the reaction mixture was stirred at ambient temperature for 30 minutes. The solvent was removed by evaporation and the residue was added to stirred diphenyl ether (150 ml), which has been preheated to 250°C. After 30 minutes, the mixture was cooled to ambient temperature and the resulting precipitate was collected and washed with hot petroleum ether (1.5 L) to give a mixture (27.0 g) of 5-methyl-4-hydroxy-2-methoxycarbonylquinoline and 7-methyl-4-hydroxy-2-methoxycarbonylquinoline. The mixture was dissolved in boiling methanol (1.3 L) and kept at ambient temperature for two days to afford (6.45 g, 16%) of 7-methyl-4-hydroxy-2-methoxycarbonylquinoline, NMR (DMSO-*d*₆) 2.40 (s, 3), 3.92 (s, 3), 6.56 (s, 1), 7.16 (d, 1), 7.66 (s, 1), 7.94 (d, 1) ppm.

B. In a similar manner, other compounds of formula (G) were prepared as follows:

- 8-methoxy-4-hydroxy-2-methoxycarbonylquinoline;
- 20 5-amino-4-hydroxy-2-methoxycarbonylquinoline;
- 5-nitro-4-hydroxy-2-methoxycarbonylquinoline;
- 5-carboxymethylamino-4-hydroxy-2-methoxycarbonylquinoline;
- 7-chloro-4-hydroxy-2-methoxycarbonylquinoline;
- 5-di(acetyl)amino-4-hydroxy-2-methoxycarbonylquinoline;
- 25 5-acetyl-amino-4-hydroxy-2-methoxycarbonylquinoline;
- 5,7-dichloro-4-hydroxy-2-methoxycarbonylquinoline;
- 6-chloro-4-hydroxy-2-methoxycarbonylquinoline;
- 6-nitro-4-hydroxy-2-methoxycarbonylquinoline;
- 6-amino-4-hydroxy-2-methoxycarbonylquinoline;
- 30 7-benzyloxy-4-hydroxy-2-methoxycarbonylquinoline;
- 4,7-dihydroxy-2-methoxycarbonylquinoline;
- 7-prop-1-oxy-4-hydroxy-2-methoxycarbonylquinoline;
- 7-carboxymethoxy-4-hydroxy-2-methoxycarbonylquinoline;
- 7-diethylaminoethoxy-4-hydroxy-2-methoxycarbonylquinoline;
- 35 7-methoxy-4-hydroxy-2-methoxycarbonylquinoline;
- 7-(2-(4-hydroxy-2-carboxypyrrolidinyl)ethoxy)-4-hydroxy-2-methoxycarbonylquinoline;

46
624

- 8-methyl-4-hydroxy-2-methoxycarbonylquinoline;
6-diethylaminomethyl-4-hydroxy-2-methoxycarbonylquinoline;
6-benzyloxy-4-hydroxy-2-methoxycarbonylquinoline;
4,6-dihydroxy-2-methoxycarbonylquinoline;
5 6-carboxymethoxy-4-hydroxy-2-methoxycarbonylquinoline;
6-ethoxy-4-hydroxy-2-methoxycarbonylquinoline;
6-methoxy-4-hydroxy-2-methoxycarbonylquinoline;
6-prop-2-oxo-4-hydroxy-2-methoxycarbonylquinoline;
7-fluoro-4-hydroxy-2-methoxycarbonylquinoline;
10 7-trifluoromethyl-4-hydroxy-2-methoxycarbonylquinoline;
7-hydroxymethyl-4-hydroxy-2-methoxycarbonylquinoline;
7-cyano-4-hydroxy-2-methoxycarbonylquinoline;
7-nitro-4-hydroxy-2-methoxycarbonylquinoline;
6-carboxy-4-hydroxy-2-methoxycarbonylquinoline;
15 7-trifluoromethoxy-4-hydroxy-2-methoxycarbonylquinoline;
6-trifluoromethoxy-4-hydroxy-2-methoxycarbonylquinoline;
7-acetyl-4-hydroxy-2-methoxycarbonylquinoline;
5-ethoxycarbonyl-4-hydroxy-2-methoxycarbonylquinoline;
6-ethyl-4-hydroxy-2-methoxycarbonylquinoline;
20 7-carboxy-4-hydroxy-2-methoxycarbonylquinoline;
6-aminocarbonyl-4-hydroxy-2-methoxycarbonylquinoline;
6,7-dimethoxy-4-hydroxy-2-methoxycarbonylquinoline;
6-chloro-7-methyl-4-hydroxy-2-methoxycarbonylquinoline;
6-fluoro-7-methyl-4-hydroxy-2-methoxycarbonylquinoline;
25 6-fluoro-4-hydroxy-2-methoxycarbonylquinoline;
6-fluoro-7-chloro-4-hydroxy-2-methoxycarbonylquinoline;
7-bromo-4-hydroxy-2-methoxycarbonylquinoline;
6,7-dimethyl-4-hydroxy-2-methoxycarbonylquinoline;
6-methoxy-7-methyl-4-hydroxy-2-methoxycarbonylquinoline;
30 6-methoxy-7-chloro-4-hydroxy-2-methoxycarbonylquinoline;
6-chloro-6-fluoro-4-hydroxy-2-methoxycarbonylquinoline;
6,7-dichloro-4-hydroxy-2-methoxycarbonylquinoline;
6,8-difluoro-4-hydroxy-2-methoxycarbonylquinoline;
6,7-difluoro-4-hydroxy-2-methoxycarbonylquinoline;
35 6-dimethylamino-4-hydroxy-2-methoxycarbonylquinoline;
5-fluoro-6-methyl-4-hydroxy-2-methoxycarbonylquinoline;

47
625

6-methyl-7-chloro-4-hydroxy-2-methoxycarbonylquinoline;
6-acetyl-4-hydroxy-2-methoxycarbonylquinoline;
6-methylthio-4-hydroxy-2-methoxycarbonylquinoline;
4,5-dihydroxy-2-methoxycarbonylquinoline;
5 7-ethyl-4-hydroxy-2-methoxycarbonylquinoline;
5-methyl-4-hydroxy-2-methoxycarbonylquinoline;
5-hydroxymethoxy-4-hydroxy-2-methoxycarbonylquinoline;
5-(3-ethoxycarbonylpropoxy)-4-hydroxy-2-methoxycarbonylquinoline; and
5-(3-carboxypropoxy)-4-hydroxy-2-methoxycarbonylquinoline.

10

PREPARATION 3

Compounds of Formula (H)

A. 7-methyl-4-hydroxy-2-methoxycarbonylquinoline (6.45 g, 30.14 mmol) was suspended in MeOH (150 mL) and water (100 mL), and LiOH (3.08 g, 75.5 mmol) was added and stirred at ambient temperature for 2 hours. The methanol was evaporated *in vacuo* and residue was crystallized by addition of 2N hydrochloric acid. The resulting solid was filtered, washed with water and dried to afford 7-methyl-4-hydroxy-2-carboxyquinoline (6.0 g, 98%), NMR (DMSO- d_6) 2.40 (s, 3), 6.68 (s, 1), 7.22 (d, 1), 7.68 (s, 1), 7.96 (d, 1).

B. In a similar manner, the following compounds of formula (H) were prepared:

- 20 8-methoxy-4-hydroxy-2-carboxyquinoline;
5-amino-4-hydroxy-2-carboxyquinoline;
5-nitro-4-hydroxy-2-carboxyquinoline;
5-carboxymethylamino-4-hydroxy-2-carboxyquinoline;
7-chloro-4-hydroxy-2-carboxyquinoline;
25 5-di(acetyl)amino-4-hydroxy-2-carboxyquinoline;
5-acetylamino-4-hydroxy-2-carboxyquinoline;
5,7-dichloro-4-hydroxy-2-carboxyquinoline;
6-chloro-4-hydroxy-2-carboxyquinoline;
6-nitro-4-hydroxy-2-carboxyquinoline;
30 6-amino-4-hydroxy-2-carboxyquinoline;
7-benzyloxy-4-hydroxy-2-carboxyquinoline;
4,7-dihydroxy-2-carboxyquinoline;
7-prop-1-oxy-4-hydroxy-2-carboxyquinoline;
7-carboxymethoxy-4-hydroxy-2-carboxyquinoline;
35 7-diethylaminoethoxy-4-hydroxy-2-carboxyquinoline;
7-methoxy-4-hydroxy-2-carboxyquinoline;

48
626

- 7-(2-(4-hydroxy-2-carboxypyrrolidinyl)ethoxy)-4-hydroxy-2-carboxyquinoline;
8-methyl-4-hydroxy-2-carboxyquinoline;
6-diethylaminomethyl-4-hydroxy-2-carboxyquinoline;
3-methyl-4-hydroxy-2-carboxyquinoline;
5 6-benzyloxy-4-hydroxy-2-carboxyquinoline;
4,6-dihydroxy-2-carboxyquinoline;
6-carboxymethoxy-4-hydroxy-2-carboxyquinoline;
6-ethoxy-4-hydroxy-2-carboxyquinoline;
6-methoxy-4-hydroxy-2-carboxyquinoline;
10 6-prop-2-oxy-4-hydroxy-2-carboxyquinoline;
7-fluoro-4-hydroxy-2-carboxyquinoline;
7-trifluoromethyl-4-hydroxy-2-carboxyquinoline;
7-hydroxymethyl-4-hydroxy-2-carboxyquinoline;
7-cyano-4-hydroxy-2-carboxyquinoline;
15 7-nitro-4-hydroxy-2-carboxyquinoline;
2,6-dicarboxy-4-hydroxyquinoline;
7-trifluoromethoxy-4-hydroxy-2-carboxyquinoline;
6-trifluoromethoxy-4-hydroxy-2-carboxyquinoline;
7-acetyl-4-hydroxy-2-carboxyquinoline;
20 5-ethoxycarbonyl-4-hydroxy-2-carboxyquinoline;
6-ethyl-4-hydroxy-2-carboxyquinoline;
2,7-dicarboxy-4-hydroxyquinoline;
6-aminocarbonyl-4-hydroxy-2-carboxyquinoline;
6,7-dimethoxy-4-hydroxy-2-carboxyquinoline;
25 6-methyl-7-chloro-4-hydroxy-2-carboxyquinoline;
6-chloro-7-methyl-4-hydroxy-2-carboxyquinoline;
6-fluoro-7-methyl-4-hydroxy-2-carboxyquinoline;
6-fluoro-4-hydroxy-2-carboxyquinoline;
6-fluoro-7-chloro-4-hydroxy-2-carboxyquinoline;
30 7-bromo-4-hydroxy-2-carboxyquinoline;
6,7-dimethyl-4-hydroxy-2-carboxyquinoline;
6-methoxy-7-methyl-4-hydroxy-2-carboxyquinoline;
6-methoxy-7-chloro-4-hydroxy-2-carboxyquinoline;
6-chloro-8-fluoro-4-hydroxy-2-carboxyquinoline;
35 6,7-dichloro-4-hydroxy-2-carboxyquinoline;
6,8-difluoro-4-hydroxy-2-carboxyquinoline;

627

- 6,7-difluoro-4-hydroxy-2-carboxyquinoline;
6-dimethylamino-4-hydroxy-2-carboxyquinoline;
5-fluoro-6-methyl-4-hydroxy-2-carboxyquinoline;
6-acetyl-4-hydroxy-2-carboxyquinoline;
5 6-methylthio-4-hydroxy-2-carboxyquinoline;
4,5-dihydroxy-2-carboxyquinoline;
5-hydroxymethoxy-4-hydroxy-2-carboxyquinoline;
7-methyl-4-hydroxy-2-carboxyquinoline;
5-methyl-4-hydroxy-2-carboxyquinoline;
10 5-(3-ethoxycarbonylpropoxy)-4-hydroxy-2-carboxyquinoline; and
5-(3-carboxypropoxy)-4-hydroxy-2-carboxyquinoline.

PREPARATION 4

Compounds of formulae (Fb), (Ga) and (Gb)

- 15 A. To a solution of $\text{SnCl}_2 \cdot \text{H}_2\text{O}$ (140 g, 0.62 mol) in ethanol (350 mL) was added a solution of 2,6-dichloro-3-nitrotoluene (25 g, 0.12 mol) in ethanol (50 mL). The reaction mixture was refluxed for 1 hour. The reaction mixture was concentrated under reduced pressure. The residue was dissolved in water (100 mL), pH was adjusted to approximately pH 12 with 1N NaOH solution and extracted with ethyl acetate. The ethyl acetate layer was washed with brine,
20 dried over sodium sulfate, and concentrated to afford 2,6-dichloro-3-aminotoluene (21 g, 98%); NMR (CDCl_3) 2.42 (s, 3), 6.62 (d, 1), 7.14 (d, 1) ppm.

- B. To a solution of 2,6-dichloro-3-aminotoluene (20.5 g, 0.11 mol) in methanol (300 mL) was added dimethyl acetylenedicarboxylate (15 mL, 0.12 mol) and the reaction mixture was refluxed for 2 hours. The reaction mixture was concentrated under reduced
25 pressure to a yellow solid. Diphenyl ether (350 mL) was heated to 230-240°C, and the yellow solid was added to it. The temperature was maintained at 230-240°C for 20 minutes and the reaction mixture was cooled slowly to ambient temperature and diluted with petroleum ether (1L). The solid was filtered and washed with hot ethyl acetate to afford a brown solid, 2-(methoxycarbonyl)-4-oxo-6,8-dichloro-7-methylquinoline (28.5 g, 85%); NMR (CDCl_3) 2.62 (s,
30 3), 4.04 (s, 3), 7.02 (s, 1), 8.24 (s, 1) ppm.

- C. 2-(Methoxycarbonyl)-4-oxo-6,8-dichloro-7-methylquinoline (28.5 g, 99.6 mmol) was suspended in methanol (1 L) and a solution of $\text{LiOH} \cdot \text{H}_2\text{O}$ (20.5 g, 0.5 mol) in water (200 mL) was added to the solution. The resulting reaction mixture was stirred at ambient temperature for 0.5 hours. Pd/C (5.8 g) was added to the reaction mixture and the resulting
35 reaction mixture was shaken under 50 Psi hydrogen overnight. The reaction mixture was filtered, concentrated under reduced pressure to remove methanol, diluted with water (300 mL)

and the pH was adjusted to between pH 3 and pH 4 by 2N HCl. The precipitate was collected by filtration, washed with water and dried to afford a white solid, 2-carboxy-4-oxo-7-methylquinoline (20 g, 90%); NMR (DMSO- d_6) 2.40 (s, 3), 6.60 (s, 1), 7.20 (d, 1), 7.68 (s, 1), 7.96 (d, 1) ppm.

- 5 D. Alternatively, to a solution of 4-chloro-3-methyl aniline (20.0 g, 0.141 mol) in MeOH (400 mL) was added drop-wise dimethyl acetylenedicarboxylate (21.07 g, 0.148 mol). The reaction mixture was stirred at ambient temperature for 30 minutes. The solvent was removed by evaporation and the residue was added to stirred diphenyl ether (300 mL), which has been preheated to 250°C. After 30 minutes, the mixture was cooled to ambient
10 temperature and the resulting precipitate was collected and washed with 1L of hot petroleum ether to give a mixture (29.0 g) of 2-methoxycarbonyl-6-chloro-7-methyl-4-oxoquinoline and 2-methoxycarbonyl-6-chloro-5-methyl-4-oxoquinoline as a gray solid. The mixture was dissolved in boiling methanol (1 L) and filtered hot. The collected solids were boiled in 1.2 L of methanol and filtered hot to afford (6.45 g, 16%) of 2-methoxycarbonyl-6-chloro-7-methyl-4-oxoquinoline:
15 ^1H NMR (DMSO- d_6) 2.41 (s, 3), 3.92 (s, 3), 6.58 (s, 1), 7.86 (s, 1), 7.96 (s, 1) ppm.

- E. 2-Methoxycarbonyl-6-chloro-7-methyl-4-oxoquinoline (7.00 g, 28.00 mmol) was suspended in 300 mL of MeOH and 100 mL of water. Lithium hydroxide (3.40 g, 90 mmol) was added and the reaction was stirred at room temp for 2 hours. The methanol was evaporated *in vacuo* and the product was crystallized by addition of 2N hydrochloric acid. The solid was
20 filtered, washed with water and dried to afford 5.9 g (88%) of 2-carboxy-6-chloro-7-methyl-4-oxoquinoline: ^1H NMR (DMSO- d_6) 2.40 (s, 3), 6.60 (s, 1), 7.84 (s, 1), 7.98 (s, 1) ppm.

PREPARATION 5

Compounds of Formulae (K) and (L)

- 25 A. 2-carboxy-4-hydroxyquinoline (5 g, 1.0 eq) was dissolved in 50 mL DMF. Cesium carbonate (20 g, 2.3 eq) was added to the solution and the resulting reaction mixture was heated at 50°C for 20 minutes. Benzyl bromide (10g, 2.1eq) was added. The resulting reaction mixture was stirred at 50°C for 1 hour. Then the reaction mixture was poured into 500 mL ice-water, the precipitate was collected by filtration, and dried *in vacuo* to afford 2-benzyloxycarbonyl-4-benzyloxyquinoline (9.1 g). 2-benzyloxycarbonyl-4-benzyloxyquinoline
30 (9.0 g) was dissolved in 50 mL THF, and 2 N LiOH solution (20 mL) was added, and the resulting reaction mixture was stirred at ambient temperature for 2 hours. The solvent was then removed *in vacuo*, and the residue acidified by the addition of 2N NaHSO₄ to pH 3-4. The white precipitate was collected to afford 2-carboxy-4-benzyloxyquinoline (7.2 g), which was
35 used without further purification.
- B. In a similar manner, other compounds of formula (K) and (L) were prepared.

81
629

PREPARATION 6

Compounds of Formula (M)

A. To a suspension of 2-carboxy-6-chloro-7-methyl-4-oxoquinoline (7.5 g, 31.69 mmol) in dichloromethane:DMF (350 mL, 2.5:1) was added HOBT (5.13 g, 38 mmol) and EDCI (7.25 g, 38 mmol) and the reaction mixture was stirred for 10 minutes. A solution of 4-ethoxycarbonyl-1-(1-amino-3-(1,1-dimethylethoxycarbonyl)propyl)carbonylpiperazine (10.8 g, 31.64 mmol) in 50 mL dichloromethane was added. The reaction was stirred at ambient temperature for 6 hours. The solvent was evaporated *in vacuo* and the residue was partitioned in ethyl acetate and water. The aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with water, brine and concentrated to afford an off-white foam that was purified by flash chromatography (2% methanol in dichloromethane) to afford 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-7-methyl-6-chloro-4-hydroxyquinoline as a white foam, (14.4 g, 80%).

B. In a similar manner, other compounds of formula (M) were prepared.

C. Alternatively, 2-carboxy-4-hydroxyoxoquinoline (640 mg, 3.2 mmol), EDCI (674 mg, 3.5 mmol), and HOBT (525 mg, 3.5 mmol) were combined in 20 mL CH₂Cl₂ with triethylamine (0.67 mL, 4.8 mmol). The resulting reaction mixture was stirred at ambient temperature for 10 minutes, then 4-ethoxycarbonyl-1-(1-amino-3-(1,1-dimethylethoxycarbonyl)propyl)-carbonylpiperazine (1.1 g, 3.3 mmol) was added. The resulting mixture was stirred at ambient temperature for 2 hours. The reaction mixture was washed with water, 2N NaHSO₄, and brine, then concentrated *in vacuo* to afford an oil, which was purified by flash column chromatography on silica gel to afford 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-4-hydroxyquinoline (1.28 g).

D. Alternatively, to a solution of 2-carboxy-6-chloro-8-fluoro-4-hydroxyquinoline (1.0 g, 4.14 mmol) in DMF (50 mL) was added diisopropylethyl amine (3.0 eq., 2.2 mL). The mixture was stirred at ambient temperature for 30 minutes. EDCI (1.2 eq., 969 mg) and HOBT (1.1 eq., 628 mg) were added, followed by the addition of 4-ethoxycarbonyl-1-(1-amino-3-(1,1-dimethylethoxycarbonyl)propyl)carbonylpiperazine (1.493 g, 1.05 eq.) and the mixture was stirred overnight at ambient temperature. The solvent, DMF, was evaporated *in vacuo* to afford a crude product, which was dissolved in ethyl acetate, washed with saturated NaHCO₃, 1M NaHSO₄, and brine. The organic layer was evaporated. Flash column chromatography with 1%-3% MeOH in CH₂Cl₂ afforded the coupling product, 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-6-chloro-8-fluoro-4-hydroxyquinoline in acetic acid, (2.01 g).

PREPARATION 7

630

Compounds of Formula (N)

A. To 20 mL POCl₃ was added 2-carboxy-7-methyl-4-hydroxyquinoline (2.5 g, 12.3 mmol) and PCl₅ (11.5 g, 55 mmol). The mixture was heated to 130°C for 3 hours. The reaction mixture was cooled and poured onto ice. The solution was neutralized with solid NaOH and adjusted to pH 11 with solid KOH. The tan precipitate was filtered, slurried in 250 mL water and adjusted to pH 2 with concentrated HCl. The resultant solid was filtered and dried to afford 2-carboxy-7-methyl-4-chloroquinoline (1.34 g, 50%).

B. In a similar manner, other compounds of formula (N) were prepared:

PREPARATION 8**Compounds of Formula (O)**

A. A solution of 4-ethoxycarbonyl-1-(1-amino-3-(methoxycarbonyl)propyl)-carbonylpiperazine (0.97 g, 3.23 mmol), 4-chloro-2-carboxyquinoline (0.67 g, 3.23 mmol), EDCI (0.68 g, 3.55 mmol) and HOBT (0.48 g, 3.55 mmol) was combined in 30 mL of THF. The reaction mixture was stirred overnight at ambient temperature. The reaction was diluted with ethyl acetate and washed with water. The organic layer was concentrated to give a dark oil (0.87 g) that was purified by flash chromatography through silica gel with 2:1 ethyl acetate-hexanes to provide 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-chloroquinoline, (0.46 g).

B. A solution of 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-chloroquinoline (0.15 g, 0.313 mmol) was dissolved in 5 mL THF and LiOH (0.25 M, 1.9 mL, 0.47 mmol) was added. The reaction was stirred for 2 hours. The reaction was concentrated to an oil, acidified with 10% HCl, extracted into ethyl acetate, and concentrated to provide pure 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-chloroquinoline (167 mg): ¹H NMR 1.20 (t, 3), 1.90 (m, 1), 2.05 (m, 1), 2.35 (m, 2), 3.35-3.60 (m, 8), 3.65 (m, 2), 4.05 (q, 2), 5.07 (m, 1), 7.95 (m, 1), 8.02 (m, 1), 8.23 (s, 1), 8.30 (m, 1), 8.98 (m, 1) ppm.

C. Alternatively, to a solution of 2-carboxy-7-methyl-4-chloroquinoline (1.3 g, 5.9 mmol) in THF (50 mL) at 0°C was added *N*-methylmorpholine (1.7 mL, 14.7 mmol) followed by iso-butylchloroformate (0.84 mL, 6.45 mmol). The reaction was stirred for 0.5 hours, then 4-ethoxycarbonyl-1-(1-amino-3-(1,1-dimethylethoxycarbonyl)propyl)carbonylpiperazine (2.0 g, 5.9 mmol) was added and the reaction was warmed to ambient temperature. Aqueous work-up afforded a crude product. The sample was purified by flash chromatography through silica gel (3:2 ethyl acetate:hexanes) to afford 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-7-methyl-4-chloroquinoline (0.95 g, 30%).

D. In a similar manner, other compounds of formula (O) were prepared:

EXAMPLE 1

Compounds of Formula (Ia)

A. 2-Carboxy-4-benzyloxyquinoline (800 mg, 1.0 eq) and EDCI (680 mg, 1.1 eq),
5 HOBt (520 mg, 1.1 eq) were combined in 25 mL methylene chloride with triethylamine (1.0 mL,
3.2 eq). The resulting reaction mixture was stirred at ambient temperature for 10 minutes, and
then 4-ethoxycarbonyl-1-(1-amino-3-(benzyloxycarbonyl)propyl)carbonylpiperazine was added
(1.0 g, 1.25 eq). The resulting reaction mixture was stirred at ambient temperature for 12 hours.
The reaction mixture was then washed with water, 2N NaHSO₄, and brine, then concentrated *in*
10 *vacuo* to afford an oil, which was purified by flash column chromatography on silica gel to afford
2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-benzyloxycarbonylpropyl]aminocarbonyl-4-
benzyloxyquinoline (1.6 g). Then 50 mg of 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-
benzyloxycarbonylpropyl]aminocarbonyl-4-benzyloxyquinoline was dissolved in 2 mL MeOH and
1 mL water, and lithium hydroxide added (10 mg), and the resulting mixture was stirred at
15 ambient temperature for 2 hours. Standard work-up afforded 2-[1S-(4-
(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-benzyloxyquinoline
(30 mg).

B. In a similar manner, the following compounds of formula (Ia) were prepared:
2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-benzyloxyquinoline;
20 2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-
phenyl-1-carboxy)methoxyquinoline;
2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-benzyloxycarbonylpropyl]aminocarbonyl-4-
benzyloxy-8-methoxyquinoline; and
2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-benzyloxy-
25 8-methoxyquinoline.

EXAMPLE 2

Compounds of Formula (Ib)

A. Methyl α -bromophenylacetate (0.22 g, 1 mmol) was added to a solution of 2-
[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]-
30 aminocarbonyl-7-methyl-6-chloro-4-hydroxyquinoline (0.42 g, 0.74 mmol) and cesium carbonate
(0.48 g, 1.48 mmol) in 10 mL CH₃CN/DMF (4:1) and stirred at 40°C for 30 minutes. The
reaction mixture was filtered, evaporated, dissolved in ethyl acetate, washed with water, brine
and concentrated to afford 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-
dimethylethoxycarbonyl)propyl]aminocarbonyl-7-methyl-6-chloro-4-(1-phenyl-1-
35 methoxycarbonyl)methoxyquinoline as a reddish oil (0.55 g). The crude material was carried
on to the next step.

632

B. A solution of 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-7-methyl-6-chloro-4-(1-phenyl-1-methoxycarbonyl)methoxyquinoline (0.55 g,) in MeOH (5 mL) was saponified by reaction with LiOH (3mL, 0.25 M) for 40 minutes. The solvent was evaporated and the residue was purified by preparative HPLC to afford 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-7-methyl-6-chloro-4-(1-phenyl-1-carboxy)methoxyquinoline as two pure diastereomers (A) and (B) as white solids (A 180 mg, B 190 mg): ¹H NMR of B (DMSO-d₆) 1.18 (t, 3), 1.20 (s, 9), 1.82 (m, 1), 2.0 (m, 1), 2.22 (m, 2), 2.54 (s, 3), 3.46 (m, 8), 4.04 (q, 2), 5.00 (m, 1), 6.38 (s, 1), 7.2 (m, 3), 7.45 (s, 1), 7.62 (m, 2), 8.04 (s, 1), 8.10 (s, 1), 8.86 (d, 1) ppm.

C. A solution of 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-7-methyl-6-chloro-4-(1-phenyl-1-carboxy)methoxyquinoline (190 mg, 0.23 mmol) in 50% TFA-dichloromethane (6 mL) was stirred at ambient temperature for 1 hour. The solvent was evaporated and purified by preparative HPLC to afford 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-6-chloro-4-(1-phenyl-1-carboxy)methoxyquinoline in trifluoroacetic acid; as a white solid (116 mg, 66%) as a TFA salt: ¹H NMR (DMSO-d₆) 1.12 (t, 3), 1.85 (m, 1), 2.05 (m, 1), 2.30 (m, 2), 2.55 (s, 3), 3.45 (m, 6), 3.65 (m, 2), 4.05 (q, 2), 5.02 (m, 1), 6.39 (s, 1), 7.45 (m, 3), 7.56 (s, 1), 7.69 (d, 2), 8.10 (s, 1), 8.20 (s, 1), 8.88 (d, 1) ppm.

D. Alternatively, 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-4-hydroxyquinoline (100 mg, 1.0 eq) and cesium carbonate (190 mg, 3.0 eq.) were combined in 5 mL of DMF, and methyl α -bromophenylacetate (66 mg, 1.5 eq) was added. The resulting reaction mixture was stirred at 50°C for 1 hour. Then the mixture was poured into 50 mL ice-water, extracted with 2x50ml ethyl acetate, and the organic phase was washed with 3x30ml water, and then brine. The crude product was purified by flash column chromatography (acetate/hexane = 1/1) to provide 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-4-(1-phenyl-1-methoxycarbonyl)methoxyquinoline (120 mg), which was dissolved in 2 mL of trifluoroacetic acid. The resulting reaction mixture was stirred at ambient temperature for 20 minutes, and then concentrated *in vacuo*. The residual oil was dissolved in 30 mL ethyl acetate, washed with saturated NaHCO₃, brine, and dried *in vacuo* to afford (90 mg). 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(1-phenyl-1-methoxycarbonyl)methoxyquinoline (60 mg) in 3 mL MeOH was added to a solution of 15 mg (3 eq.) LiOH in 2 mL water. The resulting reaction mixture was stirred at ambient temperature for 2 hours. then the MeOH solvent was removed *in vacuo*. The pH was adjusted to pH 3-4 with 2 N NaHSO₂, and extracted by 2X20 mL acetate to afford a white solid, 2-[1S-

633

(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(1-phenyl-1-carboxy)methoxyquinoline (40 mg).

E.. In a similar manner, the following compounds of formula (Ib) were prepared:

2-[1S-(4-(3-methylphenyl)piperazin-1-yl)carbonyl-3-(1,1-

5 dimethylethoxycarbonyl)propyl]aminocarbonyl-4-benzyloxyquinoline;

2-[1S-(4-(3-methylphenyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-benzyloxyquinoline;

2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-phenyl-1-carboxy)methoxyquinoline;

0 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-phenyl-1-carboxy)methoxyquinoline;

2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-chloro-4-(1-carboxy-1-phenyl)methoxyquinoline in trifluoroacetic acid;

5 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-naphth-1-yl-1-carboxy)methoxyquinoline;

2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-6-fluoro-4-(1-carboxy-1-(2-fluoro)phenyl)methoxyquinoline in trifluoroacetic acid;

2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-ethoxycarbonyl-1-phenyl)methoxyquinoline in trifluoroacetic acid;

0 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(5-methylisoxazol-3-yl)methoxyquinoline in trifluoroacetic acid;

2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(2-methylthiazol-4-yl)methoxyquinoline in trifluoroacetic acid;

5 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-methoxycarbonylpropyl]aminocarbonyl-4-(1-phenyl-1-ethoxycarbonyl-1-chloro)methoxyquinoline;

2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6,8-difluoro-4-(1-carboxy-1-phenyl)methoxyquinoline in trifluoroacetic acid;

2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-chloro-6-methyl-4-(1-phenyl-1-carboxy)methoxyquinoline in trifluoroacetic acid;

0 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-6-fluoro-4-(1-carboxy-1-thien-3-yl)methoxyquinoline in trifluoroacetic acid;

2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-chloro-7-methyl-4-(5-methylisoxazol-3-yl)methoxyquinoline;

5 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-chloro-7-methyl-4-(2-methylthiazol-4-yl)methoxyquinoline in trifluoroacetic acid;

A6
634

- 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-8-fluoro-4-(1-carboxy-1-(4-chloro)phenyl)methoxyquinoline in trifluoroacetic acid;
- 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-6-fluoro-4-(1-carboxy-1-(3-methoxy)phenyl)methoxyquinoline in trifluoroacetic acid;
- 5 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-dimethylamino-4-(1-phenyl-1-carboxy)methoxyquinoline;
- 2-[1S-(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-phenyl-1-carboxy)methoxyquinoline;
- 2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-phenyl-1-carboxy)methoxyquinoline;
- 10 2-[1S-(4-(3-methylphenyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-phenyl-1-carboxy)methoxyquinoline;
- 2-[1S-(4-(3-methylphenyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-phenyl-1-carboxy)methoxyquinoline in trifluoroacetic acid;
- 15 2-[1S-(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)carbonyl-3-methoxycarbonylpropyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-phenyl-1-carboxy)methoxyquinoline;
- 2-[1S-(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-phenyl-1-carboxy)methoxyquinoline;
- 20 2-[1S-(4-(furan-2-ylcarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-phenyl-1-carboxy)methoxyquinoline in trifluoroacetic acid;
- 2-[1S-(4-(methoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-phenyl-1-carboxy)methoxyquinoline in trifluoroacetic acid;
- 25 2-[1S-(4-(1,1-dimethylethylaminocarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-phenyl-1-carboxy)methoxyquinoline in trifluoroacetic acid;
- 2-[1S-(4-(phenyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-phenyl-1-carboxy)methoxyquinoline; and
- 30 2-[1S-(4-(phenyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-phenyl-1-carboxy)methoxyquinoline in trifluoroacetic acid.

E. Alternatively, 2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-hydroxyquinoline (100 mg, 1.0 eq) and cesium carbonate (300 mg, 2.5 eq) were combined in 10 mL of DMF. Methyl 4-(bromomethyl)benzoate (65 mg, 1.1 eq) was added to the solution and the resulting mixture was stirred at 50°C for 30 minutes. The reaction mixture was poured into 200 mL of ice water, extracted with 2x100 mL ethyl

635

acetate, and the organic phase was washed with 3x100 mL water, followed by a brine wash.

The crude mixture was purified by flash column chromatography to provide 2-[(4-

(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(4-

methoxycarbonyl)benzyloxyquinoline (107 mg). To a solution of 2-[(4-

5 (ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(4-

methoxycarbonyl)benzyloxyquinoline (78 mg) in 4 mL THF was added a solution of 16 mg

LiOH in 3 mL of water. The resulting reaction mixture was stirred at ambient temperature for 2

hours, followed by standard work-up to provided 65 mg of 2-[(4-(ethoxycarbonyl)piperazin-1-

10 yl)carbonylmethyl]aminocarbonyl-4-(4-carboxy)benzyloxyquinoline.

F. In a similar manner, the following compounds of formula (Ib) were prepared:

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(3-

methoxycarbonyl)benzyloxyquinoline; and

2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(3-

carboxy)benzyloxyquinoline.

15 G. Alternatively, to a suspension of NaH (53.0 mg, 2.20 mmol), DMF (8 mL) was

added a solution of 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-

dimethylethoxycarbonyl)propyl]aminocarbonyl-6-chloro-8-fluoro-4-hydroxyquinoline (500mg,

0.88 mmol) in DMF (2 mL). The reaction mixture was stirred at ambient temperature for 30

minutes. A solution of methyl α -bromophenylacetate (4 eq., 831 mg) in DMF (3 mL) was

20 added dropwise and the reaction mixture was heated at 50°C overnight. The solvent, DMF,

was evaporated *in vacuo*. The residue was treated with ethyl acetate, washed with water (2X)

and brine, followed by evaporation and flash column chromatography with 1-2% MeOH in DCM

to afford 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-

dimethylethoxycarbonyl)propyl]aminocarbonyl-6-chloro-8-fluoro-4-(1-methoxycarbonyl-1-

25 phenyl)methoxyquinoline (324mg). 2-[1S-(4-(Ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-

dimethylethoxycarbonyl)propyl]aminocarbonyl-6-chloro-8-fluoro-4-(1-methoxycarbonyl-1-

phenyl)methoxyquinoline (324 mg, 0.45 mmol) was then treated with TFA: DCM (1:1, 1.8 mL)

at ambient temperature for 4 hours. Evaporation, dilution with DCM, and repeated evaporation

gave a crude product. Flash column chromatography with 100% ethyl acetate and 3-5%

30 MeOH (with 0.1% acetic acid) in ethyl acetate afforded 2-[1S-(4-(ethoxycarbonyl)piperazin-1-

yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-chloro-8-fluoro-4-(1-methoxycarbonyl-1-

phenyl)methoxyquinoline in acetic acid; (233 mg): NMR (CD₃OD) 1.25 (t, 3), 1.99 (m, 1), 2.2

(m, 1), 2.45 (m, 2), 3.4-3.8 (m, 11), 4.16 (q, 2), 5.25 (m, 1), 6.38 (s, 1), 7.45 (m, 3), 7.68 (m,

4), 8.10 (s, 1), 9.05 (m, 1) ppm.

35 H. 2-[1S-(4-(Ethoxycarbonyl)piperazin-1-yl)carbonyl-3-

carboxypropyl]aminocarbonyl-6-chloro-8-fluoro-4-(1-methoxycarbonyl-1-

636

phenyl)methoxyquinoline (154 mg, 0.233 mmol) was added to a mixture of THF:H₂O, 3:1, 6.0 mL) and LiOH (4 eq.). The mixture was stirred at ambient temperature for 1.5 hours. The pH value was adjusted to 3.0 with 1N HCl solution, followed by extraction with ethyl acetate and evaporation of solvent to give a crude product. Flash column chromatography with 100% ethyl acetate and 5-10% MeOH (with 0.1% AcOH) in ethyl acetate afforded 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-chloro-8-fluoro-4-(1-carboxy-1-phenyl)methoxyquinoline in acetic acid (30 mg): NMR (CD₃OD) 1.25 (t, 3), 1.99 (m, 1), 2.2 (m, 1), 2.45 (m, 2), 3.4-3.9 (m, 8), 4.16 (q, 2), 5.20 (m, 1), 6.35 (s, 1), 7.45-7.75 (m, 7), 8.05 (s, 1), 9.02 (m, 1) ppm.

10

EXAMPLE 3

Compounds of formulae (Ic), (Id) and (Ie)

A. To a mixture of 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-7-methyl-4-chloroquinoline (475 mg, 0.87 mmol) and CsCO₃ (1.13 g, 4 mmol) in 20 mL DMSO was added methyl 3-hydroxybenzoate (160 mg, 1 mmol). The reaction was heated at 60°C overnight. The reaction was filtered and purified by preparative HPLC to afford 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-7-methyl-4-(3-methoxycarbonyl)-phenoxyquinoline (200 mg, 35%).

20

B. 2-[1S-(4-(Ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-7-methyl-4-(3-methoxycarbonyl)phenoxyquinoline (200 mg, 0.3 mmol) was dissolved in a mixture of methylene chloride and trifluoroacetic acid (5 mL, 4:1 mixture) and stirred for 3 hours. The solution was evaporated to an oil and dissolved in MeOH (10 mL). Lithium hydroxide (3 mL, 0.25 M) was added and the solution was stirred overnight. The reaction was evaporated, adjusted to pH <7 with TFA and purified by preparative HPLC to afford 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(3-carboxy)phenoxyquinoline in trifluoroacetic acid, (25 mg, 15%). ¹H NMR: (DMSO-d₆) 1.15 (t, 3), 1.80 (m, 1), 2.00 (m, 1), 2.55 (s, 3), 3.30-3.60 (m, 8), 4.05 (q,), 4.95 (m, 1), 7.05 (s, 1), 7.61 (m, 2), 7.65 (d, 1), 7.75 (s, 1), 8.25 (d, 1), 8.91 (d, 2) ppm.

25

30

C. In a similar manner, the following compounds of formula (Ic) were prepared: 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(3-carboxy)phenoxyquinoline in 2,2,2-trifluoro-1,1-ethanediol; 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(2-carboxy)phenoxyquinoline in 2,2,2-trifluoro-1,1-ethanediol;

35

2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(2-amino-5-carboxy)phenoxyquinoline in 2,2,2-trifluoro-1,1-ethanediol;

2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(4-carboxy)phenoxyquinoline in 2,2,2-trifluoro-1,1-ethanediol;

5 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(3-carboxymethyl)phenoxyquinoline in trifluoroacetic acid;

2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(3-(1-amino-1-carboxy)methyl)phenoxyquinoline in trifluoroacetic acid;

10 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(3-(2-amino-2-carboxy)ethyl)phenoxyquinoline in trifluoroacetic acid;

2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(2-methyl-5-carboxy)phenoxyquinoline in trifluoroacetic acid;

2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(5-carboxy-2-diethylaminomethyl)phenoxyquinoline in trifluoroacetic acid;

15 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(3-tetrazol-5-yl)phenoxyquinoline in 2,2,2-trifluoro-1,1-ethanediol; and

2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(3-trifluoromethylsulfonylamino)phenoxyquinoline in trifluoroacetic acid.

D. A solution of 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(methoxycarbonyl)propyl]aminocarbonyl-4-chloroquinoline (0.15 g, 0.313 mmol) and 1,2,3,4-tetrahydroisoquinoline (0.15 mmol) was mixed in 3 mL of DMSO and heated to 100°C for 18 hours. The reaction was purified by reversed-phase HPLC. The product was dissolved in 0.25 M LiOH solution and stirred for 6 hours. Purification by reversed-phase HPLC afforded. 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)quinoline in trifluoroacetic acid, to form a compound of formula (Id).

E. In a similar manner, other compounds of formula (Id) were prepared.

F.. A solution of 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-7-methyl-4-bromoquinoline (10 mg, 0.17 mmol), 3-carboxyphenylboronic acid (0.26 mmol), Pd(PPh₃) (40 mg), and 2 M sodium carbonate (217 μL) was combined in 10 mL of toluene-ethanol and heated at 80°C overnight. The reaction was purified by reversed-phase HPLC. The product was dissolved in 10 mL of 1/1 TFA-methylene chloride solution and stirred for 2 hours. The product was concentrated *in vacuo* to afford 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(3-carboxy)phenylquinoline in trifluoroacetic acid.

35 G. In a similar manner, other compounds of formula (Ie) were prepared.

638

EXAMPLE 4**Receptor Binding Studies**

The ability of the compounds of the invention to bind to the platelet adenosine diphosphate ("ADP") receptor was tested using human washed platelets and rat washed platelets by displacement assays.

Methods:

One day old platelet concentrates were purchased from a local blood bank. The platelet concentrates were spun at 680 g for 10 minutes and the resulting pellets were resuspended in modified Tyrode's buffer (135 mM NaCl, 3.6 mM KCl, 1.8 mM MgCl₂, 9 mM HEPES, 0.18 mg/mL BSA, 4.5 mM glucose, pH 6.6) supplemented by 2% acid citrate dextrose (ACD). This platelet suspension was spun at 680 g for 10 minutes and the final pellet was resuspended in platelet binding buffer (20mM Tris buffer, pH 7.5, 140 mM NaCl, 4 mM KCl, 2 mM MgCl₂, 1 mM EDTA, 0.1% BSA, 5 mM glucose, 2 µg/mL aprotinin, and 2 µg/mL leupeptin).

Platelets were isolated from rat whole blood as described in Example 13 with the final pellet resuspended in platelet binding buffer. The platelet number for binding to rat platelets (5 x 10⁶ per well) was normalized to the number of platelets for binding to human platelet (4-6 x 10⁶ per well).

Binding reactions were initiated by mixing [³²P]-2-methylthio-ADP (0.3-0.5 nM), test compounds and washed platelets in 96-well plates. The reactions were kept at ambient temperature for 60 minutes under constant shaking and were stopped by fast-filtration onto 96-well, glass-fiber (GFC) filter plates followed by washing 5 times with ice-cold 50 mM Tris buffer (pH 7.5). The amount of [³²P]-2-methylthio-ADP bound to the filters was measured by scintillation counting. Non-specific binding was determined in the presence of 10 µM unlabelled 2-methylthio-ADP. Competition studies were done using a single concentration of [³²P]-2-methylthio-ADP (0.3 nM) and varying concentrations of test compounds.

Results:

The compounds of the invention, when tested in this assay, demonstrated their ability to inhibit the binding of [³²P]-2-methylthio-ADP binding to the human platelet ADP receptor and the rat platelet ADP receptor.

EXAMPLE 5**ADP-Induced Aggregation *In Vitro* Studies**

The compounds of the invention were evaluated as functional antagonists of the platelet ADP receptor using both human and rat washed platelets.

Methods:

Human venous blood was collected from healthy, drug-free volunteers into 1/6 volume 3.2% acid/citrate/dextrose. Whole blood from Nembutal-anesthetized rats was collected from

639

the abdominal aorta into 1/10 volume 3.8% acid/citrate/dextrose. Platelet rich plasma (PRP) was prepared by centrifugation at 800 g for 3-4 successive 1.5-minute intervals, with removal of the PRP after each spin. Alternatively, some PRP preps were performed by centrifugation at 100 g for 15 minutes. Washed platelets were prepared from the PRP by centrifugation at 680 g for 15 minutes and the platelet pellet resuspended in Tyrode's buffer (137 mM NaCl, 2.7 mM KCl, 12 mM NaHCO₂, 0.42 mM NaH₂PO₄, 1 mM MgCl₂, 2 mM CaCl₂, 0.35% BSA, 5.5 mM glucose, 5 mM HEPES, pH 7.35 supplemented with f.c. 10% ACD solution. The platelets were washed a total of two times under these acidic conditions and the platelet pellet collected by centrifugation at 680 g for 15 minutes at ambient temperature. The final platelet pellet was resuspended at 2×10^8 platelets/mL in Tyrode's buffer containing 0.02 units/mL apyrase. This platelet suspension was kept at 37°C for at least 30 minutes prior to studies.

Inhibition of ADP-induced aggregation was measured at 37°C in a 4-channel aggregometer. The platelet suspension (0.5 mL) was stirred at 1200 rpm. Human fibrinogen (400 µg) was added at time zero for 1 minute followed by 2 minute pre-incubation in the presence or absence of antagonist. Platelet aggregation was induced with the addition of 10 or 31.6 µM ADP (submaximal response) in human platelets or 3 or 10 µM ADP (submaximal response) in rat and monitored for 5 minutes. ADP-induced aggregation was quantified by measuring increase in light transmission (%T) compared to Tyrode's buffer control. IC₅₀ values were determined using the 4-parameter equation.

Results:

The compounds of the invention, when tested in this assay, demonstrated the ability to inhibit ADP-induced platelet aggregation *in vitro* in human and rat washed platelets.

EXAMPLE 6

Efficacy Assay

Inhibition of thrombus formation by compounds of the invention was evaluated in the rat arterio-venous (A-V) shunt model.

Methods:

Male Sprague-Dawley rats (350-400 g, 10-18 per group) were anesthetized with Nembutal (65 mg/kg, i.p). The left carotid artery and the right jugular vein were each cannulated with a piece of PE-50 tubing (8 cm, siliconized). Fifty minutes after anesthesia, the arterial and venous catheters were connected (A-V shunt) by a piece of shunt tubing (Tygon S-50-HL, 6 cm) that contained a silk thread (6-0 silk suture, 10 cm) coated with collagen (Horn, 100 µg/ml). Blood was allowed to flow through the A-V shunt for 10 minutes. The amount of thrombus deposited on the silk thread was measured as dry weight (24 hours at ambient temperature). A compound of the invention (1, 3 and 10 mg/kg) (as the appropriate salt form) or vehicle (15% DMSO in saline, 1 mL/kg) was injected via the jugular vein catheter 5 minutes

82
640

before the A-V shunt. Blood samples (1 mL) were taken immediately before the dosing and at the end of the A-V shunt for measurements of ex vivo platelet aggregation and plasma levels of the compound of the invention.

Results:

When tested in this assay, compounds of the invention demonstrated the ability to dose-dependently inhibit platelet aggregation and thrombus formation in the rat A-V shunt model. Both the inhibition of platelet aggregation and thrombus formation were also parallel in relation to the changes in plasma drug concentrations. Thus, the inhibition of thrombus formation is correlated with the inhibition of platelet aggregation induced by the compound of the invention.

EXAMPLE 7

This example illustrates the preparation of representative pharmaceutical compositions for oral administration containing a compound of the invention, or a pharmaceutically acceptable salt thereof:

A.	<u>Ingredients</u>	<u>% wt./wt.</u>
	Compound of the invention	20.0%
	Lactose	79.5%
	Magnesium stearate	0.5%

The above ingredients are mixed and dispensed into hard-shell gelatin capsules containing 100 mg each, one capsule would approximate a total daily dosage.

B.	<u>Ingredients</u>	<u>% wt./wt.</u>
	Compound of the invention	20.0%
	Magnesium stearate	0.9%
	Starch	8.6%
	Lactose	69.6%
	PVP (polyvinylpyrrolidone)	0.9%

The above ingredients with the exception of the magnesium stearate are combined and granulated using water as a granulating liquid. The formulation is then dried, mixed with the magnesium stearate and formed into tablets with an appropriate tableting machine.

C.	<u>Ingredients</u>	
	Compound of the invention	0.1 g
	Propylene glycol	20.0 g
	Polyethylene glycol 400	20.0 g
	Polysorbate 80	1.0 g
	Water	q.s. 100 mL

The compound of the invention is dissolved in propylene glycol, polyethylene glycol 400

63
6al

and polysorbate 80. A sufficient quantity of water is then added with stirring to provide 100 mL of the solution which is filtered and bottled.

D.	<u>Ingredients</u>	<u>% wt./wt.</u>
	Compound of the invention	20.0%
5	Peanut Oil	78.0%
	Span 60	2.0%

The above ingredients are melted, mixed and filled into soft elastic capsules.

10	E.	<u>Ingredients</u>	<u>% wt./wt.</u>
		Compound of the invention	1.0%
		Methyl or carboxymethyl cellulose	2.0%
		0.9% saline	q.s. 100 mL

The compound of the invention is dissolved in the cellulose/saline solution, filtered and bottled for use.

15

EXAMPLE 8

This example illustrates the preparation of a representative pharmaceutical formulation for parenteral administration containing a compound of the invention, or a pharmaceutically acceptable salt thereof:

20	<u>Ingredients</u>	
	Compound of the invention	0.02 g
	Propylene glycol	20.0 g
	Polyethylene glycol 400	20.0 g
	Polysorbate 80	1.0 g
	0.9% Saline solution	q.s. 100 mL

25

The compound of the invention is dissolved in propylene glycol, polyethylene glycol 400 and polysorbate 80. A sufficient quantity of 0.9% saline solution is then added with stirring to provide 100 mL of the I.V. solution which is filtered through a 0.2 m membrane filter and packaged under sterile conditions.

30

EXAMPLE 9

This example illustrates the preparation of a representative pharmaceutical composition in suppository form containing a compound of the invention, or a pharmaceutically acceptable salt thereof:

35	<u>Ingredients</u>	<u>% wt./wt.</u>
	Compound of the invention	1.0%
	Polyethylene glycol 1000	74.5%

84
642

Polyethylene glycol 4000

24.5%

The ingredients are melted together and mixed on a steam bath, and poured into molds containing 2.5 g total weight.

5

EXAMPLE 10

This example illustrates the preparation of a representative pharmaceutical formulation for insufflation containing a compound of the invention, or a pharmaceutically acceptable salt thereof:

	<u>Ingredients</u>	<u>% wt./wt.</u>
10	Micronized compound of the invention	1.0%
	Micronized lactose	99.0%

The ingredients are milled, mixed, and packaged in an insufflator equipped with a dosing pump.

15

EXAMPLE 11

This example illustrates the preparation of a representative pharmaceutical formulation in nebulized form containing a compound of the invention, or a pharmaceutically acceptable salt thereof:

	<u>Ingredients</u>	<u>% wt./wt.</u>
20	Compound of the invention	0.005%
	Water	89.995%
	Ethanol	10.000%

The compound of the invention is dissolved in ethanol and blended with water. The formulation is then packaged in a nebulizer equipped with a dosing pump.

25

EXAMPLE 12

This example illustrates the preparation of a representative pharmaceutical formulation in aerosol form containing a compound of the invention, or a pharmaceutically acceptable salt thereof:

	<u>Ingredients</u>	<u>% wt./wt.</u>
30	Compound of the invention	0.10%
	Propellant 11/12	98.90%
	Oleic acid	1.00%


The compound of the invention is dispersed in oleic acid and the propellants. The resulting mixture is then poured into an aerosol container fitted with a metering valve.

35

While the present invention has been described with reference to the specific embodiments thereof, it should be understood by those skilled in the art that various changes may be made and equivalents may be substituted without departing from the true spirit and scope of the invention. In addition, many modifications may be made to adapt a particular situation, material, composition of matter, process, process step or steps, to the objective, spirit and scope of the present invention. All such modifications are intended to be within the scope of the claims appended hereto.

What is claimed is:

1. A compound of formula (I):



wherein:

m and n are independently 1 to 4;

R^1 is hydrogen, alkyl, carboxyalkyl, aryl, aralkyl, alkylcarbonyl, aryloxyalkylcarbonyl, carboxyalkylcarbonyl, alkoxycarbonylalkylcarbonyl, alkoxycarbonylalkyl, alkoxycarbonyl, arylcarbonyl, aryloxycarbonyl, aralkoxycarbonyl, cycloalkylcarbonyl, haloalkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, alkoxycarbonylaminocarbonyl, or heterocyclcarbonyl;

R^2 is hydrogen, alkyl, aryl, aralkyl, alkylsulfonylalkyl, aralkoxyalkyl, hydroxyalkyl, aminoalkyl, haloalkylsulfonylaminoalkyl, carboxyalkylthioalkyl, alkoxycarbonylalkylthioalkyl, carboxyalkyl, (carboxy)(hydroxy)alkyl, carboxyalkoxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, carboxyalkoxycarbonylalkyl, alkoxycarbonylalkoxycarbonylalkyl, aminocarbonylalkyl, aralkoxycarbonylaminoalkyl, alkoxycarbonylalkylaminocarbonylalkyl, carboxyalkylaminocarbonylalkyl, (alkoxycarbonylalkyl)(alkyl)aminocarbonylalkyl, (carboxyalkyl)(alkyl)aminocarbonylalkyl, or heterocyclalkyl;

R^3 is aryl or aryloxy each independently optionally substituted by one or more substituents selected from the group consisting of alkyl, halo, haloalkyl, cyano, nitro, tetrazolyl, $-R^5-OR^7$, $-R^5-C(O)OR^7$, $-R^5-C(O)N(R^7)_2$, $-R^5-C(O)R^7$, $-R^5-N(R^7)_2$, $-R^5-N(R^7)C(O)R^7$, $-R^5-N(R^7)C(O)OR^8$, $-R^5-N(R^7)-S(O)_2R^7$, and $-R^5-C[N(R^7)_2]-C(O)OR^7$;

or R^3 is aralkyl or aralkoxy, wherein the alkyl radical in the aralkyl or aralkoxy substituent is optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, $-R^5-OR^7$, $-R^5-C(O)OR^7$, $-R^5-C(O)N(R^7)_2$, $-R^5-C(O)R^7$, $-R^5-N(R^7)_2$, $-R^5-N(R^7)C(O)R^7$, and $-R^5-N(R^7)C(O)OR^8$, and wherein the aryl radical in the aralkyl or aralkoxy substituent is independently optionally substituted by one or more substituents selected from the group consisting of alkyl, halo, haloalkyl, cyano, nitro, tetrazolyl, $-R^5-OR^7$, $-R^5-C(O)OR^7$, $-R^5-C(O)N(R^7)_2$, $-R^5-C(O)R^7$, $-R^5-N(R^7)_2$, $-R^5-N(R^7)C(O)R^7$, $-R^5-N(R^7)C(O)OR^8$, $-R^5-N(R^7)-S(O)_2R^7$, and $-R^5-C[N(R^7)_2]-C(O)OR^7$;

645

each R^4 is independently selected from the group consisting of hydrogen, alkyl, alkoxy, aralkoxy, halo, haloalkyl, haloalkoxy, hydroxy, cyano, alkylthio, carboxy, alkoxycarbonyl, aminocarbonyl, alkylcarbonyl, nitro, amino, monoalkylamino, dialkylamino, carboxyalkylamino, alkylcarbonylamino, di(alkylcarbonyl)amino, hydroxyalkyl, dialkylaminoalkyl, carboxyalkoxy, alkoxycarbonylalkoxy, dialkylaminoalkoxy, and heterocyclylalkoxy;

each R^5 is independently selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, aralkyl, carboxy, alkoxycarbonyl, aralkoxycarbonyl, carboxyalkyl, and alkoxycarbonylalkyl;

R^6 is hydrogen, alkyl, carboxyalkyl, or alkoxycarbonylalkyl;

each R^7 is hydrogen, alkyl, aryl, aralkyl, or haloalkyl;

each R^8 is a bond or a straight or branched alkylene chain; and

each R^9 is hydrogen, alkyl, aralkyl or haloalkyl;

as a single stereoisomer, a mixture of individual stereoisomers, or a racemic mixture; or a pharmaceutically acceptable salt thereof.

2. The compound of Claim 1 wherein:

m is 1;

n is 1 or 2;

R^1 is hydrogen, aryl, aralkyl, or alkoxycarbonyl;

R^2 is hydrogen, carboxyalkyl, alkoxycarbonylalkyl or aralkoxycarbonylalkyl;

R^3 is aryl optionally substituted by one or more substituents selected from the group consisting of alkyl, halo, haloalkyl, cyano, nitro, $-R^6-OR^7$, $-R^6-C(O)OR^7$, $-R^6-C(O)N(R^7)_2$, $-R^6-C(O)R^7$, $-R^6-N(R^7)_2$, $-R^6-N(R^7)C(O)R^7$, and $-R^6-N(R^7)C(O)OR^6$;

each R^4 is independently selected from the group consisting of hydrogen, alkyl, alkoxy, aralkoxy, halo, haloalkyl, haloalkoxy, hydroxy, cyano, alkylthio, carboxy, alkoxycarbonyl, aminocarbonyl, alkylcarbonyl, nitro, amino, monoalkylamino, dialkylamino, carboxyalkylamino, alkylcarbonylamino, di(alkylcarbonyl)amino, hydroxyalkyl, dialkylaminoalkyl, carboxyalkoxy, alkoxycarbonylalkoxy, dialkylaminoalkoxy, and heterocyclylalkoxy;

R^5 is hydrogen;

R^6 is hydrogen or alkyl;

each R^7 is hydrogen, alkyl, aryl, aralkyl, or haloalkyl;

each R^8 is a bond or a straight or branched alkylene chain; and

R^9 is hydrogen, alkyl, aralkyl or haloalkyl.

3. The compound of Claim 2 wherein:

m is 1;

n is 1 or 2;

R¹ is hydrogen or alkoxycarbonyl;

R² is hydrogen, carboxyalkyl, alkoxycarbonylalkyl or aralkoxycarbonylalkyl;

R³ is aryl optionally substituted by one or more substituents selected from the group consisting of carboxy or alkoxycarbonyl;

each R⁴ is independently selected from the group consisting of hydrogen, alkyl, halo, or haloalkyl;

R⁵ is hydrogen; and

R⁶ is hydrogen.

4. The compound of Claim 4, namely, 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(3-carboxy)phenylquinoline in trifluoroacetic acid.

5. The compound of Claim 1 wherein:

m is 1;

n is 1 or 2;

R¹ is hydrogen, aryl, aralkyl, or alkoxycarbonyl;

R² is hydrogen, carboxyalkyl, alkoxycarbonylalkyl or aralkoxycarbonylalkyl;

R³ is aryloxy optionally substituted by one or more substituents selected from the group consisting of alkyl, halo, haloalkyl, cyano, nitro, tetrazolyl, -R⁸-OR⁷, -R⁸-C(O)OR⁷, -R⁸-C(O)N(R⁷)₂, -R⁸-C(O)R⁷, -R⁸-N(R⁷)₂, -R⁸-N(R⁷)C(O)R⁷, -R⁸-N(R⁷)C(O)OR⁷, -R⁸-N(R⁷)-S(O)₂-R⁷, and -R⁸-C[N(R⁷)₂]-C(O)OR⁷;

each R⁴ is independently selected from the group consisting of hydrogen, alkyl, alkoxy, aralkoxy, halo, haloalkyl, haloalkoxy, hydroxy, cyano, alkylthio, carboxy, alkoxycarbonyl, aminocarbonyl, alkylcarbonyl, nitro, amino, monoalkylamino, dialkylamino, carboxyalkylamino, alkylcarbonylamino, di(alkylcarbonyl)amino, hydroxyalkyl, dialkylaminoalkyl, carboxyalkoxy, alkoxycarbonylalkoxy, dialkylaminoalkoxy, and heterocyclylalkoxy;

R⁵ is selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, aralkyl, carboxy, alkoxycarbonyl, aralkoxycarbonyl, carboxyalkyl, and alkoxycarbonylalkyl;

R⁶ is hydrogen, alkyl, carboxyalkyl, or alkoxycarbonylalkyl;

each R⁷ is hydrogen, alkyl, aryl, aralkyl, or haloalkyl;

each R⁸ is a bond or a straight or branched alkylene chain; and

R⁹ is hydrogen, alkyl, aralkyl or haloalkyl.

6. The compound of Claim 5 wherein:

m is 1;

n is 1 or 2;

R¹ is hydrogen or alkoxy carbonyl;

R² is hydrogen, carboxyalkyl, alkoxy carbonylalkyl or aralkoxy carbonylalkyl;

R³ is aryloxy optionally substituted by one or more substituents selected from the group consisting of alkyl, tetrazolyl, -R⁸-C(O)OR⁷, -R⁸-N(R⁷)₂, -R⁸-N(R⁷)-S(O)₂-R⁷, and -R⁸-C[N(R⁷)₂]-C(O)OR⁷;

each R⁴ is independently selected from the group consisting of hydrogen, alkyl, halo, or haloalkyl;

R⁵ is hydrogen;

R⁶ is hydrogen;

each R⁷ is hydrogen, alkyl, aryl, aralkyl, or haloalkyl; and

each R⁸ is a bond or a straight or branched alkylene chain.

7. The compound of Claim 6 selected from the group consisting of the following:

2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(3-carboxy)phenoxyquinoline in 2,2,2-trifluoro-1,1-ethanediol;

2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(2-carboxy)phenoxyquinoline in 2,2,2-trifluoro-1,1-ethanediol;

2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(2-amino-5-carboxy)phenoxyquinoline in 2,2,2-trifluoro-1,1-ethanediol;

2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(4-carboxy)phenoxyquinoline in 2,2,2-trifluoro-1,1-ethanediol;

2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(3-carboxymethyl)phenoxyquinoline in trifluoroacetic acid;

2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(3-(1-amino-1-carboxy)methyl)phenoxyquinoline in trifluoroacetic acid;

2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(3-(2-amino-2-carboxy)ethyl)phenoxyquinoline in trifluoroacetic acid;

2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(2-methyl-5-carboxy)phenoxyquinoline in trifluoroacetic acid;

2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(5-carboxy-2-diethylaminomethyl)phenoxyquinoline in trifluoroacetic acid;

2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(3-tetrazol-64⁸
5-yl)phenoxyquinoline in 2,2,2-trifluoro-1,1-ethanediol;
2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(3-
trifluoromethylsulfonylamino)phenoxyquinoline in trifluoroacetic acid; and
2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-
(3-carboxy)phenoxyquinoline in trifluoroacetic acid.

8. The compound of Claim 1 wherein

m is 1;

n is 1 or 2;

R¹ is hydrogen, aryl, aralkyl, or alkoxycarbonyl;

R² is hydrogen, carboxyalkyl, alkoxycarbonylalkyl or aralkoxycarbonylalkyl;

R³ is aralkyl wherein the alkyl radical in the aralkyl substituent is optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, -R⁸-OR⁷, -R⁸-C(O)OR⁷, -R⁸-C(O)N(R⁷)₂, -R⁸-C(O)R⁷, -R⁸-N(R⁷)₂, -R⁸-N(R⁷)C(O)R⁷, and -R⁸-N(R⁷)C(O)OR⁶, and wherein the aryl radical in the aralkyl substituent is independently optionally substituted by one or more substituents selected from the group consisting of alkyl, halo, haloalkyl, cyano, nitro, tetrazolyl, -R⁸-OR⁷, -R⁸-C(O)OR⁷, -R⁸-C(O)N(R⁷)₂, -R⁸-C(O)R⁷, -R⁸-N(R⁷)₂, -R⁸-N(R⁷)C(O)R⁷, -R⁸-N(R⁷)C(O)OR⁶, -R⁸-N(R⁷)-S(O)₂-R⁷, and -R⁸-C[N(R⁷)₂]-C(O)OR⁷;

each R⁴ is independently selected from the group consisting of hydrogen, alkyl, alkoxy, aralkoxy, halo, haloalkyl, haloalkoxy, hydroxy, cyano, alkylthio, carboxy, alkoxycarbonyl, aminocarbonyl, alkylcarbonyl, nitro, amino, monoalkylamino, dialkylamino, carboxyalkylamino, alkylcarbonylamino, di(alkylcarbonyl)amino, hydroxyalkyl, dialkylaminoalkyl, carboxyalkoxy, alkoxycarbonylalkoxy, dialkylaminoalkoxy, and heterocyclalkoxy;

R⁵ is selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, aralkyl, carboxy, alkoxycarbonyl, aralkoxycarbonyl, carboxyalkyl, and alkoxycarbonylalkyl;

R⁶ is hydrogen, alkyl, carboxyalkyl, or alkoxycarbonylalkyl;

each R⁷ is hydrogen, alkyl, aryl, aralkyl, or haloalkyl;

each R⁸ is a bond or a straight or branched alkylene chain; and

R⁹ is hydrogen, alkyl, aralkyl or haloalkyl.

9. The compound of Claim 1 wherein:

m is 1;

n is 1 or 2;

649

R^1 is hydrogen, aryl, aralkyl, or alkoxy carbonyl;

R^2 is hydrogen, carboxyalkyl, alkoxy carbonylalkyl or aralkoxy carbonylalkyl;

R^3 is aralkoxy wherein the alkyl radical in the aralkyl substituent is not optionally substituted and wherein the aryl radical in the aralkoxy substituent is optionally substituted by one or more substituents selected from the group consisting of alkyl, halo, haloalkyl, cyano, nitro, tetrazolyl, $-R^5-OR^7$, $-R^5-C(O)OR^7$, $-R^5-C(O)N(R^7)_2$, $-R^5-C(O)R^7$, $-R^5-N(R^7)_2$, $-R^5-N(R^7)C(O)R^7$, $-R^5-N(R^7)C(O)OR^9$, $-R^5-N(R^7)-S(O)_2R^7$, and $-R^5-C[N(R^7)_2]-C(O)OR^7$;

each R^4 is independently selected from the group consisting of hydrogen, alkyl, alkoxy, aralkoxy, halo, haloalkyl, haloalkoxy, hydroxy, cyano, alkylthio, carboxy, alkoxy carbonyl, aminocarbonyl, alkyl carbonyl, nitro, amino, monoalkylamino, dialkylamino, carboxyalkylamino, alkyl carbonylamino, di(alkyl carbonyl)amino, hydroxyalkyl, dialkylaminoalkyl, carboxyalkoxy, alkoxy carbonylalkoxy, dialkylaminoalkoxy, and heterocyclylalkoxy;

R^5 is selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, aralkyl, carboxy, alkoxy carbonyl, aralkoxy carbonyl, carboxyalkyl, and alkoxy carbonylalkyl;

R^6 is hydrogen, alkyl, carboxyalkyl, or alkoxy carbonylalkyl;

each R^7 is hydrogen, alkyl, aryl, aralkyl, or haloalkyl;

each R^8 is a bond or a straight or branched alkylene chain; and

R^9 is hydrogen, alkyl, aralkyl or haloalkyl.

10. The compound of Claim 9 wherein:

m is 1;

n is 1 or 2;

R^1 is hydrogen, aryl, aralkyl, or alkoxy carbonyl;

R^2 is hydrogen, carboxyalkyl, alkoxy carbonylalkyl or aralkoxy carbonylalkyl;

R^3 is aralkoxy wherein the aryl radical in the aralkoxy substituent is optionally substituted by one or more substituents selected from the group consisting of alkyl, halo, haloalkyl, $-R^5-OR^7$, $-R^5-C(O)OR^7$, $-R^5-C(O)N(R^7)_2$, and $-R^5-N(R^7)_2$;

each R^4 is independently selected from the group consisting of hydrogen, alkyl, alkoxy, halo, or haloalkyl;

R^5 is hydrogen;

R^6 is hydrogen;

each R^7 is hydrogen, alkyl, aryl, aralkyl, or haloalkyl; and

each R^8 is a bond or a straight or branched alkylene chain.

11. The compound of Claim 10 selected from the group consisting of the following:

7E
650

- 2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-benzyloxyquinoline;
 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-benzyloxycarbonylpropyl]aminocarbonyl-4-benzyloxyquinoline;
 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-benzyloxyquinoline;
 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-benzyloxycarbonylpropyl]aminocarbonyl-4-benzyloxy-8-methoxyquinoline;
 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-benzyloxy-8-methoxyquinoline;
 2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(4-methoxycarbonyl)benzyloxyquinoline;
 2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(4-carboxy)benzyloxyquinoline;
 2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(3-methoxycarbonyl)benzyloxyquinoline;
 2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-4-(3-carboxy)benzyloxyquinoline;
 2-[1S-(4-(3-methylphenyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-4-benzyloxyquinoline; and
 2-[1S-(4-(3-methylphenyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-benzyloxyquinoline.

12. The compound of Claim 1 wherein:

m is 1;

n is 1 or 2;

R¹ is hydrogen, aryl, alkyl, or alkoxycarbonyl;

R² is hydrogen, carboxyalkyl, alkoxycarbonylalkyl or aralkoxycarbonylalkyl;

R³ is aralkoxy wherein the alkyl radical in the aralkoxy substituent is substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, -R⁸-OR⁷, -R⁸-C(O)OR⁷, -R⁸-C(O)N(R⁷)₂, -R⁸-C(O)R⁷, -R⁸-N(R⁷)₂, -R⁸-N(R⁷)C(O)R⁷, and -R⁸-N(R⁷)C(O)OR⁸, and wherein the aryl radical in the aralkoxy substituent is optionally substituted by one or more substituents selected from the group consisting of alkyl, halo, haloalkyl, cyano, nitro, tetrazolyl, -R⁸-OR⁷, -R⁸-C(O)OR⁷, -R⁸-C(O)N(R⁷)₂, -R⁸-C(O)R⁷, -R⁸-N(R⁷)₂, -R⁸-N(R⁷)C(O)R⁷, -R⁸-N(R⁷)C(O)OR⁸, -R⁸-N(R⁷)-S(O)₂-R⁷, and -R⁸-C[N(R⁷)₂]-C(O)OR⁷;

each R^4 is independently selected from the group consisting of hydrogen, alkyl, alkoxy, aralkoxy, halo, haloalkyl, haloalkoxy, hydroxy, cyano, alkylthio, carboxy, alkoxycarbonyl, aminocarbonyl, alkylcarbonyl, nitro, amino, monoalkylamino, dialkylamino, carboxyalkylamino, alkylcarbonylamino, di(alkylcarbonyl)amino, hydroxyalkyl, dialkylaminoalkyl, carboxyalkoxy, alkoxycarbonylalkoxy, dialkylaminoalkoxy, and heterocyclalkoxy;

R^5 is selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, aralkyl, carboxy, alkoxycarbonyl, aralkoxycarbonyl, carboxyalkyl, and alkoxycarbonylalkyl;

R^6 is hydrogen, alkyl, carboxyalkyl, or alkoxycarbonylalkyl;

each R^7 is hydrogen, alkyl, aryl, aralkyl, or haloalkyl;

each R^8 is a bond or a straight or branched alkylene chain; and

R^9 is hydrogen, alkyl, aralkyl or haloalkyl.

13. The compound of Claim 12 wherein:

m is 1;

n is 1 or 2;

R^1 is hydrogen, aryl, aralkyl, or alkoxycarbonyl;

R^2 is hydrogen, carboxyalkyl, alkoxycarbonylalkyl or aralkoxycarbonylalkyl;

R^3 is aralkoxy wherein the alkyl radical in the aralkoxy substituent is substituted by $-R^6-C(O)OR^7$, and wherein the aryl radical in the aralkoxy substituent is optionally substituted by one or more substituents selected from the group consisting of halo and $-R^6-OR^7$;

each R^4 is independently selected from the group consisting of hydrogen, alkyl, alkoxy, halo, haloalkyl, amino, monoalkylamino, or dialkylamino;

R^5 is hydrogen;

R^6 is hydrogen;

each R^7 is hydrogen, alkyl, aryl, aralkyl, or haloalkyl; and

each R^8 is a bond or a straight or branched alkylene chain.

14. The compound of Claim 13 selected from the group consisting of the following:

2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-(1,1-


dimethylethoxycarbonyl)propyl]aminocarbonyl-4-(1-phenyl-1-methoxycarbonyl)methoxyquinoline;

2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(1-phenyl-1-methoxycarbonyl)methoxyquinoline;

- 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(1-phenyl-1-carboxy)methoxyquinoline;
- 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-phenyl-1-carboxy)methoxyquinoline;
- 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-phenyl-1-carboxy)methoxyquinoline;
- 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-chloro-4-(1-carboxy-1-phenyl)methoxyquinoline in trifluoroacetic acid;
- 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-naphth-1-yl-1-carboxy)methoxyquinoline;
- 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-chloro-8-fluoro-4-(1-methoxycarbonyl-1-phenyl)methoxyquinoline in acetic acid;
- 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-chloro-8-fluoro-4-(1-carboxy-1-phenyl)methoxyquinoline in acetic acid;
- 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-6-fluoro-4-(1-carboxy-1-(2-fluoro)phenyl)methoxyquinoline in trifluoroacetic acid;
- 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-4-(1-ethoxycarbonyl-1-phenyl)methoxyquinoline in trifluoroacetic acid;
- 2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-phenyl-1-carboxy)methoxyquinoline;
- 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-6-fluoro-4-(1-carboxy-1-(4-chloro)phenyl)methoxyquinoline in trifluoroacetic acid;
- 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-6-fluoro-4-(1-carboxy-1-(3-methoxy)phenyl)methoxyquinoline in trifluoroacetic acid;
- 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6,8-difluoro-4-(1-carboxy-1-phenyl)methoxyquinoline in trifluoroacetic acid;
- 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-dimethylamino-4-(1-phenyl-1-carboxy)methoxyquinoline;
- 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-chloro-6-methyl-4-(1-phenyl-1-carboxy)methoxyquinoline in trifluoroacetic acid;
- 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-6-chloro-4-(1-phenyl-1-carboxy)methoxyquinoline in trifluoroacetic acid;
- 2-[1S-(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)carbonyl-3-methoxycarbonylpropyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-phenyl-1-carboxy)methoxyquinoline;

- 2-[1S-(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-phenyl-1-carboxy)methoxyquinoline;
- 2-[1S-(4-(methoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-phenyl-1-carboxy)methoxyquinoline in trifluoroacetic acid;
- 2-[1S-(4-(1,1-dimethylethylaminocarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-phenyl-1-carboxy)methoxyquinoline in trifluoroacetic acid;
- 2-[1S-(4-(furan-2-ylcarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-phenyl-1-carboxy)methoxyquinoline in trifluoroacetic acid;
- 2-[1S-(4-(3-methylphenyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-phenyl-1-carboxy)methoxyquinoline;
- 2-[1S-(4-(3-methylphenyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-phenyl-1-carboxy)methoxyquinoline in trifluoroacetic acid;
- 2-[1S-(4-(phenyl)piperazin-1-yl)carbonyl-3-(1,1-dimethylethoxycarbonyl)propyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-phenyl-1-carboxy)methoxyquinoline; and
- 2-[1S-(4-(phenyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-fluoro-7-methyl-4-(1-phenyl-1-carboxy)methoxyquinoline in trifluoroacetic acid.

15. A pharmaceutical composition useful in treating a mammal having a disease-state characterized by thrombotic activity, which composition comprises a pharmaceutically acceptable excipient and a compound of formula (I):



wherein:

m and n are independently 1 to 4;

R¹ is hydrogen, alkyl, carboxyalkyl, aryl, aralkyl, alkylcarbonyl, aryloxyalkylcarbonyl, carboxyalkylcarbonyl, alkoxycarbonylalkylcarbonyl, alkoxycarbonylalkyl, alkoxycarbonyl, arylcarbonyl, aryloxycarbonyl, aralkoxycarbonyl, cycloalkylcarbonyl, haloalkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, alkoxycarbonylaminocarbonyl, or heterocyclylcarbonyl;

R² is hydrogen, alkyl, aryl, aralkyl, alkylsulfonylalkyl, aralkoxyalkyl, hydroxyalkyl, aminoalkyl, haloalkylsulfonylaminoalkyl, carboxyalkylthioalkyl, alkoxycarbonylalkylthioalkyl,

carboxyalkyl, (carboxy)(hydroxy)alkyl, carboxyalkoxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, carboxyalkoxycarbonylalkyl, alkoxycarbonylalkoxycarbonylalkyl, aminocarbonylalkyl, aralkoxycarbonylaminoalkyl, alkoxycarbonylalkylaminocarbonylalkyl, carboxyalkylaminocarbonylalkyl, (alkoxycarbonylalkyl)(alkyl)aminocarbonylalkyl, (carboxyalkyl)(alkyl)aminocarbonylalkyl, or heterocyclalkyl;

R^3 is aryl or aryloxy each independently optionally substituted by one or more substituents selected from the group consisting of alkyl, halo, haloalkyl, cyano, nitro, tetrazolyl, $-R^5-OR^7$, $-R^5-C(O)OR^7$, $-R^5-C(O)N(R^7)_2$, $-R^5-C(O)R^7$, $-R^5-N(R^7)_2$, $-R^5-N(R^7)C(O)R^7$, $-R^5-N(R^7)C(O)OR^8$, $-R^5-N(R^7)-S(O)_2R^7$, and $-R^5-C[N(R^7)_2]-C(O)OR^7$;

or R^3 is aralkyl or aralkoxy, wherein the alkyl radical in the aralkyl or aralkoxy substituent is optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, $-R^5-OR^7$, $-R^5-C(O)OR^7$, $-R^5-C(O)N(R^7)_2$, $-R^5-C(O)R^7$, $-R^5-N(R^7)_2$, $-R^5-N(R^7)C(O)R^7$, and $-R^5-N(R^7)C(O)OR^8$, and wherein the aryl radical in the aralkyl or aralkoxy substituent is independently optionally substituted by one or more substituents selected from the group consisting of alkyl, halo, haloalkyl, cyano, nitro, tetrazolyl, $-R^5-OR^7$, $-R^5-C(O)OR^7$, $-R^5-C(O)N(R^7)_2$, $-R^5-C(O)R^7$, $-R^5-N(R^7)_2$, $-R^5-N(R^7)C(O)R^7$, $-R^5-N(R^7)C(O)OR^8$, $-R^5-N(R^7)-S(O)_2R^7$, and $-R^5-C[N(R^7)_2]-C(O)OR^7$;

each R^4 is independently selected from the group consisting of hydrogen, alkyl, alkoxy, aralkoxy, halo, haloalkyl, haloalkoxy, hydroxy, cyano, alkylthio, carboxy, alkoxycarbonyl, aminocarbonyl, alkylcarbonyl, nitro, amino, monoalkylamino, dialkylamino, carboxyalkylamino, alkylcarbonylamino, di(alkylcarbonyl)amino, hydroxyalkyl, dialkylaminoalkyl, carboxyalkoxy, alkoxycarbonylalkoxy, dialkylaminoalkoxy, and heterocyclalkoxy;

each R^5 is independently selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, aralkyl, carboxy, alkoxycarbonyl, aralkoxycarbonyl, carboxyalkyl, and alkoxycarbonylalkyl;

R^6 is hydrogen, alkyl, carboxyalkyl, or alkoxycarbonylalkyl;

each R^7 is hydrogen, alkyl, aryl, aralkyl, or haloalkyl;


each R^8 is a bond or a straight or branched alkylene chain; and

each R^9 is hydrogen, alkyl, aralkyl or haloalkyl;

as a single stereoisomer, a mixture of individual stereoisomers, or a racemic mixture; or a pharmaceutically acceptable salt thereof.

37
655

16. A method of treating a disease-state characterized by thrombotic activity, which method comprises administering to a mammal having a disease-state characterized by thrombotic activity a therapeutically effective amount of a compound of formula (I):



wherein:

m and n are independently 1 to 4;

R^1 is hydrogen, alkyl, carboxyalkyl, aryl, aralkyl, alkylcarbonyl, aryloxyalkylcarbonyl, carboxyalkylcarbonyl, alkoxycarbonylalkylcarbonyl, alkoxycarbonylalkyl, alkoxycarbonyl, arylcarbonyl, aryloxycarbonyl, aralkoxycarbonyl, cycloalkylcarbonyl, haloalkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, alkoxycarbonylaminocarbonyl, or heterocyclcarbonyl;

R^2 is hydrogen, alkyl, aryl, aralkyl, alkylsulfonylalkyl, aralkoxyalkyl, hydroxyalkyl, aminoalkyl, haloalkylsulfonylaminoalkyl, carboxyalkylthioalkyl, alkoxycarbonylalkylthioalkyl, carboxyalkyl, (carboxy)(hydroxy)alkyl, carboxyalkoxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, carboxyalkoxycarbonylalkyl, alkoxycarbonylalkoxycarbonylalkyl, aminocarbonylalkyl, aralkoxycarbonylaminoalkyl, alkoxycarbonylalkylaminocarbonylalkyl, carboxyalkylaminocarbonylalkyl, (alkoxycarbonylalkyl)(alkyl)aminocarbonylalkyl, (carboxyalkyl)(alkyl)aminocarbonylalkyl, or heterocyclalkyl;

R^3 is aryl or aryloxy each independently optionally substituted by one or more substituents selected from the group consisting of alkyl, halo, haloalkyl, cyano, nitro, tetrazolyl, $-R^5-OR^7$, $-R^5-C(O)OR^7$, $-R^5-C(O)N(R^7)_2$, $-R^5-C(O)R^7$, $-R^5-N(R^7)_2$, $-R^5-N(R^7)C(O)R^7$, $-R^5-N(R^7)C(O)OR^8$, $-R^5-N(R^7)-S(O)_2R^7$, and $-R^5-C[N(R^7)_2]-C(O)OR^7$;

or R^3 is aralkyl or aralkoxy, wherein the alkyl radical in the aralkyl or aralkoxy substituent is optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, $-R^5-OR^7$, $-R^5-C(O)OR^7$, $-R^5-C(O)N(R^7)_2$, $-R^5-C(O)R^7$, $-R^5-N(R^7)_2$, $-R^5-N(R^7)C(O)R^7$, and $-R^5-N(R^7)C(O)OR^8$, and wherein the aryl radical in the aralkyl or aralkoxy substituent is independently optionally substituted by one or more substituents selected from the group consisting of alkyl, halo, haloalkyl, cyano, nitro, tetrazolyl, $-R^5-OR^7$, $-R^5-C(O)OR^7$, $-R^5-C(O)N(R^7)_2$, $-R^5-C(O)R^7$, $-R^5-N(R^7)_2$, $-R^5-N(R^7)C(O)R^7$, $-R^5-N(R^7)C(O)OR^8$, $-R^5-N(R^7)-S(O)_2R^7$, and $-R^5-C[N(R^7)_2]-C(O)OR^7$;

each R^4 is independently selected from the group consisting of hydrogen, alkyl, alkoxy, aralkoxy, halo, haloalkyl, haloalkoxy, hydroxy, cyano, alkylthio, carboxy, alkoxycarbonyl, aminocarbonyl, alkylcarbonyl, nitro, amino, monoalkylamino, dialkylamino, carboxyalkylamino, alkylcarbonylamino, di(alkylcarbonyl)amino, hydroxyalkyl, dialkylaminoalkyl, carboxyalkoxy, alkoxycarbonylalkoxy, dialkylaminoalkoxy, and heterocyclialkoxyl;

each R^5 is independently selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, aralkyl, carboxy, alkoxycarbonyl, aralkoxycarbonyl, carboxyalkyl, and alkoxycarbonylalkyl;

R^6 is hydrogen, alkyl, carboxyalkyl, or alkoxycarbonylalkyl;


each R^7 is hydrogen, alkyl, aryl, aralkyl, or haloalkyl;

each R^8 is a bond or a straight or branched alkylene chain; and

each R^9 is hydrogen, alkyl, aralkyl or haloalkyl;

as a single stereoisomer, a mixture of individual stereoisomers, or a racemic mixture; or a pharmaceutically acceptable salt thereof.

17. A compound of formula (II):



wherein:

m and n are independently 1 to 4;

R^1 is hydrogen, alkyl, carboxyalkyl, aryl, aralkyl, alkylcarbonyl, aryloxyalkylcarbonyl, carboxyalkylcarbonyl, alkoxycarbonylalkylcarbonyl, alkoxycarbonylalkyl, alkoxycarbonyl, arylcarbonyl, aryloxycarbonyl, aralkoxycarbonyl, cycloalkylcarbonyl, haloalkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, alkoxycarbonylaminocarbonyl, or heterocyclialkylcarbonyl;

R^2 is hydrogen, alkyl, aryl, aralkyl, alkylsulfonylalkyl, aralkoxyalkyl, hydroxyalkyl, aminoalkyl, haloalkylsulfonylaminoalkyl, carboxyalkylthioalkyl, alkoxycarbonylalkylthioalkyl, carboxyalkyl, (carboxy)(hydroxy)alkyl, carboxyalkoxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, carboxyalkoxycarbonylalkyl, alkoxycarbonylalkoxycarbonylalkyl, aminocarbonylalkyl, aralkoxycarbonylaminoalkyl, alkoxycarbonylalkylaminocarbonylalkyl, carboxyalkylaminocarbonylalkyl,

(alkoxycarbonylalkyl)(alkyl)aminocarbonylalkyl, (carboxyalkyl)(alkyl)aminocarbonylalkyl, or heterocyclalkyl;

R^5 is heteroaryl optionally substituted by one or more substituents selected from the group consisting of alkyl, halo, haloalkyl, cyano, nitro, tetrazolyl, $-R^6-OR^7$, $-R^6-C(O)OR^7$, $-R^6-C(O)N(R^7)_2$, $-R^6-C(O)R^7$, $-R^6-N(R^7)_2$, $-R^6-N(R^7)C(O)R^7$, $-R^6-N(R^7)C(O)OR^6$, $-R^6-N(R^7)-S(O)_2-R^7$, and $-R^6-C[N(R^7)_2]-C(O)OR^7$;

or R^5 is heteroarylalkoxy, wherein the alkoxy radical in the heteroarylalkoxy substituent is optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, $-R^6-OR^7$, $-R^6-C(O)OR^7$, $-R^6-C(O)N(R^7)_2$, $-R^6-C(O)R^7$, $-R^6-N(R^7)_2$, $-R^6-N(R^7)C(O)R^7$, and $-R^6-N(R^7)C(O)OR^6$, and wherein the heteroaryl radical in the heteroarylalkoxy substituent is independently optionally substituted by one or more substituents selected from the group consisting of alkyl, halo, haloalkyl, cyano, nitro, tetrazolyl, $-R^6-OR^7$, $-R^6-C(O)OR^7$, $-R^6-C(O)N(R^7)_2$, $-R^6-C(O)R^7$, $-R^6-N(R^7)_2$, $-R^6-N(R^7)C(O)R^7$, $-R^6-N(R^7)C(O)OR^6$, $-R^6-N(R^7)-S(O)_2-R^7$, and $-R^6-C[N(R^7)_2]-C(O)OR^7$;

each R^4 is independently selected from the group consisting of hydrogen, alkyl, alkoxy, aralkoxy, halo, haloalkyl, haloalkoxy, hydroxy, cyano, alkylthio, carboxy, alkoxycarbonyl, aminocarbonyl, alkylcarbonyl, nitro, amino, monoalkylamino, dialkylamino, carboxyalkylamino, alkylcarbonylamino, di(alkylcarbonyl)amino, hydroxyalkyl, dialkylaminoalkyl, carboxyalkoxy, alkoxycarbonylalkoxy, dialkylaminoalkoxy, and heterocyclalkoxy;

each R^3 is independently selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, aralkyl, carboxy, alkoxycarbonyl, aralkoxycarbonyl, carboxyalkyl, and alkoxycarbonylalkyl;

R^6 is hydrogen, alkyl, carboxyalkyl, or alkoxycarbonylalkyl;

each R^7 is hydrogen, alkyl, aryl, aralkyl, or haloalkyl;

each R^8 is a bond or a straight or branched alkylene chain; and

each R^9 is hydrogen, alkyl, aralkyl or haloalkyl;

as a single stereoisomer, a mixture of individual stereoisomers, or a racemic mixture; or a pharmaceutically acceptable salt thereof.

18. The compound of Claim 17 wherein:

m is 1;

n is 1 or 2;

R^1 is hydrogen, aryl, aralkyl, or alkoxycarbonyl;

R^2 is hydrogen, carboxyalkyl, alkoxycarbonylalkyl or aralkoxycarbonylalkyl;

80
658

R^3 is heteroaryl optionally substituted by one or more substituents selected from the group consisting of alkyl, halo, haloalkyl, $-R^5-OR^7$, $-R^5-C(O)OR^7$, $-R^5-C(O)N(R^7)_2$, and $-R^5-N(R^7)_2$;

each R^4 is independently selected from the group consisting of hydrogen, alkyl, alkoxy, halo, haloalkyl, amino, monoalkylamino, or dialkylamino;

R^5 is hydrogen;

R^6 is hydrogen;

each R^7 is hydrogen, alkyl, aryl, aralkyl, or haloalkyl; and

each R^8 is a bond or a straight or branched alkylene chain.

19. The compound of Claim 18, namely, 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)quinoline in trifluoroacetic acid.

20. The compound of Claim 17 wherein:

m is 1;

n is 1 or 2;

R^1 is hydrogen, aryl, aralkyl, or alkoxy carbonyl;

R^2 is hydrogen, carboxyalkyl, alkoxy carbonylalkyl or aralkoxy carbonylalkyl;

R^3 is heteroarylalkoxy, wherein the alkoxy radical in the heteroarylalkoxy substituent is optionally substituted by one or more substituents selected from the group consisting of halo and $-R^5-C(O)OR^7$, and wherein the heteroaryl radical in the heteroarylalkoxy substituent is independently optionally substituted by one or more substituents selected from the group consisting of alkyl, halo, haloalkyl, $-R^5-OR^7$, $-R^5-C(O)OR^7$, $-R^5-C(O)N(R^7)_2$, and $-R^5-N(R^7)_2$;

each R^4 is independently selected from the group consisting of hydrogen, alkyl, alkoxy, halo, haloalkyl, amino, monoalkylamino, or dialkylamino;

R^5 is hydrogen;

R^6 is hydrogen;


each R^7 is hydrogen, alkyl, aryl, aralkyl, or haloalkyl; and

each R^8 is a bond or a straight or branched alkylene chain.

21. The compound of Claim 20 selected from the group consisting of the following:
2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(5-methylisoxazol-3-yl)methoxyquinoline in trifluoroacetic acid;

- 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(2-methylthiazol-4-yl)methoxyquinoline in trifluoroacetic acid;
- 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-methoxycarbonylpropyl]aminocarbonyl-4-(1-phenyl-1-ethoxycarbonyl-1-chloro)methoxyquinoline;
- 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-7-methyl-6-fluoro-4-(1-carboxy-1-thien-3-yl)methoxyquinoline in trifluoroacetic acid;
- 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-chloro-7-methyl-4-(5-methylisoxazol-3-yl)methoxyquinoline; and
- 2-[1-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-6-chloro-7-methyl-4-(2-methylthiazol-4-yl)methoxyquinoline in trifluoroacetic acid.

22. A pharmaceutical composition useful in treating a mammal having a disease-state characterized by thrombotic activity, which composition comprises a pharmaceutically acceptable excipient and a compound of formula (II):



wherein:

m and n are independently 1 to 4;

R¹ is hydrogen, alkyl, carboxyalkyl, aryl, aralkyl, alkylcarbonyl, aryloxyalkylcarbonyl, carboxyalkylcarbonyl, alkoxycarbonylalkylcarbonyl, alkoxycarbonylalkyl, alkoxycarbonyl, arylcarbonyl, aryloxycarbonyl, aralkoxycarbonyl, cycloalkylcarbonyl, haloalkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, alkoxycarbonylaminocarbonyl, or heterocyclcarbonyl;

R² is hydrogen, alkyl, aryl, aralkyl, alkylsulfonylalkyl, aralkoxyalkyl, hydroxyalkyl, aminoalkyl, haloalkylsulfonylaminoalkyl, carboxyalkylthioalkyl, alkoxycarbonylalkylthioalkyl, carboxyalkyl, (carboxy)(hydroxy)alkyl, carboxyalkoxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, carboxyalkoxycarbonylalkyl, alkoxycarbonylalkoxycarbonylalkyl, aminocarbonylalkyl, aralkoxycarbonylaminoalkyl, alkoxycarbonylalkylaminocarbonylalkyl, carboxyalkylaminocarbonylalkyl, (alkoxycarbonylalkyl)(alkyl)aminocarbonylalkyl, (carboxyalkyl)(alkyl)aminocarbonylalkyl, or heterocyclalkyl;

R³ is heteroaryl optionally substituted by one or more substituents selected from the group consisting of alkyl, halo, haloalkyl, cyano, nitro, tetrazolyl, -R⁸-OR⁷, -R⁸-C(O)OR⁷,

82
660

$-R^5-C(O)N(R^7)_2$, $-R^5-C(O)R^7$, $-R^5-N(R^7)_2$, $-R^5-N(R^7)C(O)R^7$, $-R^5-N(R^7)C(O)OR^8$,
 $-R^5-N(R^7)-S(O)_2-R^7$, and $-R^5-C[N(R^7)_2]-C(O)OR^7$;

or R^5 is heteroarylalkoxy, wherein the alkoxy radical in the heteroarylalkoxy substituent is optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, $-R^5-OR^7$, $-R^5-C(O)OR^7$, $-R^5-C(O)N(R^7)_2$, $-R^5-C(O)R^7$, $-R^5-N(R^7)_2$, $-R^5-N(R^7)C(O)R^7$, and $-R^5-N(R^7)C(O)OR^8$, and wherein the heteroaryl radical in the heteroarylalkoxy substituent is independently optionally substituted by one or more substituents selected from the group consisting of alkyl, halo, haloalkyl, cyano, nitro, tetrazolyl, $-R^5-OR^7$, $-R^5-C(O)OR^7$, $-R^5-C(O)N(R^7)_2$, $-R^5-C(O)R^7$, $-R^5-N(R^7)_2$, $-R^5-N(R^7)C(O)R^7$, $-R^5-N(R^7)C(O)OR^8$, $-R^5-N(R^7)-S(O)_2-R^7$, and $-R^5-C[N(R^7)_2]-C(O)OR^7$;

each R^4 is independently selected from the group consisting of hydrogen, alkyl, alkoxy, aralkoxy, halo, haloalkyl, haloalkoxy, hydroxy, cyano, alkylthio, carboxy, alkoxycarbonyl, aminocarbonyl, alkylcarbonyl, nitro, amino, monoalkylamino, dialkylamino, carboxyalkylamino, alkylcarbonylamino, di(alkylcarbonyl)amino, hydroxyalkyl, dialkylaminoalkyl, carboxyalkoxy, alkoxycarbonylalkoxy, dialkylaminoalkoxy, and heterocyclalkoxy;

each R^5 is independently selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, aralkyl, carboxy, alkoxycarbonyl, aralkoxycarbonyl, carboxyalkyl, and alkoxycarbonylalkyl;

R^6 is hydrogen, alkyl, carboxyalkyl, or alkoxycarbonylalkyl;


each R^7 is hydrogen, alkyl, aryl, aralkyl, or haloalkyl;

each R^8 is a bond or a straight or branched alkylene chain; and

each R^9 is hydrogen, alkyl, aralkyl or haloalkyl;

as a single stereoisomer, a mixture of individual stereoisomers, or a racemic mixture; or a pharmaceutically acceptable salt thereof.

23. A method of treating a disease-state characterized by thrombotic activity, which method comprises administering to a mammal having a disease-state characterized by thrombotic activity a therapeutically effective amount of a compound of formula (II):



wherein:

m and n are independently 1 to 4;

82
661

R^1 is hydrogen, alkyl, carboxyalkyl, aryl, aralkyl, alkylcarbonyl, aryloxyalkylcarbonyl, carboxyalkylcarbonyl, alkoxycarbonylalkylcarbonyl, alkoxycarbonylalkyl, alkoxycarbonyl, arylcarbonyl, aryloxycarbonyl, aralkoxycarbonyl, cycloalkylcarbonyl, haloalkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, alkoxycarbonylaminocarbonyl, or heterocyclcarbonyl;

R^2 is hydrogen, alkyl, aryl, aralkyl, alkylsulfonylalkyl, aralkoxyalkyl, hydroxyalkyl, aminoalkyl, haloalkylsulfonylaminoalkyl, carboxyalkylthioalkyl, alkoxycarbonylalkylthioalkyl, carboxyalkyl, (carboxy)(hydroxy)alkyl, carboxyalkoxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, carboxyalkoxycarbonylalkyl, alkoxycarbonylalkoxycarbonylalkyl, aminocarbonylalkyl, aralkoxycarbonylaminoalkyl, alkoxycarbonylalkylaminocarbonylalkyl, carboxyalkylaminocarbonylalkyl, (alkoxycarbonylalkyl)(alkyl)aminocarbonylalkyl, (carboxyalkyl)(alkyl)aminocarbonylalkyl, or heterocyclalkyl;

R^3 is heteroaryl optionally substituted by one or more substituents selected from the group consisting of alkyl, halo, haloalkyl, cyano, nitro, tetrazolyl, $-R^5-OR^7$, $-R^5-C(O)OR^7$, $-R^5-C(O)N(R^7)_2$, $-R^5-C(O)R^7$, $-R^5-N(R^7)_2$, $-R^5-N(R^7)C(O)R^7$, $-R^5-N(R^7)C(O)OR^6$, $-R^5-N(R^7)-S(O)_2R^7$, and $-R^5-C[N(R^7)_2]-C(O)OR^7$;

or R^3 is heteroarylalkoxy, wherein the alkoxy radical in the heteroarylalkoxy substituent is optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, $-R^5-OR^7$, $-R^5-C(O)OR^7$, $-R^5-C(O)N(R^7)_2$, $-R^5-C(O)R^7$, $-R^5-N(R^7)_2$, $-R^5-N(R^7)C(O)R^7$, and $-R^5-N(R^7)C(O)OR^6$, and wherein the heteroaryl radical in the heteroarylalkoxy substituent is independently optionally substituted by one or more substituents selected from the group consisting of alkyl, halo, haloalkyl, cyano, nitro, tetrazolyl, $-R^5-OR^7$, $-R^5-C(O)OR^7$, $-R^5-C(O)N(R^7)_2$, $-R^5-C(O)R^7$, $-R^5-N(R^7)_2$, $-R^5-N(R^7)C(O)R^7$, $-R^5-N(R^7)C(O)OR^6$, $-R^5-N(R^7)-S(O)_2R^7$, and $-R^5-C[N(R^7)_2]-C(O)OR^7$;

each R^4 is independently selected from the group consisting of hydrogen, alkyl, alkoxy, aralkoxy, halo, haloalkyl, haloalkoxy, hydroxy, cyano, alkylthio, carboxy, alkoxycarbonyl, aminocarbonyl, alkylcarbonyl, nitro, amino, monoalkylamino, dialkylamino, carboxyalkylamino, alkylcarbonylamino, di(alkylcarbonyl)amino, hydroxyalkyl, dialkylaminoalkyl, carboxyalkoxy, alkoxycarbonylalkoxy, dialkylaminoalkoxy, and heterocyclalkoxy;

each R^5 is independently selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, aralkyl, carboxy, alkoxycarbonyl, aralkoxycarbonyl, carboxyalkyl, and alkoxycarbonylalkyl;

R^6 is hydrogen, alkyl, carboxyalkyl, or alkoxycarbonylalkyl;

each R^7 is hydrogen, alkyl, aryl, aralkyl, or haloalkyl;

~~24~~
662

each R⁸ is a bond or a straight or branched alkylene chain; and
each R⁹ is hydrogen, alkyl, aralkyl or haloalkyl;
as a single stereoisomer, a mixture of individual stereoisomers, or a racemic mixture;
or a pharmaceutically acceptable salt thereof.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 03/39079

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/4709 C07D215/22 C07D413/12 C07D417/12 C07D409/12
C07D215/48 A61P9/10 A61P7/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
Y	EP 0 739 886 A (LG CHEMICAL LIMITED) 30 October 1996 (1996-10-30) claims 1-4; example 51	1-23
Y	WO 94/18185 A (PENTAPHARM AG ;STUERZEBECKER JOERG (DE); VIEWEG HELMUT (DE); WIKST) 18 August 1994 (1994-08-18) claims 1,2,16; example 1	1-23
	-/-	

☒ Further documents are listed in the continuation of box C

☒ Patent family members are listed in annex

* Special categories of cited documents *

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubt on priority claims) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *Z* document member of the same patent family

Date of the actual completion of the international search

4 May 2004

Date of mailing of the international search report

11/05/2004

Name and mailing address of the ISA

European Patent Office, P.O. Box 5816 Palantian 2
ML - 2280 HW Rapsak
Tel (+31-70) 340-2040, Tr 31 651 epo nl
Fax (+31-70) 340-3016

Authorized officer

Schuemacher, A

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 03/39079

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
Y	KAMM W ET AL: "TRANSPORT OF PEPTIDOMIMETIC THROMBIN INHIBITORS WITH A 3-AMIDINO-PHENYLALANINE STRUCTURE: PERMEABILITY AND EFFLUX MECHANISM IN MONOLAYERS OF A HUMAN INTESTINAL CELL LINE (CACO-2)" PHARMACEUTICAL RESEARCH, NEW YORK, NY, US, vol. 18, no. 8, 2001, pages 1110-1118, XP009003114 ISSN: 0724-8741 figure 1; examples 10,11	1-23
Y	PIERCE A C ET AL: "Estimation of Binding Affinities for Selective Thrombin Inhibitors via Monte Carlo Simulations" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 44, no. 7, 2001, pages 1043-1050, XP002226501 ISSN: 0022-2623 figure 2; example 12	1-23
A	US 4 258 192 A (OKAMOTO SHOSUKE ET AL) 24 March 1981 (1981-03-24) claim 1; example 1	1-23
A	US 5 346 907 A (KERWIN, JAMES F., JR. ET AL) 13 September 1994 (1994-09-13) claim 1	1,17
P,X	WO 02/098856 A (SCHERING AKTIENGESELLSCHAFT, GERMANY) 12 December 2002 (2002-12-12) the whole document	1-23

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 03/39079

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 16 and 23 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependant claims and are not drafted in accordance with the second and third sentences of Rule 84(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims. It is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

National Application No

PCT/US 03/39079

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0739886	A	30-10-1996	AU 696380 B2	10-09-1998
			CA 2188690 A1	23-04-1998
			WO 9749673 A1	31-12-1997
			NZ 299659 A	19-12-1997
			AU 7048196 A	07-05-1998
			EP 0739886 A2	30-10-1996
			JP 2844329 B2	06-01-1999
			JP 8301833 A	19-11-1996
			JP 11005780 A	12-01-1999
			US 5747535 A	05-05-1998
			AT 251146 T	15-10-2003
			DE 69630160 D1	06-11-2003
			ES 2202385 T3	01-04-2004
			KR 173034 B1	30-03-1999
			US 5977114 A	02-11-1999
			US 5985899 A	16-11-1999
			RU 2142939 C1	20-12-1999
WO 9418185	A	18-08-1994	AT 223392 T	15-09-2002
			AU 5878194 A	29-08-1994
			CA 2133761 A1	18-08-1994
			WO 9418185 A1	18-08-1994
			CZ 9402459 A3	18-10-1995
			DE 59410179 D1	10-10-2002
			EP 0635008 A1	25-01-1995
			HU 68042 A2	22-03-1995
			JP 7509731 T	26-10-1995
			US 5607937 A	04-03-1997
US 4258192	A	24-03-1981	US 4201863 A	06-05-1980
US 5346907	A	13-09-1994	EP 0336356 A2	11-10-1989
			EP 0442878 A1	28-08-1991
			JP 3503650 T	15-08-1991
			WO 8910355 A1	02-11-1989
			CA 2062755 A1	08-01-1991
			EP 0480969 A1	22-04-1992
			GR 90100516 A ,B	10-12-1991
			IE 902295 A1	16-01-1991
			JP 4506660 T	19-11-1992
			PT 94623 A	20-03-1991
			WO 9100725 A2	24-01-1991
WO 02098856	A	12-12-2002	US 2003060474 A1	27-03-2003
			EP 1412349 A2	28-04-2004
			WO 02098856 A2	12-12-2002

90
667
State of California

SECRETARY OF STATE

APOSTILLE

(Convention de La Haye du 5 octobre 1961)

1. **Country: United States of America**
This public document
2. **has been signed by MARY ANN J. FLORES**
3. **acting in the capacity of Notary Public, State of California**
4. **bears the seal/stamp of MARY ANN J. FLORES, Notary Public,**
State of California

CERTIFIED

5. **At Sacramento, California**
6. **the 8th day of July 2005**
7. **by Deputy Secretary of State, State of California**
8. **No. 246717**
9. **Seal/Stamp:**

10. **Signature**



[Handwritten signature]

Secretary of State

BY *[Handwritten signature]*




AT
658

ALIF RNIA ALL-PURPOSE ACKN WLEDGMENT

State of California

County of Contra Costa } ss.

On June 23, 2005 before me, Mary Ann J. Flores, Notary
Date Name and Title of Officer (e.g., "Jane Doe, Notary Public")
personally appeared Judi Bryant and Shendong Yuan
Name(s) of Signer(s)



☒ personally known to me

☐ proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

WITNESS my hand and official seal.

Place Notary Seal Above

Mary Ann J. Flores
Signature of Notary Public

OPTIONAL

Though the information below is not required by law, it may prove valuable to persons relying on the document and could prevent fraudulent removal and reattachment of this form to another document.

Description of Attached Document

Title or Type of Document: Assignment 52143B (Colombia)

Document Date: _____ Number of Pages: _____

Signer(s) Other Than Named Above: _____

Capacity(ies) Claimed by Signer(s)

Signer's Name: _____

- ☐ Individual
☐ Corporate Officer — Title(s): _____
☐ Partner — ☐ Limited ☐ General
☐ Attorney In Fact
☐ Trustee
☐ Guardian or Conservator
☐ Other: _____

Signer Is Representing: _____



Signer's Name: _____

- ☐ Individual
☐ Corporate Officer — Title(s): _____
☐ Partner — ☐ Limited ☐ General
☐ Attorney In Fact
☐ Trustee
☐ Guardian or Conservator
☐ Other: _____

Signer Is Representing: _____



92
669
State of California

SECRETARY OF STATE

APOSTILLE


(Convention de La Haye du 5 octobre 1961)

1. *Country: United States of America*
This public document
2. *has been signed by CINDY LOU STEWART*
3. *acting in the capacity of Notary Public, State of California*
4. *bears the seal/stamp of CINDY LOU STEWART, Notary Public,*
State of California

CERTIFIED

5. *At Sacramento, California*
6. *the 8th day of July 2005*
7. *by Deputy Secretary of State, State of California*
8. *No. 246719*
9. *Seal/Stamp:*

10. *Signature*



[Handwritten signature]

Secretary of State

[Handwritten signature]



93
670

ALIF RNIA ALL-PURPOSE ACKNOWLEDGMENT

State of California

County of San Diego } ss.

On June 28, 2005

before me,

Cindy Lou Stewart, Notary

personally appeared

Rajiv Mehra

Name and Title of Officer (e.g., "Jane Doe, Notary Public")

Name(s) of Signer(s)

☒ personally known to me

☐ proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.



Place Notary Seal Above

WITNESS my hand and official seal.

Cindy Lou Stewart

Signature of Notary Public

OPTIONAL

Though the information below is not required by law, it may prove valuable to persons relying on the document and could prevent fraudulent removal and reattachment of this form to another document.

Description of Attached Document

Title or Type of Document:

Assignment 52143B (Colombia)

Document Date:

Number of Pages: 1

Signer(s) Other Than Named Above:

Capacity(ies) Claimed by Signer(s)

Signer's Name:

- ☐ Individual
☐ Corporate Officer — Title(s):
☐ Partner — ☐ Limited ☐ General
☐ Attorney In Fact
☐ Trustee
☐ Guardian or Conservator
☐ Other:

Signer Is Representing:

Signer's Name:

- ☐ Individual
☐ Corporate Officer — Title(s):
☐ Partner — ☐ Limited ☐ General
☐ Attorney In Fact
☐ Trustee
☐ Guardian or Conservator
☐ Other:

Signer Is Representing:

94
671

State of California

SECRETARY OF STATE

APOSTILLE


(Convention de La Haye du 5 octobre 1961)

1. Country: *United States of America*
This public document
2. *has been signed by AMY RIOS*
3. *acting in the capacity of Notary Public, State of California*
4. *bears the seal/stamp of AMY RIOS, Notary Public,
State of California*

CERTIFIED

5. *At Sacramento, California*
6. *the 8th day of July 2005*
7. *by Deputy Secretary of State, State of California*
8. *No. 246716*
9. *Seal/Stamp:*

10. Signature



[Signature]

Secretary of State



98
672


CALIFORNIA ALL-PURPOSE ACKNOWLEDGMENT

State of California
County of San Mateo } ss.

On June 24, 2005 before me, Amy Rios, Notary Public
Date Name and Title of Officer (e.g., "Jane Doe, Notary Public")
personally appeared Michael M. Morrissey
Name(s) of Signer(s)

☒ personally known to me
☐ proved to me on the basis of satisfactory evidence

to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.



WITNESS my hand and official seal.

Amy Rios
Signature of Notary Public

OPTIONAL

Though the information below is not required by law, it may prove valuable to persons relying on the document and could prevent fraudulent removal and reattachment of this form to another document.

Description of Attached Document

Title or Type of Document: Assignment Document

Document Date: June 24, 2005 Number of Pages: 1


Signer(s) Other Than Named Above: Wei Xu

Capacity(ies) Claimed by Signer

Signer's Name: Michael Morrissey

- ☒ Individual
☐ Corporate Officer — Title(s): _____
☐ Partner — ☐ Limited ☐ General
☐ Attorney-in-Fact
☐ Trustee
☐ Guardian or Conservator
☐ Other: _____

Signer Is Representing: _____



State of California

SECRETARY OF STATE

APOSTILLE


(Convention de La Haye du 5 octobre 1961)

1. Country: *United States of America*
This public document
2. *has been signed by AMY RIOS*
3. *acting in the capacity of Notary Public, State of California*
4. *bears the seal/stamp of AMY RIOS, Notary Public,
State of California*

CERTIFIED

5. *At Sacramento, California*
6. *the 8th day of July 2005*
7. *by Deputy Secretary of State, State of California*
8. *No. 246715*
9. *Seal/Stamp:*

10. *Signature*



[Signature]

Secretary of State

[Signature]

BY

OSP 05 90772

97
674

CALIFORNIA ALL-PURPOSE ACKNOWLEDGMENT

State of California

County of

San Mateo

} ss.

On June 24, 2005

Date

before me,

Amy Rios, Notary Public

Name and Title of Officer (s.e., "Jane Doe, Notary Public")

personally appeared


Wei Xu

Name(s) of Signer(s)

☒ personally known to me

☐ proved to me on the basis of satisfactory evidence

to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies); and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.



WITNESS my hand and official seal.

Amy Rios
Signature of Notary Public

OPTIONAL

Though the information below is not required by law, it may prove valuable to persons relying on the document and could prevent fraudulent removal and reattachment of this form to another document.

Description of Attached Document

Title or Type of Document:

Assignment Document

Document Date:

June 24, 2005

Number of Pages:

1

Signer(s) Other Than Named Above:

Michael M. Marrissey

Capacity(ies) Claimed by Signer

Signer's Name:

Wei Xu

☒ Individual

☐ Corporate Officer — Title(s):

☐ Partner — ☐ Limited ☐ General

☐ Attorney-in-Fact

☐ Trustee

☐ Guardian or Conservator

☐ Other:

Signer is Representing:



28
675

State of California

SECRETARY OF STATE

APOSTILLE

(Convention de La Haye du 5 octobre 1961)

1. Country: *United States of America*
This public document
2. *has been signed by MARY ANN J. FLORES*
3. *acting in the capacity of Notary Public, State of California*
4. *bears the seal/stamp of MARY ANN J. FLORES, Notary Public,
State of California*

CERTIFIED

5. *At Sacramento, California*
6. *the 8th day of July 2005*
7. *by Deputy Secretary of State, State of California*
8. *No. 246718*
9. *Seal/Stamp:*

10. Signature



[Handwritten Signature]

Secretary of State

BY *[Handwritten Signature]*



29
676

ALIFORNIA ALL-PURPOSE ACKN WLEDGMENT

State of California

County of

Contra Costa

ss.

On

June 21, 2005

Date

before me,

Mary Ann J. Flores, Notary

Name and Title of Officer (i.e., "John Doe, Notary Public")

personally


appeared

Brad Buckman, Gus King Wei

Name(s) of Signer(s)

☒ personally known to me

☐ proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) here are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.



WITNESS my hand and official seal.

Place Notary Seal Above

Mary Ann J. Flores
Signature of Notary Public

OPTIONAL

Though the information below is not required by law, it may prove valuable to persons relying on the document and could prevent fraudulent removal and reattachment of this form to another document.

Description of Attached Document

Title or Type of Document:

Assignment 52143B (Columbia)

Document Date:

Number of Pages:

1

Signer(s) Other Than Named Above:

Capacity(ies) Claimed by Signer(s)

Signer's Name:

- ☐ Individual
☐ Corporate Officer — Title(s):
☐ Partner — ☐ Limited ☐ General
☐ Attorney in Fact
☐ Trustee
☐ Guardian or Conservator
☐ Other:

Signer Is Representing:



Signer's Name:


- ☐ Individual
☐ Corporate Officer — Title(s):
☐ Partner — ☐ Limited ☐ General
☐ Attorney in Fact
☐ Trustee
☐ Guardian or Conservator
☐ Other:

Signer Is Representing:



DOCUMENTO DE CESIÓN ASSIGNMENT DOCUMENT

El/los suscritos,
(I/ We, the undersigned)

- 1) BRYANT, Judi
con domicilio en Mill Valley, California, Estados Unidos de América
(domiciled in)
- 2) BUCKMAN, Brad,
con domicilio en Oakland, California, Estados Unidos de América
- 3) ISLAM, Imadul
con domicilio en Hercules, California, Estados Unidos de América
- 4) MOHAN, Raju
con domicilio en Encinitas, California, Estados Unidos de América
- ✓ 5) MORRISSEY, Michael  624.205
con domicilio en Danville, California, Estados Unidos de América
- 6) WEI, Guo, Ping
con domicilio en San Ramon, California, Estados Unidos de América
- ✓ 7) XU, Wei 
con domicilio en Danville, California, Estados Unidos de América
- 8) YUAN, Shendong
con domicilio en Richmond, California, Estados Unidos de América

declaro que soy el/los inventor/es de la invención que lleva el título
(declare that I/ We am/are the inventor/s of the invention titled)

2-AMINOCARBONYL-QUINOLINE COMPOUNDS AS PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS

y que he/mos cedido el derecho sobre esta invención en Colombia, junto con los privilegios
(and that I/ We have assigned my/our rights over this invention in Colombia, together with its
privileges)

y anexidades a favor de
(and attachments, to)

SCHERING AKTIENGESELLSCHAFT
Berlin, Alemania

**DOCUMENTO DE CESIÓN
ASSIGNMENT DOCUMENT**

El/los suscritos,
(I/ We, the undersigned)

- ✓ 1) BRYANT, Judi 
con domicilio en Mill Valley, California, Estados Unidos de América
(domiciled in)
- ✓ 2) BUCKMAN, Brad, 
con domicilio en Oakland, California, Estados Unidos de América
- 3) ISLAM, Imadul
con domicilio en Hercules, California, Estados Unidos de América
- 4) MOHAN, Raju
con domicilio en Encinitas, California, Estados Unidos de América
- 5) MORRISSEY, Michael
con domicilio en Danville, California, Estados Unidos de América
- ✓ 6) WEI, Guo Ping 
con domicilio en San Ramon, California, Estados Unidos de América
- ✓ 7) XU, Wei
con domicilio en Danville, California, Estados Unidos de América
- ✓ 8) YUAN, Shendong 
con domicilio en Richmond, California, Estados Unidos de América

declaro que soy el/los inventor/es de la invención que lleva el título
(declare that I/ We am/are the inventor/s of the invention titled)

**2-AMINOCARBONYL-QUINOLINE COMPOUNDS AS PLATELET ADENOSINE
DIPHOSPHATE RECEPTOR ANTAGONISTS**

y que he/mos cedido el derecho sobre esta invención en Colombia, junto con los privilegios
(and that I/ We have assigned my/our rights over this invention in Colombia, together with its
privileges)

y anexidades a favor de
(and attachments, to)

SCHERING AKTIENGESELLSCHAFT
Berlin, Alemania

679
**DOCUMENTO DE CESIÓN
ASSIGNMENT DOCUMENT**

El/los suscritos,
(I/ We, the undersigned)

- 1) BRYANT, Judi
con domicilio en Mill Valley, California, Estados Unidos de América
(domiciled in)
- 2) BUCKMAN, Brad,
con domicilio en Oakland, California, Estados Unidos de América
- 3) ISLAM, Imadul
con domicilio en Hercules, California, Estados Unidos de América
- ✓ 4) MOHAN, Raju *Raju Mohan*
con domicilio en Encinitas, California, Estados Unidos de América
- 5) MORRISSEY, Michael
con domicilio en Danville, California, Estados Unidos de América
- 6) WEI, Guo Ping
con domicilio en San Ramon, California, Estados Unidos de América
- 7) XU, Wei
con domicilio en Danville, California, Estados Unidos de América
- 8) YUAN, Shendong
con domicilio en Richmond, California, Estados Unidos de América


declaro que soy el/los inventor/es de la invención que lleva el título
(declare that I/ We am/are the inventor/s of the invention titled)

**2-AMINOCARBONYL-QUINOLINE COMPOUNDS AS PLATELET ADENOSINE
DIPHOSPHATE RECEPTOR ANTAGONISTS**

y que he/mos cedido el derecho sobre esta invención en Colombia, junto con los privilegios
(and that I/ We have assigned my/our rights over this invention in Colombia, together with its
privileges)

y anexidades a favor de
(and attachments, to)

SCHERING AKTIENGESELLSCHAFT
Berlin, Alemania



Candy Lou Stewart

R ef. 4-7-2/1

521430

103

COLOMBIA

680

DOCUMENTO DE CESIÓN ASSIGNMENT DOCUMENT

El/los suscritos,
(I/ We, the undersigned)

- ✓ 1) BRYANT, Judi
con domicilio en Mill Valley, California, Estados Unidos de América
(domiciled in)
- ✓ 2) BUCKMAN, Brad,
con domicilio en Oakland, California, Estados Unidos de América
- ✓ 3) ISLAM, Imadul
con domicilio en Hercules, California, Estados Unidos de América Imadul Islam
- ✓ 4) MOHAN, Raju
con domicilio en Encinitas, California, Estados Unidos de América
- ✓ 5) MORRISSEY, Michael
con domicilio en Danville, California, Estados Unidos de América
- ✓ 6) WEI, Guo, Ping
con domicilio en San Ramon, California, Estados Unidos de América
- ✓ 7) XU, Wei
con domicilio en Danville, California, Estados Unidos de América
- ✓ 8) YUAN, Shendong
con domicilio en Richmond, California, Estados Unidos de América

declaro que soy el/los inventor/es de la invención que lleva el título
(declare that I/ We am/are the inventor/s of the invention titled)

2-AMINOCARBONYL-QUINOLINE COMPOUNDS AS PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS

y que he/mos cedido el derecho sobre esta invención en Colombia, junto con los privilegios
(and that I/ We have assigned my/our rights over this invention in Colombia, together with its
privileges)

y anexidades a favor de
(and attachments, to)

SCHERING AKTIENGESELLSCHAFT
Berlin, Alemania

Dr. Seuß
Corporate Patents

Dr. Noeske-Jungblut
Corporate Patents

104
681

Urkundenrolle-Nr. R 410/2005

Ich habe das Mitwirkungsverbot nach § 3 Abs. 1 Nr. 7 BeurkG erläutert. Meine Frage, ob eine Vorbefassung im Sinne der Vorschrift vorliege, wurde verneint.

Die vor mir geleisteten Unterschriften

der Frau Dr. Christiane **Noeske-Jungblut** geb. Noeske,
geboren am 26. Juni 1957,

und des Herrn Dr. Thomas **Seuß**,
geboren am 17. September 1963,

- beide von Person bekannt -

des Herrn Imadul **Islam**,
geboren am 15. Februar 1958,

- ausgewiesen durch Vorlage seines gültigen Reisepasses Nr. 093531977 -

sämtlichst geschäftsansässig in 13353 Berlin, Müllerstraße 178,

beglaubige ich.

Zugleich bescheinige ich aufgrund heutiger Einsicht in die Akten des Handelsregisters beim Amtsgerichts Charlottenburg zur Geschäftsnummer HR B 283, daß Frau Dr. Noeske-Jungblut und Herr Dr. Seuß als Prokuristen gemeinsam zur Vertretung der Schering Aktiengesellschaft, Berlin, berechtigt sind.

Berlin, 29. Juni 2005


Notar

Kostenberechnung gem. §§ 141, 154 KostO

Geschäftswert: 12.000,00 €

Beglaubigungsgebühr §§ 32, 45 I

15,00 €

Wegegebühr gem. § 58

15,00 €

Gebühr für die Vertreterbescheinigung gem. § 150

13,00 €

Schreibauslagen §§ 136, 152

2,00 €

Postauslagen §§ 137, 152

4,32 €


49,32 €

16% Mehrwertsteuer

7,89 €

57,21 €

Berlin, 29. Juni 2005


Notar

Apostille
(Convention de La Haye du 5 octobre 1961)

1. Land: Bundesrepublik Deutschland

Diese öffentliche Urkunde

2. ist unterschrieben von Dimitri R e m p e n

3. in seiner Eigenschaft als Notar

4. sie ist versehen mit dem Siegel
des Notars

Bestätigt

5. In Berlin

6. am 30. Juni 2005

7. durch den Präsidenten des Landgerichts in Berlin

8. unter Nr. 9101 a E - F. 3089/2005

9. Siegel

10. Unterschrift

Im Auftrage

Bünning
(Bünning)

Vorsitzende Richterin am Landgericht

Registro Notarial Número R 410/2005

Yo expliqué la prohibición de participación según el Artículo 3 inciso 1 No. 7 de la Ley de Notarización. Mi pregunta acerca de si existía algún impedimento previo en el sentido de tal disposición fue contestada negativamente.

Autentico oficialmente las firmas que aparecen anteriormente, las cuales fueron ejecutadas en mi presencia por

La Señora Dra. Christiane Noeske-Jungblut,

apellido de soltera Noeske

nacida el 26 de Junio de 1957,

el Señor Dr. Thomas Seuß,

nacido el 17 de Septiembre de 1963,

-ambos conocidos personalmente por el Notario-

el Señor Imadul Islam,

nacido el 15 de Febrero de 1958,

-identificado mediante la presentación de su pasaporte vigente No. 093531977-

todos ellos con domicilio comercial en 13353 Berlín,
Müllerstraße 178.

Al mismo tiempo, con base en la revisión efectuada el día de hoy en las actas del Registro Comercial del Juzgado Municipal de Charlottenburg bajo HRB 283, certifico que la Señora Dra. Noeske-Jungblut y el Señor Dr. Seuß en su calidad de Apoderados se encuentran autorizados para representar conjuntamente a la compañía Schering Aktiengesellschaft domiciliada en Berlín. ✓

Berlín, 29 de Junio de 2005

Dimitri Rempen, Notario en Berlín

(Firma y Sello Oficial)

Nota de gastos Artículos 141, 154 Disposición de Impuestos:**Valor del negocio: 12.000,-- EUROS**

Impuesto Artículo 32, 45I	15,00 EUROS
Impuesto Artículo 58	15,00 EUROS
Impuesto Artículo 150	13,00 EUROS
Impuesto Artículos 136, 152	2,00 EUROS
Impuesto Artículos 137, 152	4,32 EUROS
I.V.A. 16%	7,89 EUROS
Total:	57,21 EUROS

Berlín, 29 de Junio de 2005

Dimitri Rempen, Notario (firma)

APOSTILLA

(Convención de La Haya del 5 de Octubre de 1961)

1. País: República Federal de Alemania


Este documento público

2. Ha sido firmado por: Dimitri Rempen
3. En su calidad de: Notario
4. Y lleva el sello oficial del: Notario

Confirmado

5. En: Berlín
6. El día: 30 de Junio de 2005
7. Por: El Presidente del Tribunal Regional en Berlín
8. Bajo el No.: 9101 a E-F. 3069/2005
9. Sello: EL PRESIDENTE DEL TRIBUNAL REGIONAL EN BERLIN
10. Firma:

Bünning, Jueza Presidenta en el Tribunal Regional


ADOLF WATZKE
Traductor Oficial
Res. 2433 Minjusticia

MUNICIPIO DE LEGALIZACIONES
EXISTENTES

138964
Adolf Watzke
CUYA FIRMA APARECE EN EL
DOCUMENTO DE EMPENA
LAS FIRMAS DE LOS

NO SE ASUME
RESPONSABILIDAD DEL TEXTO

2005 JUL 28 P 10:09

UCS
JEFE DE LEGALIZACIONES
SANTAFE DE BOGOTA D C